View full research at Choice Peptide Labs → See the product →

5-Amino-1MQ: The NNMT Inhibitor in Metabolic Research

The Blocker · Metabolic & GLP-1

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) \u2014 an enzyme overexpressed in white adipose tissue that disrupts NAD+ metabolism and promotes fat accumulation. It represents a fundamentally different angle on metabolic research than GLP-1 receptor approaches.

What Is 5-Amino-1MQ?

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small molecule \u2014 not technically a peptide, but commonly sold alongside them in research compound catalogs due to its metabolic research applications. It has a molecular weight of approximately 159 Da and functions as a selective inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT).

5-Amino-1MQ was developed as a research tool to probe the role of NNMT in metabolic disease. Its structure is based on the nicotinamide scaffold \u2014 the core of vitamin B3 \u2014 which allows it to compete with nicotinamide for the NNMT enzyme\u2019s active site.

While GLP-1 receptor agonists (like semaglutide) have dominated metabolic research headlines by targeting appetite and insulin signaling, 5-Amino-1MQ takes a completely different approach: intervening at the level of cellular energy metabolism and methylation chemistry.

Kraus D et al. "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity." Nature. 2014;508(7495):258-62. PMID: 24717441

Understanding NNMT

Nicotinamide N-methyltransferase (NNMT) is an enzyme that catalyzes the N-methylation of nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. The product is 1-methylnicotinamide (1-MNA), which is then excreted.

In normal physiology, NNMT plays a housekeeping role in clearing excess nicotinamide. However, in metabolic disease, NNMT becomes pathologically overexpressed \u2014 particularly in white adipose tissue (WAT), but also in liver, muscle, and certain tumors.

The NNMT-Metabolism Connection

When NNMT is overexpressed, it creates a cascade of metabolic disruptions:

Key Finding

NNMT overexpression depletes the NAD+ salvage pathway by consuming nicotinamide (a key NAD+ precursor) and converting it to the excreted metabolite 1-methylnicotinamide. Simultaneously, it depletes SAM \u2014 the universal methyl donor \u2014 disrupting methylation patterns that regulate gene expression, including genes controlling adipocyte differentiation and energy expenditure. The net effect: reduced cellular NAD+ levels, altered epigenetic programming, and a cellular environment that favors fat storage over energy expenditure.

The NAD+ Connection

NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme involved in hundreds of metabolic reactions, including those in the electron transport chain (mitochondrial energy production), sirtuins (metabolic regulators), and PARPs (DNA repair enzymes).

The NAD+ salvage pathway \u2014 in which nicotinamide is recycled back to NAD+ by the enzyme NAMPT \u2014 is the primary mechanism by which cells maintain their NAD+ pool. When NNMT diverts nicotinamide away from this salvage pathway and into methylation/excretion, it effectively drains the cellular NAD+ reservoir.

This has downstream consequences:

Reduced sirtuin activity: Sirtuins (SIRT1-7) are NAD+-dependent enzymes that regulate metabolism, mitochondrial function, and inflammation. Lower NAD+ means lower sirtuin activity.

Impaired mitochondrial function: NAD+ is essential for oxidative phosphorylation. Depletion reduces ATP production and metabolic flexibility \u2014 the ability to switch between glucose and fat oxidation.

Altered circadian regulation: NAD+ metabolism is intertwined with circadian clock genes. Disruption can further destabilize metabolic rhythms.

How 5-Amino-1MQ Inhibits NNMT

5-Amino-1MQ acts as a competitive inhibitor of NNMT. It binds to the enzyme\u2019s active site, competing with nicotinamide for the catalytic pocket. By occupying this site, it prevents NNMT from methylating nicotinamide \u2014 keeping nicotinamide available for the NAD+ salvage pathway.

The downstream effects of NNMT inhibition, as observed in preclinical models, include:

Restored NAD+ levels: By blocking NNMT-mediated nicotinamide consumption, cellular NAD+ pools are preserved or increased.

Enhanced energy expenditure: With NAD+ restored, mitochondrial function improves and metabolic rate increases.

Reduced white adipose tissue mass: NNMT inhibition in WAT shifts the balance from fat storage toward fat oxidation.

Improved insulin sensitivity: Preclinical models show improved glucose handling with NNMT inhibition.

Preclinical Research

Diet-Induced Obesity Models

The landmark 2014 study by Kraus et al., published in Nature, demonstrated that NNMT knockdown in adipose tissue protected mice against diet-induced obesity. Treated animals showed reduced body weight, decreased fat mass, and improved metabolic parameters \u2014 despite consuming the same high-fat diet as controls.

Subsequent research with 5-Amino-1MQ as a pharmacological NNMT inhibitor has replicated these findings, showing:

Reductions in body weight and fat mass in obese mouse models. Increases in energy expenditure and oxygen consumption (VO\u2082). Improvements in glucose tolerance and insulin sensitivity. Reductions in inflammatory markers in adipose tissue.

Muscle and Liver Research

Beyond adipose tissue, NNMT is being studied in skeletal muscle (where it may impair oxidative metabolism) and liver (where it may contribute to non-alcoholic fatty liver disease). 5-Amino-1MQ research in these tissues is in earlier stages but conceptually parallel to the adipose findings.

Ulanovskaya OA et al. "NNMT expression contributes to the methylation and NAD+ metabolism." Cell Chemical Biology. 2016;24(1):1-10. PMID: 27984015

A Different Angle from GLP-1 Approaches

Approach	5-Amino-1MQ (NNMT inhibition)	GLP-1 Receptor Agonists
Primary target	NNMT enzyme in adipose tissue	GLP-1 receptor in pancreas/brain
Mechanism	Restores NAD+ metabolism, enhances energy expenditure	Increases insulin secretion, reduces appetite
Effect on appetite	Minimal direct effect	Strong appetite suppression
Effect on energy expenditure	Increase (via mitochondrial function)	Minimal direct effect
Tissue specificity	White adipose tissue, muscle, liver	Pancreas, brain, GI tract
Molecular class	Small molecule	Peptide / peptide analog

The comparison highlights that 5-Amino-1MQ and GLP-1 agonists operate on fundamentally different metabolic pathways. They are not competitors \u2014 they address different aspects of metabolic dysfunction. This is why they are sometimes discussed as complementary in research Stack configurations.

Current Limitations and Research Gaps

No human clinical trials: All existing data is from cell culture and animal models. No randomized controlled trials in humans have been published.

Selectivity concerns: While 5-Amino-1MQ is described as a selective NNMT inhibitor, the degree of selectivity over other methyltransferases using SAM as a substrate requires further characterization.

Dose optimization: Optimal dosing, frequency, and duration for NNMT inhibition in humans are unknown.

Tissue distribution: The extent to which orally administered 5-Amino-1MQ reaches relevant tissues (WAT, muscle, liver) at therapeutically relevant concentrations is not fully established.

Long-term safety: Chronic NNMT inhibition could theoretically affect nicotinamide clearance and methyl donor balance. Long-term safety data is not available.

Not a peptide: 5-Amino-1MQ is a small molecule, not a peptide. Its inclusion in research compound catalogs alongside peptides reflects its metabolic research relevance rather than structural classification.

Frequently Asked Questions

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small molecule with a molecular weight of approximately 159 Da. It is not a peptide but is commonly sold alongside peptides due to its relevance in metabolic research.

What is NNMT?

Nicotinamide N-methyltransferase (NNMT) is an enzyme that methylates nicotinamide (vitamin B3) using SAM as a methyl donor. When overexpressed \u2014 particularly in white adipose tissue \u2014 it depletes NAD+ precursors and disrupts methylation patterns, contributing to metabolic dysfunction.

How does 5-Amino-1MQ work?

It competitively inhibits NNMT by binding to the enzyme\u2019s active site, preventing the methylation of nicotinamide. This preserves nicotinamide for the NAD+ salvage pathway, restoring cellular NAD+ levels and improving mitochondrial function and energy expenditure.

How is 5-Amino-1MQ different from GLP-1 agonists?

GLP-1 agonists target appetite suppression and insulin secretion through the GLP-1 receptor. 5-Amino-1MQ targets NAD+ metabolism and energy expenditure through NNMT inhibition. They work on completely different pathways and are not competitive alternatives.

What is the connection between NNMT and NAD+?

NNMT consumes nicotinamide \u2014 a key NAD+ precursor \u2014 and converts it to 1-methylnicotinamide, which is excreted. When NNMT is overexpressed, it drains the NAD+ salvage pathway, reducing cellular NAD+ levels and impairing sirtuin activity, mitochondrial function, and metabolic flexibility.

Has 5-Amino-1MQ been tested in humans?

No. All efficacy data comes from cell culture and animal models. No randomized controlled trials in humans have been published as of the current literature.

Does 5-Amino-1MQ affect appetite?

Not directly. Unlike GLP-1 agonists that act on brain appetite centers, 5-Amino-1MQ works at the cellular metabolic level \u2014 improving energy expenditure and fat oxidation rather than suppressing hunger signaling.

Is 5-Amino-1MQ safe?

Preclinical safety data is limited. Chronic NNMT inhibition could theoretically affect nicotinamide clearance and methyl donor balance. No human safety data from controlled studies is available.

Explore 5-Amino-1MQ for Your Research

5-Amino-1MQ is available for qualified research applications. View specifications, purity, and sourcing information.

View 5-Amino-1MQ Product \u2192

Disclaimer: This article is for informational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. 5-Amino-1MQ is sold as a research compound and is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before beginning any new research protocol.

View full research at Choice Peptide Labs → See the product →

AOD-9604: The hGH Fragment Studied in Metabolic Research

The Fragment · Metabolic & GLP-1

AOD-9604 is a 16-amino acid modified fragment of human growth hormone (positions 176–191) that retains hGH's fat-metabolism signaling while eliminating its growth-promoting and insulin-resistance effects. It represents one of the most successful applications of the "functional fragment" approach in peptide research.

What Is AOD-9604?

AOD-9604 is a modified C-terminal fragment of human growth hormone (hGH), encompassing amino acid positions 176–191. The original hGH molecule is 191 amino acids long; AOD-9604 captures just the final 16 residues with a tyrosine substitution at position 176 (hence "AOD" — Anti-Obesity Drug).

The peptide was originally developed by researchers at Monash University in Australia. The central hypothesis was elegant: different regions of the hGH molecule mediate different biological functions. The C-terminal region (176–191) was identified as responsible for fat metabolism signaling, while growth promotion and insulin resistance were linked to other regions of the hormone.

By isolating and slightly modifying just the fat-metabolism fragment, researchers aimed to create a compound that could influence lipolysis and lipogenesis without the side effects associated with full hGH therapy — namely acromegaly risk, insulin resistance, and tumor growth concerns.

Ng FM et al. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Horm Res. 2000;53(4):173-8. PMID: 10971096

Mechanism of Action

AOD-9604's mechanism diverges from that of full hGH in several important ways:

Fat Metabolism Signaling

AOD-9604 stimulates lipolysis (the breakdown of stored triglycerides into free fatty acids and glycerol) and inhibits lipogenesis (the conversion of dietary carbohydrates into fat for storage). These are the same two metabolic actions that make hGH attractive in body composition research — but AOD-9604 achieves them through a different receptor pathway.

Key Finding

AOD-9604 does not activate the growth hormone receptor (GHR) and does not stimulate IGF-1 production. Its fat metabolism effects appear to be mediated through a beta-3 adrenergic pathway — specifically, by modulating signaling through beta-3 adrenergic receptors on adipocytes. This is the same receptor pathway involved in brown fat thermogenesis and is distinct from hGH's somatogenic (growth) signaling.

This separation of function is the core innovation. Full hGH therapy produces fat loss as one of many effects — alongside increased IGF-1, growth of bones and soft tissue, insulin resistance, and potential mitogenic (tumor-promoting) activity. AOD-9604 strips away everything except the fat metabolism signal.

No Growth Hormone Receptor Activation

Because AOD-9604 is only 16 amino acids — far smaller than the 191-amino acid hGH — it cannot bind and dimerize the growth hormone receptor the way the full hormone does. This means:

No IGF-1 elevation: Full hGH stimulates hepatic IGF-1 production, which drives tissue growth and has mitogenic implications. AOD-9604 does not.

No insulin resistance: hGH has well-documented diabetogenic effects, impairing insulin sensitivity at higher doses. AOD-9604 has not shown this property in preclinical testing.

No growth-promoting effects: Bone growth, organ enlargement, and soft tissue proliferation — risks of exogenous hGH — are not associated with the 176–191 fragment.

Preclinical Research: Lipolysis and Lipogenesis

The primary body of AOD-9604 research focuses on fat metabolism in preclinical models:

Animal Models

In diet-induced obese (DIO) rodent models, AOD-9604 administration produced significant reductions in body fat mass without changes in lean body mass, food intake, or IGF-1 levels. The fat loss was preferentially from visceral adipose depots — the metabolically dangerous fat surrounding internal organs.

Importantly, the reduction in fat mass was not accompanied by the insulin resistance that typically accompanies hGH administration. In some studies, AOD-9604 actually showed modest improvements in glucose handling.

Stierl R et al. "Reduction in body weight and body fat mass with AOD9604." Presented at the 85th Annual Meeting of the Endocrine Society. 2003.

Cell Culture Studies

In vitro studies on adipocytes (fat cells) demonstrate that AOD-9604 directly promotes lipolytic activity — the enzymatic breakdown of stored triglycerides via hormone-sensitive lipase activation. Simultaneously, it inhibits the lipogenic pathway, reducing the conversion of glucose to fatty acids for storage.

This dual action (break down existing fat + prevent new fat storage) mirrors the metabolic profile of hGH but through a distinct receptor pathway.

The "Fragment Approach" — A Research Paradigm

AOD-9604 exemplifies a broader strategy in peptide research: identifying functional fragments within larger signaling molecules. By isolating specific domains responsible for desired effects, researchers can potentially separate therapeutic activity from adverse effects.

Parallel: ARA-290 and EPO

A similar logic drives research on ARA-290, an 11-amino acid peptide derived from the helix B surface of erythropoietin (EPO). EPO has potent tissue-protective and anti-inflammatory properties beyond its well-known role in red blood cell production — but it also elevates hematocrit, increasing blood viscosity and clot risk. ARA-290 retains EPO's tissue-protective signaling (through the innate repair receptor, IRR) without stimulating erythropoiesis.

The pattern is the same: take a large, multifunctional molecule → identify the domain responsible for the desired function → isolate and modify that fragment → eliminate the side effects of the parent compound.

Cartilage Repair Research

Emerging preclinical data has explored AOD-9604's potential in cartilage repair and osteoarthritis models. In vitro studies have shown that AOD-9604 can stimulate chondrocyte (cartilage cell) proliferation and extracellular matrix production, suggesting possible applications beyond metabolic research.

This is consistent with the broader observation that hGH fragments can have tissue-specific proliferative effects in connective tissues, even when they don't activate the classical growth hormone receptor pathway.

However, this area of research is in its early stages, and no clinical data supports cartilage-related applications at this time.

AOD-9604 vs. Full hGH

Property	AOD-9604	Full hGH
Size	16 amino acids (modified)	191 amino acids
Fat metabolism (lipolysis/lipogenesis inhibition)	Yes	Yes
Growth hormone receptor activation	No	Yes
IGF-1 elevation	No	Yes
Insulin resistance risk	No (preclinical)	Yes — dose dependent
Growth-promoting effects	No	Yes
Mitogenic/tumor risk	No evidence	Theoretical concern
Receptor pathway	Beta-3 adrenergic	Growth hormone receptor (GHR)

Current Limitations and Research Gaps

No human RCTs: Despite its initial development as a pharmaceutical candidate (it was originally designated as a drug by Metabolic Pharmaceuticals), AOD-9604 has not completed large-scale randomized controlled trials in humans. Phase I safety data was generated, but Phase II/III efficacy trials were not completed for its obesity indication.

Mechanism not fully characterized: While the beta-3 adrenergic pathway is implicated, the precise molecular mechanism by which AOD-9604 mediates fat metabolism is not as well understood as hGH's classical receptor signaling.

Dose-response uncertainty: Optimal dosing for metabolic effects in humans is not established from controlled trials.

Oral bioavailability: Like most peptides, AOD-9604 is subject to gastrointestinal degradation. Preclinical studies have used subcutaneous administration, and oral bioavailability data is limited.

Long-term safety: While AOD-9604 is designed to avoid hGH-related risks, long-term safety data from controlled studies is not available.

Frequently Asked Questions

What does AOD-9604 stand for?

AOD stands for "Anti-Obesity Drug." The 9604 is a compound identifier. It was originally developed at Monash University as a potential anti-obesity pharmaceutical based on the fat-metabolism domain of human growth hormone.

How is AOD-9604 different from hGH?

AOD-9604 is a 16-amino acid fragment of hGH (positions 176-191) that retains fat metabolism signaling but does not activate the growth hormone receptor. It does not elevate IGF-1, cause insulin resistance, or produce growth-promoting effects.

What receptor does AOD-9604 use?

AOD-9604's fat metabolism effects appear to be mediated through the beta-3 adrenergic receptor pathway on adipocytes, rather than the growth hormone receptor. This is the same receptor family involved in brown adipose tissue thermogenesis.

Does AOD-9604 cause insulin resistance?

No. Unlike full hGH, AOD-9604 has not shown insulin-resistance effects in preclinical models. Some studies have actually noted modest improvements in glucose handling.

Has AOD-9604 been tested in humans?

Phase I safety data was generated during its pharmaceutical development by Metabolic Pharmaceuticals/Metabolic. However, large-scale Phase II/III randomized controlled trials for efficacy were not completed.

What is the "fragment approach" in peptide research?

It refers to isolating specific functional domains from larger signaling molecules to retain desired effects while eliminating adverse ones. AOD-9604 (from hGH) and ARA-290 (from EPO) are two prominent examples of this strategy.

Can AOD-9604 help with cartilage repair?

Emerging preclinical data shows AOD-9604 can stimulate chondrocyte proliferation and matrix production in vitro. However, this research is in early stages with no clinical data supporting cartilage-related applications.

How is AOD-9604 administered?

Preclinical studies have primarily used subcutaneous injection. Oral bioavailability is limited due to gastrointestinal peptide degradation. Optimal human administration routes are not established from controlled trials.

Explore AOD-9604 for Your Research

AOD-9604 is available in lyophilized form for qualified research applications. View specifications, purity data, and sourcing information.

View AOD-9604 Product →

Disclaimer: This article is for informational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. AOD-9604 is sold as a research peptide and is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before beginning any new research protocol.

ARA-290 (Cibinetide): What Researchers Are Learning About This Tissue-Protective Peptide

📅 June 2026 ⏱️ 12 min read 📚 5+ sources cited

What if a peptide could capture the tissue-protective benefits of erythropoietin without stimulating red blood cell production? That's the question that led Dr. Michael Brines and colleagues at Araim Pharmaceuticals to develop ARA-290 — an 11-amino acid peptide derived from the helix B surface of erythropoietin (EPO). Known by its official pharmaceutical name cibinetide, ARA-290 represents a new class of tissue-protective compounds that researchers are studying for nerve regeneration, inflammation, and metabolic protection.

Unlike full-length EPO, ARA-290 doesn't bind the classical EPO receptor responsible for erythropoiesis. Instead, it activates a distinct receptor complex — the innate repair receptor (IRR) — that's only expressed on injured or stressed tissue. This selectivity is what makes ARA-290 uniquely interesting to researchers.

What: 11-amino acid peptide derived from EPO helix B surface
Official Name: Cibinetide (PubChem CID: 91810664)
Mechanism: Activates the innate repair receptor (EPOR/CD131 heteromer)
Key Differentiator: Tissue protection without hematocrit elevation
Clinical Status: Phase 2 trials completed; not FDA approved

How ARA-290 Works: The Innate Repair Receptor

To understand ARA-290, you need to understand the receptor it targets. The innate repair receptor (IRR) is a heteromeric complex formed by the classical EPO receptor (EPOR) paired with CD131 (also known as the β-common receptor). This is fundamentally different from the EPOR homodimer — two identical EPOR subunits — that mediates EPO's erythropoietic (red blood cell–stimulating) effects.

The IRR is not constitutively expressed on most tissues. Instead, it appears on cells at sites of injury, inflammation, or metabolic stress. When ARA-290 binds this receptor, it triggers a cascade of protective and reparative responses:

Anti-inflammatory signaling: Reduces production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β
Cell survival pathways: Activates PI3K/Akt and MAPK signaling, promoting cell survival under stress
Macrophage polarization: Shifts macrophage phenotype from pro-inflammatory (M1) to anti-inflammatory/reparative (M2)
Nerve regeneration: Promotes small fiber nerve regeneration and repair
Microcirculation improvement: Enhances blood flow and vascular function in damaged tissues

Critically, ARA-290 achieves these effects without raising hematocrit or stimulating red blood cell production. This is the key differentiator from EPO and its analogues, which carry risks of polycythemia, hypertension, and thrombotic events when used for tissue protection.

📄 Sources

Brines M, Cerami A — Trends in Molecular Medicine | Innate repair receptor characterization and signaling
FASEB Journal — IRR-mediated tissue protection mechanisms

What the Research Shows

Diabetic Peripheral Neuropathy

The most advanced clinical research on ARA-290 has focused on diabetic peripheral neuropathy (DPN) — a common and debilitating complication of diabetes that affects sensory nerves, causing pain, numbness, and loss of sensation.

In Phase 2 clinical trials, researchers administered ARA-290 at 4 mg subcutaneously daily for 28 days. The results showed:

Improved pain scores: Significant reductions in neuropathic pain compared to baseline
Enhanced sensation thresholds: Measurable improvements in sensory function testing
Small fiber density regeneration: Skin biopsy data revealed increases in intraepidermal nerve fiber density (IENFD) — an objective histological measure of nerve regeneration

The IENFD finding is particularly notable because it demonstrates actual structural nerve repair, not just symptomatic relief. Small fiber regeneration is extremely difficult to achieve with existing treatments, making this result significant in the neuropathy research community.

📄 Clinical Trial

ClinicalTrials.gov NCT02039687 — ARA-290 Phase 2 trial in painful diabetic neuropathy
Brines M et al. — Phase 2 trial publications on cibinetide

Sarcoidosis-Associated Small Fiber Neuropathy

Sarcoidosis is an inflammatory disease that can damage small nerve fibers throughout the body. ARA-290 has been studied in this population through both pilot and Phase 2b trials:

Pilot study: 22 patients received 2 mg intravenously three times per week for 4 weeks
Phase 2b trial: Evaluated three dose levels (1 mg, 4 mg, and 8 mg subcutaneously daily for 28 days)

The standout finding came from the 4 mg dose group, which showed increases in corneal nerve fiber density measured by in vivo confocal microscopy. The cornea is densely innervated and accessible to non-invasive imaging, making it an increasingly valuable biomarker for small fiber status throughout the body.

In the Phase 2b sarcoidosis trial, the 4 mg dose group demonstrated measurable increases in corneal nerve fiber length and branch density
Corneal confocal microscopy provides a non-invasive, reproducible measure of small fiber status
Results suggest ARA-290 may promote structural nerve repair beyond symptom management

Emerging Research Areas

Beyond neuropathy, researchers are exploring ARA-290's potential in several other domains:

Autoimmune conditions: The IRR's immunomodulatory effects, particularly macrophage M1→M2 polarization, suggest utility in autoimmune-driven inflammation
Metabolic protection: Preclinical data shows ARA-290 may protect pancreatic beta cells from damage, with implications for diabetes prevention and treatment
Neuropsychiatric applications: Neuroprotective and anti-inflammatory properties are being investigated in conditions involving neuroinflammation
Aging and longevity: A 2023 publication in GeroScience explored the role of IRR activation in age-related tissue decline and regenerative capacity

📄 Emerging Research

PMC9889362 — GeroScience, 2023 — Aging-related tissue protection and the innate repair receptor
Trends in Molecular Medicine — Tissue-protective cytokines beyond erythropoiesis

Safety Profile

Across completed clinical trials, ARA-290 has demonstrated a favorable safety profile:

Well tolerated across all tested dose ranges with no dose-limiting toxicities identified
Mild adverse events: Injection site reactions were the most commonly reported; fatigue and headache were uncommon
No hematocrit elevation: Confirming the peptide's selectivity for the IRR over the classical EPOR homodimer
No thrombotic events observed: A significant advantage over EPO-based therapies, which carry cardiovascular risks

The absence of hematological effects is perhaps the most important safety feature, as it directly validates the mechanistic rationale for developing ARA-290 in the first place — tissue protection without erythropoiesis.

How ARA-290 Compares to Other Research Peptides

ARA-290 is one of several peptides being investigated for tissue protection and regeneration. Here's how it compares to other compounds in this space:

ARA-290 (Cibinetide): Activates innate repair receptor (IRR) → anti-inflammatory, nerve regeneration, microcirculation improvement | Phase 2 trials in neuropathy
BPC-157: Promotes angiogenesis, gut healing, and tendon repair via multiple pathways | Strong preclinical animal data; limited human trials
SS-31 (Elamipretide): Targets mitochondrial cardiolipin → stabilizes mitochondrial membranes, reduces oxidative stress | Phase 2/3 trials in cardiac and mitochondrial diseases
TB-500 (Thymosin β4): Promotes cell migration, wound healing, and tissue recovery via actin regulation | Preclinical data; some human observational studies

Each peptide operates through distinct mechanisms and targets different aspects of tissue protection and repair. ARA-290's unique strength lies in its receptor specificity — targeting only injured tissue via the IRR — and its progression into controlled human clinical trials with objective histological endpoints.

The Discovery Story

The story of ARA-290 begins in 2008, when Dr. Michael Brines and colleagues made a crucial observation: the tissue-protective effects of erythropoietin could be separated from its red blood cell–stimulating activity.

Through careful structure-function analysis, they identified that the helix B surface of the EPO molecule was responsible for engaging tissue-protective pathways — while the erythropoietic effects required a completely different binding interface. By isolating an 11-amino acid sequence from this helix B surface, they created a peptide that could activate the IRR without touching the classical EPO receptor homodimer.

Araim Pharmaceuticals was founded to develop this discovery into a therapeutic candidate. The compound was designated cibinetide as its official International Nonproprietary Name (INN) and advanced through preclinical development into human clinical trials. The pharmaceutical name ARA-290 reflects the company's internal development designation.

This discovery opened an entirely new field of research: tissue-protective cytokines that work through the innate repair receptor rather than through classical hematopoietic signaling.

What's Next for ARA-290

ARA-290 is currently not FDA approved for any indication. Phase 2 clinical trials have been completed, and the research community is watching for next steps. Key questions going forward include:

Dose optimization: While 4 mg emerged as a promising dose in neuropathy trials, optimal dosing for different conditions and patient populations needs further study
Cycle timing: Can shorter or intermittent treatment courses produce sustained benefits? What's the ideal treatment duration?
Broader applications: Will the anti-inflammatory and tissue-protective effects translate to autoimmune, metabolic, or aging-related conditions?
Long-term durability: Do regenerated nerve fibers persist after treatment cessation? Are repeated courses needed?
Phase 3 trials: Large-scale, placebo-controlled trials will be necessary to establish efficacy for potential regulatory approval

The preclinical data and Phase 2 results provide a strong scientific foundation, but significant research remains before ARA-290 could become a widely available therapeutic option.

Frequently Asked Questions

What is ARA-290? +

ARA-290 is an 11-amino acid peptide derived from the helix B surface of erythropoietin (EPO). It was developed by Araim Pharmaceuticals to activate the innate repair receptor (IRR) — a receptor complex expressed on injured tissue — without stimulating red blood cell production. ARA-290 is also known by its official pharmaceutical name, cibinetide. It is being researched for its anti-inflammatory, tissue-protective, and nerve-regenerating properties.

How does ARA-290 differ from EPO? +

While EPO stimulates red blood cell production by binding the EPOR homodimer (two identical EPO receptor subunits), ARA-290 selectively activates the innate repair receptor (IRR), which is a heteromer of EPOR and CD131. The IRR is only expressed on injured or stressed tissue. This means ARA-290 produces tissue-protective effects — anti-inflammation, cell survival, nerve regeneration — without the hematological side effects of EPO, such as elevated hematocrit, polycythemia, or increased thrombotic risk.

What is the innate repair receptor? +

The innate repair receptor (IRR) is a heteromeric receptor complex composed of the erythropoietin receptor (EPOR) paired with CD131 (the β-common receptor). Unlike the EPOR homodimer responsible for red blood cell production, the IRR is not constitutively expressed on most tissues. It becomes upregulated at sites of injury, inflammation, or metabolic stress. When activated, it triggers anti-inflammatory, cytoprotective, and reparative signaling pathways including PI3K/Akt and MAPK activation.

Has ARA-290 been studied in humans? +

Yes. ARA-290 has been studied in multiple human clinical trials. Phase 2 trials in diabetic peripheral neuropathy used 4 mg subcutaneously daily for 28 days and showed improvements in pain scores, sensation thresholds, and small fiber density on skin biopsy. A pilot study (22 patients) and Phase 2b trial have been conducted in sarcoidosis-associated small fiber neuropathy. The peptide has been well tolerated with a favorable safety profile across these trials.

What conditions has ARA-290 been researched for? +

ARA-290 has been most extensively studied for neuropathic conditions, including diabetic peripheral neuropathy and sarcoidosis-associated small fiber neuropathy. Emerging research is exploring its potential in autoimmune conditions (via immunomodulation), metabolic diseases (beta cell protection in diabetes), neuropsychiatric conditions (neuroinflammation), and aging-related tissue decline. The peptide's mechanism — activating the IRR expressed on injured tissue — gives it broad potential applicability.

What is cibinetide? +

Cibinetide is the official International Nonproprietary Name (INN) for ARA-290. It is the same 11-amino acid peptide derived from the helix B surface of erythropoietin. "ARA-290" is the development designation used by Araim Pharmaceuticals, while "cibinetide" is the standardized pharmaceutical name used in clinical trial registrations and regulatory contexts. You may see both names used interchangeably in the scientific literature.

Does ARA-290 affect red blood cells? +

No. This is one of the most important features of ARA-290. Because it selectively activates the IRR (EPOR/CD131 heteromer) rather than the classical EPOR homodimer responsible for erythropoiesis, ARA-290 does not stimulate red blood cell production. Clinical trial data confirm no hematocrit elevation and no increase in red blood cell counts. This eliminates the risks of polycythemia, hypertension, and thrombotic events associated with EPO-based therapies.

Is ARA-290 FDA approved? +

No. As of June 2026, ARA-290 (cibinetide) is not FDA approved for any indication. It has completed Phase 2 clinical trials in diabetic neuropathy and sarcoidosis-associated small fiber neuropathy. ARA-290 remains a research compound available for laboratory and clinical study purposes. It is not approved for therapeutic use, and any use outside of controlled research settings is not recommended.

🔬 Explore Research Peptides from Choice Peptide Labs

Looking for high-quality research peptides? Choice Peptide Labs provides rigorously tested compounds for laboratory research applications.

Browse Research Peptides →

📚 Sources Cited

1. ClinicalTrials.gov NCT02039687 — Phase 2 trial in diabetic neuropathy
2. PubChem CID 91810664 — Cibinetide chemical and structural data
3. PMC9889362 — GeroScience 2023, aging and tissue protection
4. FASEB Journal — IRR characterization and signaling pathways
5. Trends in Molecular Medicine — Tissue-protective cytokines review
6. Brines M et al. — Phase 2 trial publications on cibinetide

Disclaimer: This article is for research and educational purposes only. ARA-290 (cibinetide) is not FDA approved and has not been evaluated by the Food and Drug Administration for safety or efficacy in treating any medical condition. The information presented here is based on published research and clinical trial data and should not be interpreted as medical advice. This compound is intended for laboratory research use only. Always consult with a qualified healthcare professional before making any health-related decisions.

What Is BPC-157? A Research-Backed Guide to Body Protection Compound

📖 14 min read 🔬 544 published papers reviewed 📅 June 2026

BPC-157 may have the largest preclinical evidence base of any peptide not currently approved as a medication. Over 544 published papers spanning three decades have investigated this 15-amino acid compound across gut protection, tissue repair, vascular biology, and neurological function. Here's what the research actually shows.

544

Published Papers

30+

Years of Research

15

Amino Acids

What Exactly Is BPC-157?

BPC stands for Body Protection Compound. BPC-157 is a 15-amino acid peptide fragment originally isolated from a protein found in human gastric juice — the digestive fluid in your stomach.

It was first studied in the context of gastrointestinal protection — hence the name. Researchers discovered that this small peptide appeared to play a role in protecting the stomach and intestinal lining from damage.

But the research didn't stop at the gut. Over the following three decades, BPC-157 was studied in tendon, ligament, nerve, muscle, bone, and vascular repair models — with consistently positive findings across every tissue type tested.

"More than 200 published studies have investigated BPC-157 for tissue repair, gut healing, and inflammation, and the results in animal models are consistently positive across every tissue type tested. That is one of the largest and most consistent animal research bases of any peptide not approved as a medicine."

📚 Source: Peptide Science Institute — BPC-157 Research Assessment. PSI

The Nitric Oxide Connection: How BPC-157 Works

BPC-157 doesn't act through a single, well-defined receptor. Published research suggests it operates through multiple overlapping mechanisms — which may explain why it shows effects across such diverse tissue types.

Nitric Oxide (NO) System Modulation

The most extensively studied mechanism involves the nitric oxide (NO) system. Research primarily from the Sikiric group at the University of Zagreb has demonstrated that BPC-157 interacts with the NO signaling pathway through two converging routes:

VEGFR2-Akt-eNOS pathway: BPC-157 activates vascular endothelial growth factor receptor 2 (VEGFR2), which triggers PI3K/Akt phosphorylation of endothelial nitric oxide synthase (eNOS) — the enzyme that produces nitric oxide in blood vessel walls.
Src-Caveolin-1-eNOS pathway: BPC-157 also operates through Src kinases and Caveolin-1, releasing eNOS from its inhibited state. Both pathways converge on enhanced NO production.

Why does this matter? Nitric oxide is a critical signaling molecule in the body. It regulates blood vessel dilation, blood flow, inflammation, and the formation of new blood vessels (angiogenesis). By modulating the NO system, BPC-157 affects vascular integrity and tissue repair at a fundamental level.

📚 Source: Hsieh, M.J., et al. "Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway." Scientific Reports (Nature), 10, 17078. Nature

📚 Source: Chang, C.H., et al. "BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide." Pharmaceuticals, 18(10), 1450. MDPI

What the Published Research Shows

A 2025 systematic review published in the Journal of Orthopaedic Research analyzed 544 articles from 1993 to 2024. After removing duplicates, 36 studies met inclusion criteria — 35 preclinical and 1 clinical. Here's what they consistently found:

Gastrointestinal Cytoprotection

BPC-157 was originally studied for protecting the gastric mucosa — the stomach and intestinal lining
Multiple studies examined effects on ulcer formation, NSAID-induced damage, and intestinal permeability (often called "leaky gut")
Researchers documented faster mucosal healing and reduced ulcer severity in preclinical models
The peptide's origin in gastric juice suggests a natural role in gut-protective biology

Tendon and Ligament Repair

Preclinical models showed faster healing and stronger tissue formation in transected tendons
BPC-157-treated groups demonstrated improved collagen organization and mechanical strength at repair sites
Studies examined both Achilles tendon and medial collateral ligament models

Vascular Repair and Angiogenesis

Through the NO system, BPC-157 promotes new blood vessel formation at injury sites
Studies documented improved vascular integrity in ischemic (blood-deprived) tissue models
The VEGFR2-Akt-eNOS pathway activation supports endothelial cell function and vascular remodeling

Nerve and Neurological Function

Published studies examined BPC-157 in nerve crush injury models and traumatic brain injury models
Researchers documented improved functional recovery and reduced neural inflammation in animal studies
The proposed mechanism involves both direct neuroprotective effects and improved blood supply to damaged neural tissue

Growth Hormone Receptor Expression

The 2025 systematic review found BPC-157 enhances growth hormone receptor expression
It activates multiple pathways involved in cell growth and angiogenesis
This mechanism may partially explain why BPC-157 shows effects across so many different tissue types

📚 Source: "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." Journal of Orthopaedic Research (SAGE), 2025. SAGE Journals

Beyond the Gut: Why BPC-157 Is Studied in So Many Tissue Types

The fact that a peptide discovered in stomach fluid shows effects on tendons, nerves, blood vessels, and muscle is unusual. Most peptides have a specific receptor and a specific tissue where they primarily act.

BPC-157 is different. Published research suggests it operates through fundamental cellular processes rather than tissue-specific pathways:

NO system modulation affects virtually every tissue in the body, because nitric oxide regulates blood flow and vascular integrity everywhere
Growth hormone receptor enhancement is a systemic effect — not confined to one organ system
Angiogenesis promotion benefits any tissue that needs improved blood supply during repair
Anti-inflammatory signaling reduces damage across multiple tissue types simultaneously

This mechanism profile — systemic rather than tissue-specific — is likely why the research base expanded so rapidly from gastric studies into orthopedic, neurological, and cardiovascular research.

Important Context: Preclinical vs. Clinical Evidence

This is where intellectual honesty matters. Of the 544 published papers on BPC-157:

The vast majority are preclinical — meaning they were conducted in animal models (primarily rats) and cell culture systems
Only approximately 30 human subjects have ever been studied in published research
35 of the 36 studies in the 2025 systematic review were preclinical
BPC-157 is not FDA-approved for any medical use

The consistency and breadth of preclinical findings are remarkable — few compounds show positive results across this many tissue types. But preclinical findings in animal models do not automatically translate to human outcomes. That's a limitation that applies to all preclinical research, and it's important to state clearly.

"BPC-157 has 544 published papers and massive internet hype. But only ~30 humans have ever been studied. Here is what the research actually shows, and what it doesn't."

📚 Source: "The Real BPC-157 Story: 544 Papers, 30 Human Subjects, 50 Million Views." Rethink Peptides. Read

BPC-157 and the NO System: A Deeper Look

The nitric oxide connection deserves more detail because it's central to understanding why BPC-157 has such broad effects.

What Nitric Oxide Actually Does

Nitric oxide (NO) is a gas molecule produced by your body that acts as a signaling compound. It's produced by the enzyme eNOS (endothelial nitric oxide synthase) in the walls of blood vessels. Here's what it controls:

Vasodilation — NO relaxes blood vessel walls, increasing blood flow to tissues
Angiogenesis — NO signaling drives the formation of new blood vessels during repair
Inflammation regulation — Appropriate NO levels help resolve inflammation rather than allowing it to become chronic
Platelet function — NO prevents excessive platelet aggregation (clotting) at injury sites

When BPC-157 enhances eNOS activity through both the VEGFR2-Akt and Src-Caveolin-1 pathways, it essentially upregulates the body's own vascular repair system. This is not a foreign mechanism — it's amplifying a process the body already uses.

The Convergent Pathway Model

What makes BPC-157's NO interaction unique is the convergent model: two independent signaling pathways both enhance eNOS activity. If one pathway is impaired or blocked, the other can still produce the effect. This redundancy may explain why BPC-157 shows consistent results across diverse experimental conditions.

Frequently Asked Questions About BPC-157

What does BPC-157 stand for?

BPC stands for "Body Protection Compound." It was named for its observed protective effects on the gastrointestinal system. The "157" is a designation number. BPC-157 is a 15-amino acid fragment of the larger BPC protein found in human gastric juice.

How many studies have been done on BPC-157?

Over 544 published papers from 1993 to 2024 have investigated BPC-157. A 2025 systematic review analyzed 36 of these studies that met inclusion criteria. The vast majority are preclinical (animal and cell culture studies), with approximately 30 total human subjects studied across the published literature.

How does BPC-157 work?

Published research suggests BPC-157 works primarily through nitric oxide (NO) system modulation via two converging pathways: VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS. It also enhances growth hormone receptor expression. These systemic mechanisms — rather than a single tissue-specific pathway — likely explain its broad effects across different tissue types.

Is BPC-157 the same as other peptides like TB-500?

No. BPC-157 and TB-500 are studied in similar research areas (tissue repair) but through completely different mechanisms. BPC-157 works primarily through the nitric oxide system and GH receptor expression. TB-500 works through actin sequestration and angiogenesis. They are sometimes studied in combination because their mechanisms are complementary.

Has BPC-157 been tested in human clinical trials?

The 2025 systematic review identified only 1 clinical study out of 36 analyzed papers. Approximately 30 human subjects have been studied in total across the published literature. The overwhelming majority of evidence is preclinical — in animal models and cell culture. BPC-157 is not FDA-approved for any medical use.

What is the nitric oxide (NO) system?

Nitric oxide is a gas molecule produced by the enzyme eNOS in blood vessel walls. It regulates vasodilation (blood vessel relaxation), angiogenesis (new blood vessel formation), inflammation resolution, and platelet function. BPC-157 enhances eNOS activity through two converging pathways, essentially upregulating the body's own vascular repair system.

Why was BPC-157 originally discovered in stomach fluid?

BPC-157 was isolated from a protein naturally present in human gastric juice. The research context was gastrointestinal protection — studying how the stomach protects itself from its own acid and from damage caused by NSAIDs and other irritants. The discovery that it had effects beyond the gut came later, as researchers tested it in other tissue models.

What is a Certificate of Analysis (COA) for BPC-157?

A Certificate of Analysis is an independent lab report showing purity verification and identity confirmation for a specific batch. For BPC-157, this typically includes HPLC purity testing and mass spectrometry. Choice Peptide Labs publishes a COA for every batch on the product page.

How does BPC-157 compare to other research peptides?

By volume of published research, BPC-157 has one of the largest preclinical evidence bases of any peptide — 544 papers. For comparison, TB-500 (Thymosin Beta-4) has approximately 148 published studies. The breadth of BPC-157's research across multiple tissue types is unusual among peptides, which typically show more tissue-specific effects.

Explore BPC-157 from Choice Peptide Labs

10mg vial · Published Certificate of Analysis for every batch · Dispatched within 1 business day · Cold-chain shipped

View BPC-157 Product Page →

Disclaimer: This article is for educational and informational purposes only. All information is derived from published, peer-reviewed research and describes what has been studied in preclinical and clinical models. Nothing in this article is medical advice, a recommendation for use, or a claim of therapeutic benefit. BPC-157 is a research compound not approved by the FDA for human use. All products from Choice Peptide Labs are sold for laboratory research use only and are not intended for human or veterinary consumption.

What Are CJC-1295 + Ipamorelin? A Research-Backed Guide to Dual-Pathway GH Research

📖 14 min read 🔬 Dual-pathway mechanism 📅 June 2026

CJC-1295 and Ipamorelin act on two completely different receptor systems to stimulate growth hormone release — and that's exactly why researchers study them together. One provides a sustained baseline. The other provides pulsatile peaks. Together, they approximate the body's natural GH secretion pattern.

What Are CJC-1295 and Ipamorelin?

CJC-1295 and Ipamorelin are two separate peptides studied in growth hormone secretagogue research. They are among the most referenced peptides in the GH research literature, and the combination is one of the most studied peptide pairings in published research.

CJC-1295 is a synthetic, tetrasubstituted analog of growth hormone-releasing hormone (GHRH). Developed by ConjuChem Biotechnologies, it contains four amino acid substitutions that protect against enzymatic degradation while preserving full GHRH receptor activity.

Ipamorelin is a selective ghrelin receptor agonist. It mimics ghrelin — the "hunger hormone" — to trigger growth hormone release through a completely separate pathway from CJC-1295.

The key distinction: these two peptides share a common target (growth hormone release) but act through entirely independent receptor systems.

The Dual-Pathway Mechanism

CJC-1295

Receptor: GHRH receptor (anterior pituitary)

A GHRH analog that binds to somatotroph cells in the anterior pituitary gland, stimulating baseline growth hormone production.

Activates cAMP-dependent signaling pathway
Produces sustained, elevated GH levels
Extended half-life through structural modifications
Raises the baseline of GH secretion

Ipamorelin

Receptor: Ghrelin receptor (GHS-R1a)

A selective ghrelin receptor agonist that triggers sharp, pulsatile GH release without significantly affecting other hormones.

Mimics the hunger hormone ghrelin
Creates quick bursts (peaks) of GH release
Selective: does not significantly affect cortisol, prolactin, or ACTH
Clear dose-response relationship

"Growth hormone is naturally secreted in a pulsatile pattern — sharp peaks on a sustained baseline. CJC-1295 provides the baseline. Ipamorelin provides the peaks."

Why Pulsatile Release Matters

Understanding why the combination is studied requires understanding how growth hormone is naturally released:

Natural Growth Hormone Secretion Pattern

Low baseline Sharp peaks (natural pulses) Time →

GH is not released at a constant rate. It's released in sharp bursts (pulses) on top of a low baseline — primarily during deep sleep and after exercise.

The body's natural pattern is pulsatile: sharp spikes on a steady baseline. A flat, constant GH level is not how the body works — and published research suggests pulsatile release is more physiologically relevant than sustained elevation alone.

CJC-1295 provides the sustained baseline. Ipamorelin provides the sharp peaks. Together, they approximate the natural pattern more closely than either peptide alone.

Why Researchers Study Them Together

The combination rationale rests on three published findings:

1. Dose-Response Relationship

Published neuroendocrine studies demonstrate a clear, predictable dose-response relationship with Ipamorelin. More Ipamorelin produces proportionally more GH release — a reliable and reproducible finding across studies.

2. No Desensitization

A critical finding: the GH response to Ipamorelin does not diminish with repeated dosing. Some other ghrelin-mimetic compounds show reduced effectiveness over time (receptor desensitization). Ipamorelin does not — the response remains consistent.

3. Selectivity

Unlike some other ghrelin receptor agonists, Ipamorelin is selective for growth hormone release. Published research shows it does not significantly stimulate:

Cortisol — the stress hormone (not elevated)
Prolactin — the lactation hormone (not elevated)
ACTH — adrenocorticotropic hormone (not elevated)

This selectivity is important because it means Ipamorelin's GH-releasing effect is isolated — it doesn't trigger the stress-hormone cascade that some other secretagogues do.

CJC-1295: The GHRH Analog Explained

CJC-1295 is a synthetic version of growth hormone-releasing hormone (GHRH) — the natural hypothalamic hormone that signals the pituitary to produce GH.

What makes CJC-1295 different from native GHRH:

Four amino acid substitutions protect against enzymatic degradation by DPP-4 and other peptidases
Extended half-life: Native GHRH has a half-life of minutes. CJC-1295 remains active for hours to days, depending on the formulation
Full receptor activity preserved: Despite the structural modifications, CJC-1295 maintains complete binding affinity for the GHRH receptor

The result: CJC-1295 provides a sustained elevation of the GH baseline — the flat line that the Ipamorelin peaks sit on top of.

Ipamorelin: The Selective Ghrelin Mimetic

Ipamorelin is a pentapeptide (five amino acids) that acts as a selective agonist at the ghrelin receptor (GHS-R1a). Ghrelin is a hormone produced primarily in the stomach that signals hunger to the brain — but it also triggers growth hormone release from the pituitary.

What makes Ipamorelin distinct from other ghrelin-mimetic compounds:

Feature	Ipamorelin	Other GH Secretagogues
GH selectivity	High — minimal effect on other hormones	Variable — some elevate cortisol and prolactin
Desensitization	No — response maintained with repeated dosing	Some show reduced response over time
Dose-response	Clear and linear	Variable by compound
GH release pattern	Pulsatile (sharp peaks)	Varies (some produce sustained elevation)

The Combination in Context

The CJC-1295 + Ipamorelin combination is one of the most cited peptide pairings in growth hormone secretagogue research. The rationale is mechanistic:

Two independent pathways: GHRH receptor (CJC-1295) and ghrelin receptor (Ipamorelin) are separate signaling systems. They don't compete or interfere with each other.
Additive effect: The combined GH output from activating both pathways simultaneously is greater than either pathway alone.
Natural pattern approximation: The combination produces sustained baseline + pulsatile peaks — matching the body's natural secretion pattern.
Complementary timing: CJC-1295 provides extended-duration baseline elevation. Ipamorelin provides sharp, time-limited peaks.

This dual-pathway approach is why the combination has become the standard reference pairing in GH secretagogue research — no other two-peptide combination has as clear a mechanistic rationale or as consistent a published evidence base.

Frequently Asked Questions About CJC-1295 + Ipamorelin

Why are CJC-1295 and Ipamorelin studied together?

They activate two independent receptor systems — GHRH receptor (CJC-1295) and ghrelin receptor (Ipamorelin). The combined GH output is greater than either pathway alone, and together they approximate the body's natural pulsatile secretion pattern (baseline + peaks).

What is CJC-1295?

A synthetic GHRH analog with four amino acid substitutions that protect against enzymatic degradation. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, producing sustained GH baseline elevation. Developed by ConjuChem Biotechnologies.

What is Ipamorelin?

A selective ghrelin receptor (GHS-R1a) agonist — a pentapeptide that triggers sharp, pulsatile GH release. Unlike some other secretagogues, it does not significantly affect cortisol, prolactin, or ACTH levels. It also doesn't desensitize with repeated dosing.

What does "pulsatile release" mean?

Growth hormone is not released at a constant rate. The body produces it in sharp bursts (pulses) on top of a low baseline — primarily during deep sleep and after exercise. CJC-1295 provides the baseline; Ipamorelin provides the pulses.

Why is Ipamorelin's selectivity important?

Some ghrelin-mimetic compounds stimulate cortisol (stress hormone) and prolactin alongside growth hormone. Ipamorelin is selective — it triggers GH release without significantly elevating stress or lactation hormones. This makes it a cleaner research tool for studying GH-specific effects.

Does Ipamorelin desensitize over time?

No. Published research shows the GH response to Ipamorelin does not diminish with repeated dosing. Some other ghrelin-mimetic compounds lose effectiveness over time (receptor desensitization). Ipamorelin maintains a consistent response.

What is the GHRH receptor?

Growth hormone-releasing hormone receptor. Located on somatotroph cells in the anterior pituitary. When activated by GHRH (or its analogs like CJC-1295), it stimulates the cell to produce and release growth hormone through the cAMP-dependent signaling pathway.

What is a Certificate of Analysis for CJC-1295 + Ipamorelin?

An independent lab report showing HPLC purity and mass spectrometry for each compound in the blend. Choice Peptide Labs publishes a COA for every batch on the product page.

Explore CJC-1295 + Ipamorelin from Choice Peptide Labs

10mg blend · Published Certificate of Analysis · Dispatched within 1 business day · Cold-chain shipped

View CJC-1295 + Ipamorelin Product Page →

Disclaimer: This article is for educational and informational purposes only. All information is derived from published, peer-reviewed research. CJC-1295 and Ipamorelin are research compounds not approved by the FDA for human use. All products from Choice Peptide Labs are for laboratory research use only and are not intended for human or veterinary consumption.

The Operative (Solo)

CJC-1295: The GHRH Receptor Analog in Growth Hormone Research

Growth Hormone · Research Guide

Overview

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) receptor analog that stimulates the pituitary gland to release growth hormone (GH). The version most commonly referenced in research — CJC-1295 without Drug Affinity Complex (DAC) — features a modified GHRH(1-29) sequence with a shorter half-life that preserves the natural pulsatile GH release pattern. This guide covers the peptide's mechanism, comparative positioning against other GHRH analogs, and its role as both a standalone research tool and a component of combination protocols.

Chemical Identity & Structure

CJC-1295 is based on the first 29 amino acids of human growth hormone-releasing hormone — GHRH(1-29) — with four amino acid substitutions designed to enhance resistance to dipeptidyl peptidase-IV (DPP-IV) enzymatic degradation. The modifications at positions 2, 8, 15, and 27 convert natural amino acids to non-natural D-amino acid forms, dramatically extending the peptide's functional half-life compared to native GHRH(1-29).

The molecular formula is C₁₅₂H₂₅₂N₄₄O₄₂, with a molecular weight of approximately 3647.0 Da. The peptide is a 29-amino-acid linear chain — shorter than the full 44-amino-acid native GHRH but containing the complete receptor-binding domain necessary for GHRH receptor activation at the anterior pituitary.

Key Structural Point

CJC-1295 (without DAC) retains the four D-amino acid substitutions for DPP-IV resistance but does NOT include the lysine linker and maleimidopropionic acid group that define the DAC version. This distinction is critical: without DAC, the peptide has a half-life measured in minutes to hours rather than days.

Understanding the DAC vs. No-DAC Distinction

What Is DAC?

The Drug Affinity Complex is a chemical modification that allows the peptide to covalently bind to endogenous albumin in the bloodstream. The DAC consists of a lysine residue at position 30 linked to maleimidopropionic acid (MPA), which reacts with the free thiol group of albumin's Cys-34 residue. This albumin binding dramatically extends the peptide's circulating half-life to approximately 6–8 days.

Why No-DAC Matters for Research

The no-DAC version of CJC-1295 — sometimes referred to as "Modified GRF(1-29)" or "Mod GRF" — is the form that most closely mimics the natural pulsatile pattern of growth hormone release. The body's endogenous GHRH is released in short, discrete pulses, primarily during deep sleep and after exercise. A peptide with a 6–8 day half-life produces sustained, non-pulsatile GH elevation — a pharmacokinetic profile that departs significantly from normal physiology.

Research Implication

CJC-1295 without DAC has a half-life of approximately 30 minutes following subcutaneous injection. This short duration of action preserves the episodic, pulsatile nature of GH release that is considered physiologically important for downstream IGF-1 signaling, receptor sensitivity, and tissue-specific GH effects.

The DAC Controversy

The DAC version of CJC-1295 (also known as CJC-1295 with DAC or simply "CJC-DAC") has been the subject of significant research community discussion. The concern centers on whether sustained, non-pulsatile GH elevation — which can produce chronically elevated GH levels — is desirable compared to the natural pattern of intermittent pulses separated by troughs. In natural physiology, GH receptor signaling, feedback regulation, and downstream effects (including hepatic IGF-1 production) are optimized for pulsatile input.

Pharmacokinetic Note

Research by Jetté et al. (2005) on CJC-1295 with DAC demonstrated sustained GH elevation for 6+ days, but this non-physiological pattern raised questions about potential impacts on GH receptor desensitization and long-term negative feedback mechanisms. The no-DAC version avoids these concerns by matching the natural release rhythm.

Mechanism of Action

GHRH Receptor Activation

CJC-1295 binds to the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. GHRHR is a G-protein coupled receptor (GPCR) that, upon activation, stimulates adenylyl cyclase activity, increases intracellular cyclic AMP (cAMP), activates protein kinase A (PKA), and ultimately triggers calcium-dependent exocytosis of stored growth hormone from somatotroph secretory granules.

The result is a pulse of GH release into the systemic circulation. GH then acts on target tissues directly (via GH receptor binding) and indirectly (through hepatic production of insulin-like growth factor 1, IGF-1). The magnitude of the GH pulse is dose-dependent, with CJC-1295 producing a 2–10 fold increase in GH levels depending on the dose and the subject's endogenous GH status.

Preservation of Negative Feedback

A critical advantage of the no-DAC version is that it respects the body's existing negative feedback loops. When GH and IGF-1 levels rise following a pulse, somatostatin release from the hypothalamus increases, which suppresses further GHRH-mediated GH release. This natural feedback mechanism operates on a timescale of minutes to hours — perfectly matched to the short half-life of no-DAC CJC-1295 but incompatible with the sustained elevation produced by the DAC version.

CJC-1295 vs. Sermorelin vs. Tesamorelin

Parameter	CJC-1295 (No DAC)	Sermorelin	Tesamorelin
Structure	Modified GHRH(1-29)	Native GHRH(1-29)	Modified GHRH(1-44)
Amino Acid Substitutions	4 (D-aa at positions 2, 8, 15, 27)	None	N-terminal trans-3-hexenoyl
Half-Life	~30 minutes	~10–15 minutes	~25–35 minutes
DPP-IV Resistant	Yes	No	Partially
GH Pulse Amplitude	High (2–10× baseline)	Moderate (2–4× baseline)	Moderate–High
Primary Research Context	GH research, anti-aging	GH deficiency diagnostics, aging	HIV-associated lipodystrophy
Regulatory Status	Research compound	Previously marketed (Geref®)	Approved (Egrifta®)

Sermorelin

Sermorelin is the most straightforward GHRH analog — it is simply the first 29 amino acids of native GHRH with no chemical modifications. Its short half-life (10–15 minutes) means it is rapidly cleaved by DPP-IV in the bloodstream, limiting its practical utility unless administered at high doses or with DPP-IV inhibitor co-administration. Sermorelin was previously marketed as Geref® for pediatric GH deficiency but was withdrawn from commercial production for business reasons, not safety concerns.

Tesamorelin

Tesamorelin is a modified GHRH(1-44) analog with an N-terminal trans-3-hexenoyl group that enhances stability. It is the only GHRH analog to have received regulatory approval (as Egrifta®) for a specific indication — reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Tesamorelin's approval provides the most robust clinical dataset of any GHRH analog, including safety data from Phase III trials involving over 800 subjects.

Comparative Analysis

CJC-1295 (no DAC) occupies the middle ground: more DPP-IV resistant than Sermorelin (due to its four amino acid substitutions) but without the sustained elevation concerns of the DAC version. Its half-life of ~30 minutes produces 2–10× GH elevations that are more pronounced than Sermorelin's but maintain the pulsatile pattern that Tesamorelin also preserves.

CJC-1295 as a Solo Research Compound

While CJC-1295 is most frequently discussed in the context of combination protocols (particularly with Ipamorelin), it has standalone research value. Studied independently, CJC-1295 provides clean data on GHRH receptor-mediated GH release without the confounding variable of a concomitant ghrelin mimetic.

Standalone Research Applications

GHRH receptor pharmacology: CJC-1295 serves as a tool compound for studying GHRHR signal transduction, desensitization kinetics, and dose-response relationships in pituitary somatotrophs.

GH pulsatility studies: The no-DAC version is used to investigate the importance of pulse frequency and amplitude on downstream IGF-1 production, receptor expression, and tissue-specific GH effects.

Aging research: Age-related decline in GH secretion (somatopause) is well-documented. CJC-1295 provides a controlled method for studying GHRH-mediated GH restoration in aged animal models, separate from ghrelin pathway effects.

Metabolic research: GH's role in lipolysis, protein synthesis, and glucose metabolism makes CJC-1295 a relevant tool for studying GH-dependent metabolic pathways in isolation.

Solo Research Value

Studying CJC-1295 alone provides unambiguous data on GHRH receptor-specific effects. When combined with Ipamorelin or other ghrelin mimetics, the resulting GH profile reflects two overlapping mechanisms — making it difficult to attribute specific effects to either pathway independently.

CJC-1295 + Ipamorelin: The Combination

The CJC-1295 / Ipamorelin combination is one of the most discussed pairings in growth hormone research. The rationale is mechanistic: CJC-1295 activates the GHRH receptor (increasing the amplitude of GH pulses) while Ipamorelin activates the growth hormone secretagogue receptor (GHS-R / ghrelin receptor, amplifying and extending the pulse). The two pathways converge on somatotroph cells through distinct second-messenger systems — cAMP/PKA for GHRHR and IP3/DAG/calcium for GHS-R — creating a synergistic effect on GH release.

However, researchers should note that this combination makes it challenging to isolate the contribution of each peptide. For mechanistic studies, solo administration of each compound followed by combination protocols provides cleaner experimental designs.

Pharmacokinetics & Dosing in Research

CJC-1295 without DAC is administered subcutaneously with research doses typically ranging from 100–300 mcg per injection. The peptide reaches peak plasma concentration within 10–20 minutes of injection, with the GH pulse occurring 30–60 minutes post-administration and returning to baseline within 3–4 hours.

Multi-dose protocols typically involve 1–3 injections per day, timed to coincide with natural GH pulse windows (pre-sleep, post-exercise, early morning). This timing strategy aims to amplify endogenous pulses rather than create exogenous ones — an important distinction in protocol design.

Dosing Research Notes

Research by Sinha et al. demonstrated that GHRH analog efficacy is highly dependent on the timing relative to endogenous somatostatin troughs. Administering CJC-1295 during a somatostatin trough (e.g., during deep sleep or immediately post-exercise) produces significantly larger GH pulses than dosing during somatostatin peaks, when the pituitary is actively suppressed.

Safety & Tolerability in Research

GHRH analogs as a class have demonstrated favorable tolerability profiles in clinical research. Tesamorelin's Phase III program (the largest for any GHRH analog) showed adverse event rates comparable to placebo over 52 weeks. The most commonly reported effects are injection site reactions, transient flushing, and mild headache — consistent with GHRHR activation and vasodilatory effects.

CJC-1295 without DAC's short half-life provides an additional safety layer: any adverse effects would be expected to resolve within hours, unlike longer-acting compounds that require days for clearance.

Research Context & Future Directions

The growth hormone research landscape continues to evolve. Key areas of ongoing investigation include:

Optimized pulsatile protocols: Research into optimal dosing timing, frequency, and amplitude to maximize tissue-specific GH effects (lean mass, lipolysis, bone density) while minimizing potential adverse effects on insulin sensitivity.

Combination optimization: Systematic evaluation of CJC-1295 with various ghrelin mimetics (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) to characterize synergistic dose-response relationships.

Aging & sarcopenia: GHRH analogs as tools for studying age-related GH decline and its contribution to sarcopenia, osteoporosis, and metabolic dysregulation.

Metabolic syndrome research: GH's complex effects on glucose metabolism, insulin sensitivity, and body composition make GHRH analogs relevant tools for studying the GH-metabolic axis in obesity and metabolic disease models.

Explore CJC-1295 for Your Research

High-purity CJC-1295 (5mg) for laboratory and research applications. Third-party tested with certificates of analysis available.

View CJC-1295 5mg →

Frequently Asked Questions

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) receptor analog based on the first 29 amino acids of human GHRH, with four amino acid substitutions for enhanced enzymatic stability. It activates the GHRH receptor on pituitary somatotroph cells, stimulating the release of growth hormone in a pulsatile pattern.

The Drug Affinity Complex (DAC) allows the peptide to bind to circulating albumin, extending its half-life to 6–8 days. Without DAC, the half-life is approximately 30 minutes. The no-DAC version preserves the natural pulsatile GH release pattern, while the DAC version produces sustained, non-pulsatile elevation. Most researchers prefer the no-DAC version for its physiological relevance.

Both target the GHRH receptor, but CJC-1295 has four D-amino acid substitutions that make it resistant to DPP-IV degradation, giving it a longer half-life (~30 minutes vs. ~10–15 minutes) and producing larger GH pulses. Sermorelin is the unmodified GHRH(1-29) sequence with no chemical protection from enzymatic cleavage.

Tesamorelin is a modified GHRH(1-44) analog (longer sequence) with an N-terminal trans-3-hexenoyl group for stability. It is the only GHRH analog with regulatory approval (Egrifta® for HIV-associated lipodystrophy). Both preserve pulsatile GH release, but Tesamorelin has the most extensive clinical safety dataset of any GHRH analog.

Yes. While commonly discussed in combination with Ipamorelin, CJC-1295 has standalone research value for studying GHRH receptor pharmacology, GH pulsatility, age-related GH decline, and metabolic effects of GH without the confounding variable of ghrelin receptor co-activation.

CJC-1295 and Ipamorelin activate two different receptors on the same pituitary cells through distinct signaling pathways: GHRHR (cAMP/PKA) and GHS-R/ghrelin receptor (IP3/calcium). The mechanistic synergy can produce larger GH pulses than either compound alone. However, this combination makes it difficult to isolate each peptide's individual contribution.

Research doses typically range from 100–300 mcg per subcutaneous injection, administered 1–3 times daily. Optimal timing coincides with natural GH pulse windows (pre-sleep, post-exercise) to amplify endogenous pulses rather than create exogenous ones. Dosing during somatostatin troughs produces the largest GH responses.

GHRH analogs as a class have demonstrated favorable tolerability in clinical research. The most extensive safety data comes from Tesamorelin's Phase III program, which showed adverse event rates comparable to placebo over 52 weeks. CJC-1295 without DAC's short half-life (~30 minutes) means any adverse effects would be expected to resolve rapidly. This guide covers research findings only and is not medical advice.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. All compounds discussed are intended for research purposes only. Choice Peptide Labs sells research-grade peptides exclusively for laboratory use. Always consult a qualified healthcare professional before making any health-related decisions.

Longevity & Cognitive · The Rest

DSIP: The Delta Sleep-Inducing Peptide in Rest Research

In the relentless pursuit of optimized recovery, sleep remains the single most powerful biological process available to every human. Yet the molecular mechanisms governing restorative sleep — specifically the deep, slow-wave stages where the body repairs, consolidates memory, and resets hormonal balance — are still being mapped. Among the most intriguing molecular players in this space is Delta Sleep-Inducing Peptide (DSIP), a nine-amino acid neuropeptide first identified nearly five decades ago that continues to generate scientific interest for its unique role in sleep architecture and systemic homeostasis.

This guide examines the published research surrounding DSIP — its discovery, its mechanisms, and the breadth of physiological systems it appears to influence. As with all content on this site, this is written for informational and research purposes only.

What Is DSIP?

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide composed of nine amino acids with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was first isolated in 1977 by Swiss researchers Monnier and colleagues, who collected cerebral venous blood from rabbits during electrically induced sleep. When injected into other rabbits, the substance triggered a pronounced increase in delta-wave activity — the slow, high-amplitude brain waves characteristic of the deepest stages of non-REM sleep.

Key Discovery

DSIP was identified by extracting plasma from the cerebral venous outflow of rabbits during synchronized delta-wave sleep, then demonstrating that this fraction induced delta activity when transferred to recipient animals — a landmark experiment in sleep peptide research.

Unlike many peptides that act through a single receptor and pathway, DSIP exhibits a multifunctional profile. While its name references sleep, the research literature reveals a peptide involved in pain modulation, stress response regulation, endocrine function, and circadian rhythm maintenance. This breadth of activity has made it a subject of ongoing investigation in both basic and translational neuroscience.

DSIP and Slow-Wave Sleep Architecture

The defining characteristic of DSIP in the literature is its association with delta-wave (slow-wave) sleep. Slow-wave sleep (SWS) represents the deepest, most restorative phase of the sleep cycle, characterized by synchronized neural oscillations at frequencies of 0.5–4 Hz. It is during SWS that the glymphatic system clears metabolic waste from the brain, growth hormone secretion peaks, and immune function is consolidated.

Early animal studies demonstrated that peripheral administration of DSIP increased the duration and intensity of delta-wave activity without suppressing REM sleep — a distinction that sets it apart from most pharmacological sleep aids. Rather than sedating the brain, DSIP appeared to promote the natural architecture of restorative sleep.

Research Context: A series of studies in the 1980s and 1990s examined DSIP's effects on sleep EEG parameters in animal models. Researchers observed consistent increases in delta power and improvements in sleep efficiency scores, with effects that persisted beyond the acute administration window. See: Schoenenberger & Monnier, 1983.

What makes DSIP particularly interesting to sleep researchers is that its effects appear to be homeostatic rather than pharmacological. Instead of forcing sleep through receptor saturation (as benzodiazepines do via GABA-A receptors), DSIP seems to modulate the endogenous sleep-wake regulatory system, aligning with the body's natural circadian and sleep-pressure mechanisms. This distinction is significant: pharmacologically induced sleep often lacks the restorative properties of natural slow-wave sleep, while DSIP-associated sleep profiles more closely resemble physiological rest.

Beyond Sleep: Pain, Stress, and Endocrine Research

Pain Perception Modulation

One of the most compelling findings in DSIP research is its effect on pain perception. Multiple animal studies have demonstrated that DSIP administration produces analgesic effects — reducing pain sensitivity in models of both acute and chronic pain. The mechanism appears to involve modulation of endogenous opioid pathways, with DSIP enhancing the activity of enkephalins and endorphins without directly binding to opioid receptors.

This indirect modulation is noteworthy because it suggests DSIP may support pain management without the tolerance and dependency concerns associated with direct opioid agonists. Researchers have hypothesized that this mechanism operates through DSIP's influence on stress-responsive neurochemical systems, which are deeply intertwined with pain signaling.

Stress Response and Cortisol Regulation

DSIP has been studied extensively for its relationship with the hypothalamic-pituitary-adrenal (HPA) axis — the body's central stress-response system. Chronic stress drives sustained cortisol elevation, which damages hippocampal neurons, disrupts sleep architecture, suppresses immune function, and accelerates cellular aging.

Research Finding

In animal models, DSIP administration has been associated with normalization of corticotropin-releasing hormone (CRH) activity and reduced circulating cortisol levels. These effects were observed most prominently in animals subjected to chronic stress conditions, suggesting a role for DSIP in restoring HPA axis equilibrium rather than simply suppressing cortisol production.

This cortisol-modulating effect is particularly relevant when considered alongside DSIP's sleep-promoting properties. Cortisol and sleep exist in a bidirectional feedback loop: elevated cortisol disrupts sleep, and poor sleep elevates cortisol. By addressing both sides of this loop simultaneously, DSIP represents a unique research tool for studying the mechanisms of stress-sleep interaction.

Endocrine and Circadian Effects

Beyond cortisol, DSIP research has explored its effects on other endocrine axes. Studies have noted influences on luteinizing hormone (LH), growth hormone, and thyroid-stimulating hormone (TSH) secretion patterns. While the clinical significance of these effects requires further characterization, they suggest that DSIP interacts with the broader neuroendocrine system rather than operating in a sleep-specific silo.

DSIP has also been studied in the context of circadian rhythm maintenance. Disruption of circadian timing — through shift work, jet lag, or aging — is associated with a cascade of negative health outcomes. Research suggests that DSIP may support the entrainment of circadian rhythms, potentially through its influence on melatonin secretion and core body temperature regulation.

The Multi-System Homeostatic Model

One of the most intellectually challenging aspects of DSIP is the growing recognition that it may function as a systemic homeostatic regulator rather than a simple sleep-promoting molecule. The evidence for this comes from the sheer breadth of physiological systems DSIP appears to influence:

Sleep architecture — delta-wave enhancement and sleep efficiency
Pain perception — endogenous opioid pathway modulation
Stress response — HPA axis normalization and cortisol regulation
Endocrine function — effects on growth hormone, LH, and TSH
Circadian rhythm — sleep-wake cycle entrainment
Blood pressure regulation — reported hypotensive effects in some studies
Thermoregulation — influence on body temperature rhythms

This multi-system activity pattern is consistent with the concept of allostatic regulation — the process by which the body dynamically adjusts multiple physiological parameters to maintain stability under changing conditions. If DSIP functions as an allostatic signal rather than a pathway-specific modulator, it would explain why its effects extend so far beyond sleep.

Contextual Note: The idea of a peptide acting as a broad homeostatic signal is not unique to DSIP. Other neuropeptides, including orexin and vasopressin, display similarly broad physiological footprints. DSIP's profile, however, is distinctive in the degree to which its effects converge on recovery and restorative processes. See: Kastin et al., 1990.

Research Considerations and Limitations

It is important to address the limitations of the current DSIP literature honestly:

Species differences: Much of the foundational DSIP research was conducted in rabbits and rodents. Translating these findings to human physiology requires caution.
Dose-response variability: DSIP effects are not always consistent across studies, and optimal dosing parameters for specific outcomes remain poorly defined.
Mechanistic gaps: Despite decades of research, the precise receptor(s) through which DSIP exerts its effects have not been conclusively identified. Some researchers have proposed that DSIP may act through intracellular mechanisms rather than classical membrane-bound receptors.
Endogenous levels and bioavailability: Questions remain about how endogenous DSIP is produced, how it crosses the blood-brain barrier, and what its natural circulating concentrations are.
Clinical trial data: Robust, large-scale human clinical trials are limited. Most human observations come from smaller studies or clinical observations from Eastern European and Russian research groups.

These limitations do not diminish the scientific interest in DSIP — they simply define the current boundaries of the evidence base. For researchers, DSIP represents a peptide with a fascinating and still-unfolding profile that warrants continued investigation.

DSIP in the Context of Rest and Longevity Research

The connection between sleep quality and longevity is no longer debated. Epidemiological data consistently shows that individuals with poor slow-wave sleep have higher rates of cardiovascular disease, metabolic dysfunction, neurodegenerative disease, and all-cause mortality. The glymphatic system — the brain's waste-clearance pathway — operates primarily during deep sleep, and its dysfunction has been linked to Alzheimer's pathology.

If DSIP genuinely supports the maintenance and quality of slow-wave sleep, its relevance to longevity research is substantial. A peptide that enhances restorative sleep without the drawbacks of pharmacological sedation — without suppressing REM sleep, without creating dependency, without altering natural sleep architecture — would represent a valuable research tool in the study of age-related sleep decline.

Research Implication

Age-related decline in slow-wave sleep begins as early as the mid-30s and accelerates through middle age. By age 60, many individuals have lost 60–70% of their deep sleep compared to young adulthood. Understanding and potentially supporting slow-wave sleep mechanisms is a significant focus of longevity research.

Frequently Asked Questions

What does DSIP stand for?

DSIP stands for Delta Sleep-Inducing Peptide. It was named for its ability to induce delta-wave (slow-wave) activity in the brain when first discovered in 1977.

How was DSIP discovered?

DSIP was isolated from the cerebral venous blood of rabbits during electrically induced synchronized sleep. When the extracted plasma fraction was injected into recipient rabbits, it induced delta-wave sleep activity, leading to the identification of the peptide.

How many amino acids does DSIP contain?

DSIP is a nine-amino acid neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

Does DSIP only affect sleep?

No. While named for its sleep-related properties, research has demonstrated that DSIP also influences pain perception, stress response and cortisol regulation, endocrine function, blood pressure, and thermoregulation. It is increasingly viewed as a multi-system homeostatic regulator.

Is DSIP the same as a sleeping pill?

No. Unlike pharmacological sleep aids that sedate the brain through receptor saturation, DSIP appears to work with the body's natural sleep-wake regulatory systems. Research suggests it promotes the architecture of restorative sleep rather than simply inducing unconsciousness.

Has DSIP been studied in humans?

Yes, though the human literature is more limited than the animal research. Several smaller studies and clinical observations, many originating from Eastern European and Russian research groups, have examined DSIP's effects on sleep quality, stress parameters, and pain perception in human subjects.

What is the relationship between DSIP and the HPA axis?

DSIP has been studied for its ability to modulate the hypothalamic-pituitary-adrenal (HPA) axis — the body's central stress-response system. Research in animal models suggests DSIP can help normalize corticotropin-releasing hormone activity and reduce elevated cortisol levels, particularly under chronic stress conditions.

Why is DSIP relevant to longevity research?

Sleep quality — particularly slow-wave sleep — is directly linked to longevity outcomes. Slow-wave sleep supports glymphatic clearance, growth hormone secretion, immune function, and cellular repair. Age-related decline in deep sleep is a recognized factor in cognitive decline and metabolic disease, making DSIP's sleep-related properties highly relevant to aging research.

Explore DSIP for Your Research

High-purity DSIP (10mg) available for research applications. HPLC-verified, third-party tested.

View DSIP 10mg →

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. All peptides discussed are sold for research purposes only and are not approved by the FDA for human consumption. Always consult a qualified healthcare provider before making decisions about your health. Choice Peptide Labs does not claim that any product discussed can treat, cure, or prevent any disease.

The Timer · Longevity Peptides

Epithalon: The Telomerase-Activating Tetrapeptide

Revised June 2026 · Research Guide · 9 min read

Among the small peptide molecules that have drawn attention in longevity research, Epithalon (also known as Epitalon or Epithalamin) occupies a position of quiet fascination. This tetrapeptide — just four amino acids — is among the smallest bioactive peptides known to science, yet it has been associated with one of the most significant cellular processes in aging biology: telomerase activation. First identified through decades of research led by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Epithalon has become one of the most studied peptides in the gerontological research literature.

This guide examines Epithalon's pineal gland origin, its precise molecular structure, the Khavinson telomerase research, and its dual role in both telomere maintenance and melatonin secretion modulation.

Origin: The Pineal Gland Connection

Epithalon was identified through a research program that systematically investigated peptide extracts from the pineal gland — a small, pine cone-shaped neuroendocrine organ situated in the epithalamus of the brain. The pineal gland is best known for its production of melatonin (N-acetyl-5-methoxytryptamine), the hormone that regulates circadian rhythm. However, Khavinson's research group hypothesized that the pineal gland also produced short regulatory peptides with broader geroprotective functions.

Through fractionation of bovine pineal gland extracts, the Khavinson group isolated a tetrapeptide fraction with the ability to normalize melatonin secretion in aged animals and, critically, to activate telomerase activity in human cells. This fraction was identified as the tetrapeptide Ala-Glu-Asp-Gly, which was subsequently named Epithalon (from "epithalamus" + "peptide").

Molecular Structure

Molecular Identity

Sequence: Ala-Glu-Asp-Gly (AEDG) — 4 amino acids. Molecular weight: ~390 Da. Classification: Tetrapeptide. Origin: Isolated from pineal gland extracts. Alternative names: Epitalon, Epithalamin.

At just 390 daltons, Epithalon is remarkably small — smaller than many naturally occurring oligopeptides. Its four amino acids carry a net negative charge at physiological pH (due to the Glu and Asp residues), and its minimal size confers favorable pharmacokinetic properties including the potential for membrane penetration and resistance to some enzymatic degradation pathways.

🧬

Size Matters

With only four amino acids and a molecular weight of ~390 Da, Epithalon is among the smallest bioactive peptides ever characterized with documented cellular effects — placing it near the boundary between peptide and oligopeptide chemistry.

Telomerase Activation: The Khavinson Research

The most significant finding associated with Epithalon is its capacity to activate telomerase — the ribonucleoprotein enzyme responsible for adding telomeric repeats (TTAGGG) to chromosome ends. Telomerase is minimally composed of two core components: TERT (telomerase reverse transcriptase, the catalytic subunit) and TERC (telomerase RNA component, which provides the template sequence for telomere elongation). In most somatic human cells, TERT expression is epigenetically silenced, resulting in progressive telomere shortening with each cell division — a hallmark of cellular aging (replicative senescence).

Khavinson et al. Research

In studies using cultured human fibroblasts (diploid somatic cells), Khavinson and colleagues demonstrated that Epithalon treatment activated telomerase enzyme activity, resulting in telomere elongation and an extension of the proliferative lifespan of the cells beyond their normal Hayflick limit. The effect was associated with increased TERT gene expression. (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2003; Neuroendocrinology Letters, 2003)

The experimental design was notable for its specificity: human dermal fibroblasts were treated with Epithalon at low concentrations, and telomerase activity was measured by the TRAP (Telomeric Repeat Amplification Protocol) assay. Treated cells showed:

Increased telomerase activity detectable within the treatment period
Elonogation of telomeres — cells treated with Epithalon showed longer telomeres than untreated controls of the same passage number
Extended replicative lifespan — treated cells continued dividing beyond the point at which control cells entered senescence

🔬

The Core Finding

Epithalon treatment of human fibroblasts resulted in telomerase activation and measurable telomere elongation — placing this four-amino acid peptide among the few molecules shown to directly influence the telomere maintenance machinery in human somatic cells. This finding has been reproduced across multiple studies from the Khavinson laboratory.

Why Telomerase Activation Matters in Aging Research

Telomere shortening is one of the recognized hallmarks of aging (López-Otín et al., 2013, Cell). As somatic cells divide, telomeres progressively shorten until they reach a critical length, triggering a DNA damage response (via p53/p21 and p16/Rb pathways) that drives the cell into irreversible growth arrest — replicative senescence. Senescent cells accumulate with age and secrete a pro-inflammatory mixture (the senescence-associated secretory phenotype, or SASP) that contributes to tissue dysfunction.

Telomerase activation is therefore a direct intervention at one of the most fundamental aging mechanisms. By restoring telomere length, telomerase-expressing cells can bypass the Hayflick limit and continue proliferating, potentially delaying senescence onset in affected tissues.

Melatonin Secretion Modulation

In addition to its telomerase effects, Epithalon has been studied for its influence on melatonin secretion. As a pineal gland-derived peptide, Epithalon appears to have a regulatory relationship with the pineal gland's primary hormonal output. In aged animal models, pineal gland function deteriorates — a phenomenon known as pineal aging — leading to reduced nocturnal melatonin production and disrupted circadian rhythms.

Melatonin Research

Khavinson's group reported that Epithalon administration in aged rats restored nocturnal melatonin secretion patterns to levels resembling younger animals. This effect was attributed to Epithalon's ability to modulate pineal gland gene expression and support melatonin biosynthesis. (Khavinson & Morozov, Neuroendocrinology Letters, 2003)

The connection between Epithalon and melatonin is biologically elegant: the pineal gland produces both the peptide and the hormone, and the peptide appears to function as an autocrine/paracrine regulator that maintains the gland's own secretory capacity. As the pineal gland ages and loses this regulatory peptide input, melatonin output declines — a decline that Epithalon may partially restore.

In Vivo Research: Animal Model Findings

Beyond the cell culture studies, Khavinson's group conducted extensive in vivo research using rodent models. Key findings from the animal literature include:

Lifespan extension: Epithalon administration to aging mice was associated with a statistically significant increase in mean and maximum lifespan compared to untreated controls, reported in studies published across multiple gerontology journals
Organ function: Aged animals treated with Epithalon showed improved indices of immune function, reproductive function, and pineal gland morphology
Circadian restoration: Age-disrupted melatonin rhythms were partially normalized with Epithalon treatment, consistent with the pineal regulatory hypothesis
Onco-resistance: Some studies reported reduced spontaneous tumor incidence in Epithalon-treated aging animals, though this finding requires further investigation

Summary

Epithalon represents a unique convergence of minimalism and biological potency. At just four amino acids, it has demonstrated telomerase activation in human somatic cells, telomere elongation beyond normal replicative limits, and melatonin secretion modulation in aged pineal glands. The Khavinson research group's work — spanning cell culture, animal models, and gerontological theory — positions Epithalon as one of the most intriguing molecules in longevity peptide research. While the research remains largely in the preclinical and early translational domain, the specificity of its mechanism — direct activation of telomerase in human cells — gives it a mechanistic clarity that few anti-aging compounds can claim.

Frequently Asked Questions

Epithalon (Epitalon) is a tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It has a molecular weight of approximately 390 daltons and was originally isolated from bovine pineal gland extracts by Professor Vladimir Khavinson's research group in St. Petersburg, Russia.

Epithalon has been shown to upregulate TERT (telomerase reverse transcriptase) gene expression in human fibroblasts, leading to increased telomerase enzymatic activity. The precise upstream signaling pathway by which this four-amino acid peptide influences TERT transcription is still under investigation, but the downstream outcome — measurable telomerase activation and telomere elongation — has been demonstrated in multiple cell culture studies.

Telomere shortening is a recognized hallmark of aging. Each cell division shortens telomeres until a critical threshold triggers replicative senescence — irreversible growth arrest. Telomerase activation directly counteracts this process by adding telomeric repeats to chromosome ends, extending the replicative lifespan of cells and potentially delaying senescence onset. Epithalon is one of the few molecules shown to activate telomerase in normal human somatic cells.

Research in aged animal models has shown that Epithalon can restore nocturnal melatonin secretion patterns to levels more closely resembling those of younger animals. This effect is attributed to Epithalon's role as a pineal-derived regulatory peptide that supports the gland's biosynthetic capacity for melatonin production. As the pineal gland ages, both Epithalon secretion and melatonin production decline — exogenous Epithalon may partially restore this feedback loop.

Most of the published research on Epithalon consists of cell culture studies (human fibroblasts) and animal models (rodent aging studies). Some preliminary clinical observations from the Khavinson group have been reported in the context of gerontological research, but large-scale, randomized controlled human trials of Epithalon have not been completed. The primary evidence base remains preclinical.

Professor Vladimir Khavinson is a Russian gerontologist who led the Institute of Bioregulation and Gerontology in St. Petersburg. His research group conducted the foundational work on Epithalon over several decades, including the original isolation from pineal tissue, the characterization of its amino acid sequence, the discovery of its telomerase-activating capacity, and the in vivo aging studies. Khavinson is also credited with the broader "peptide bioregulation" theory, which posits that short tissue-specific peptides serve as regulatory molecules that maintain organ function throughout life.

The Hayflick limit is the maximum number of times a normal somatic cell population can divide before entering replicative senescence — typically 40–60 divisions for human fibroblasts. This limit is determined by progressive telomere shortening. Epithalon-treated fibroblasts were shown to bypass this limit by activating telomerase and elongating their telomeres, allowing continued proliferation beyond the normal replicative boundary.

Access Epithalon for Research

High-purity Epithalon (10mg, ≥99% purity) with third-party HPLC/MS verification — available for qualified research use.

View Epithalon 10mg →

Research Disclaimer: All content on this page is intended for scientific research and educational purposes only. Epithalon is a research peptide and is not approved for human consumption, veterinary use, or as a dietary supplement. Choice Peptide Labs supplies peptides exclusively for in vitro research purposes. All researchers must comply with applicable local, state, and federal regulations. The information presented does not constitute medical advice.

What Is GHK-Cu? A Research-Backed Guide to the Gene-Modulating Copper Peptide

📖 14 min read 🔬 50+ years of research 📅 June 2026

GHK-Cu is a naturally occurring copper-binding tripeptide that modulates the activity of over 4,000 human genes — approximately 32% of the genome. First identified by Loren Pickart in 1973, it's one of the most studied small molecules in regenerative biology. Here's what 50+ years of published research reveal.

4,000+

Genes Modulated

~32%

Of Human Genome

50+

Years of Research

3

Amino Acids

What Is GHK-Cu?

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a small, naturally occurring copper-binding tripeptide. Just three amino acids — glycine, histidine, and lysine — bound to a copper ion. It's found naturally in human plasma, saliva, and urine.

It was first isolated by researcher Loren Pickart in 1973 from human plasma during research on liver tissue regeneration. What started as a discovery about wound healing became something far larger: one of the most gene-modulatory compounds ever studied.

GHK-Cu is released from tissues in case of injury — suggesting it plays a natural role in the body's repair response. Its concentration in plasma declines significantly with age, roughly 60% lower by age 60 compared to age 20.

📚 Source: Pickart, L., et al. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." PMC. PMC6073405

The Landmark Discovery: 4,000+ Genes

The finding that transformed GHK-Cu from a wound-healing peptide to a subject of genome-wide research came from the Broad Institute's Connectivity Map (CMap) database.

Using this database — one of the largest repositories of gene expression profiles in the world — researchers analyzed GHK-Cu's effect on human gene expression. The result:

"GHK-Cu modulates the activity of more than 4,000 human genes — approximately 32% of the human genome. This is not a typo."

This isn't a theoretical prediction. The Connectivity Map uses actual gene expression data from human cell lines treated with compounds. GHK-Cu's gene expression profile was compared against thousands of other compounds, revealing its broad and systematic influence on the human genome.

What Kinds of Genes?

↑ UPREGULATED Genes

Extracellular matrix synthesis: collagen, glycosaminoglycans, decorin, elastin — the structural scaffolding of skin and connective tissue

↑ UPREGULATED Genes

Nrf2 antioxidant defense pathways — the cell's endogenous protection against oxidative stress and free radical damage

↓ DOWNREGULATED Genes

NF-κB inflammatory pathway genes — reducing the transcription-level drivers of chronic inflammation

↓ DOWNREGULATED Genes

Iron-mediated oxidative stress genes — reducing damage pathways associated with excess iron in tissue

📚 Source: "GHK-Cu and Gene Expression: The Pickart Research." Blackwell BioLabs. Read

50 Years of Research: A Timeline

1973

Loren Pickart Isolates GHK-Cu from Human Plasma

Discovered during research on liver tissue regeneration. The tripeptide was found to promote wound healing in early models.

1980s–1990s

Dermatology and Cosmetic Research

GHK-Cu's effects on collagen synthesis and skin repair were studied extensively. It was incorporated into cosmetic products based on published research.

2000s

Broad Institute Connectivity Map Analysis

Gene expression analysis using the CMap database revealed GHK-Cu modulates 4,000+ human genes — a finding that shifted the research paradigm from single-pathway to genome-wide.

2010s–2020s

Regenerative and Anti-Cancer Research

Published studies examined GHK-Cu's role in tissue regeneration, anti-cancer gene modulation, and redox homeostasis. Research expanded from dermatology into systemic biology.

2026

Springer Review: "A Representative Model System"

A comprehensive Springer review described GHK-Cu as "a representative model system linking copper biology to regenerative medicine" — recognizing its evolution from cosmetic ingredient to serious molecular biology.

📚 Source: "GHK-Cu as a multifunctional copper peptide: synthesis routes and biological roles." Springer, 2026. Springer

The Copper Connection: Why Copper Matters

GHK-Cu isn't just a peptide — it's a copper delivery system. The copper ion bound to the tripeptide is biologically active and plays critical roles:

Enzyme cofactor: Copper is required for lysyl oxidase — the enzyme that cross-links collagen and elastin fibers, giving skin and connective tissue their structural integrity
Superoxide dismutase (SOD): Copper is a cofactor for SOD, one of the body's primary antioxidant enzymes
Cytochrome c oxidase: Copper is essential for the mitochondrial electron transport chain — the final step in cellular energy production
Angiogenesis: Copper ions promote new blood vessel formation, contributing to tissue repair and wound healing

GHK-Cu delivers copper directly to cells in a bioavailable form. This copper-delivery function is separate from (and additional to) its gene expression effects — making GHK-Cu a dual-mechanism compound.

What Makes GHK-Cu Different from Other Peptides

Most peptides studied in research work through specific receptor pathways — they bind to a receptor and trigger a downstream signaling cascade. GHK-Cu operates differently:

Epigenetic modulation: GHK-Cu doesn't just activate one pathway — it shifts the cell's overall gene expression profile toward a more regenerative state
Genome-wide reach: 4,000+ genes is not a typo. No other small peptide has demonstrated this breadth of gene modulation in published research
Reversibility: The gene expression changes induced by GHK-Cu are reversible — when the compound is removed, gene expression returns toward baseline. This suggests it modulates rather than permanently alters cellular programming
Age-related decline: GHK-Cu levels drop ~60% between ages 20 and 60. This decline parallels the decline in tissue repair capacity seen with aging

"GHK-Cu does not act on a single receptor. It operates epigenetically, effectively rebooting the genetic expression of aged cells back to a younger state."

Dermatology Research: Collagen, Skin, and Connective Tissue

In dermatology-specific research, GHK-Cu has been studied for:

Collagen synthesis: Upregulation of COL1A1 and COL1A2 genes — the primary collagen genes in human skin
Elastic fiber production: Stimulation of elastin and fibrillin gene expression — the proteins that give skin its elasticity
Wound remodeling: Promotion of orderly collagen organization (rather than scar tissue formation) in skin repair models
Anti-inflammatory effects: Downregulation of inflammatory gene expression reduces the chronic inflammation that contributes to skin aging
Antioxidant defense: Nrf2 pathway activation enhances the skin's endogenous protection against UV-induced and environmental oxidative stress

A 2025 study in Cosmetics (MDPI) reviewed copper peptides in regenerative aesthetic dermatology, noting that GHK-Cu has "an excellent safety record and is widely used in cosmetic products" while maintaining "a growing body of research evidence" supporting its biological mechanisms.

📚 Source: "Copper Peptides in Regenerative Aesthetic Dermatology." Dermatologic Therapy (Wiley), 2025. Wiley

GHK-Cu Decline with Age: A Natural Loss

One of the most significant findings in GHK-Cu research: levels decline dramatically with age.

Published data shows:

Age 20: Normal GHK-Cu plasma levels
Age 60: Approximately 60% lower than age 20
Correlation: This decline parallels the decline in tissue repair capacity, collagen production, and wound healing speed seen with aging

This decline pattern — and its correlation with aging markers — has led researchers to study whether restoring GHK-Cu levels could support age-related tissue maintenance. This is still an active area of investigation, not a proven intervention.

Frequently Asked Questions About GHK-Cu

What does GHK-Cu stand for?

GHK-Cu stands for glycyl-L-histidyl-L-lysine-copper. It's a tripeptide (three amino acids: glycine, histidine, lysine) bound to a copper ion. Found naturally in human plasma, saliva, and urine.

How many genes does GHK-Cu modulate?

Gene expression research using the Broad Institute's Connectivity Map database showed GHK-Cu modulates over 4,000 human genes — approximately 32% of the human genome. It upregulates structural and antioxidant genes while downregulating inflammatory and oxidative stress genes.

Who discovered GHK-Cu?

Loren Pickart, in 1973, from human plasma during research on liver tissue regeneration. Over 50 years of continuous research have followed.

How does GHK-Cu decline with age?

GHK-Cu levels are approximately 60% lower at age 60 compared to age 20. This decline parallels the age-related decrease in tissue repair capacity, collagen production, and wound healing speed.

How does GHK-Cu work differently from receptor-based peptides?

Most peptides activate a specific receptor pathway. GHK-Cu operates epigenetically — it shifts the overall gene expression profile toward a more regenerative state. The changes are reversible: when the compound is removed, gene expression returns toward baseline.

What is the copper connection?

GHK-Cu delivers copper to cells in a bioavailable form. Copper is a cofactor for lysyl oxidase (collagen cross-linking), superoxide dismutase (antioxidant defense), and cytochrome c oxidase (mitochondrial energy production). This copper-delivery function is in addition to GHK-Cu's gene expression effects.

What is a Certificate of Analysis for GHK-Cu?

An independent lab report showing HPLC purity and mass spectrometry for a specific batch. Choice Peptide Labs publishes a COA for every batch on the product page.

Is GHK-Cu the same as "copper peptide" in skincare?

Yes. GHK-Cu is the specific copper peptide used in research and cosmetic products. It has an excellent safety record in published research. The research-grade compound from Choice Peptide Labs is the same molecule studied in published gene expression research.

Explore GHK-Cu from Choice Peptide Labs

100mg vial · Published Certificate of Analysis · Dispatched within 1 business day · Cold-chain shipped

View GHK-Cu Product Page →

Disclaimer: This article is for educational and informational purposes only. All information is derived from published, peer-reviewed research. GHK-Cu is a naturally occurring peptide studied in preclinical and cosmetic research contexts. Nothing in this article is medical advice. All products from Choice Peptide Labs are for laboratory research use only and are not intended for human consumption.

The Gatekeeper · Reproductive Peptides

Kisspeptin-10: The Gateway to the Reproductive Cascade

Revised June 2026 · Research Guide · 10 min read

Deep within the neuroendocrine architecture governing reproduction sits a peptide that acts as the master upstream switch: Kisspeptin-10. This decapeptide — just ten amino acids long — wields disproportionate influence over the hypothalamic-pituitary-gonadal (HPG) axis, the hormonal cascade responsible for reproductive function, gonadal steroidogenesis, and fertility signaling in both sexes. Its discovery and the subsequent elucidation of its mechanism fundamentally reshaped our understanding of reproductive neuroendocrinology.

This guide examines Kisspeptin-10's molecular identity, its receptor mechanism, its position in the HPG signaling hierarchy, and the research landscape surrounding this deceptively small yet biologically powerful peptide.

Origin: The KISS1 Gene Product

Kisspeptin-10 is the minimal bioactive fragment cleaved from a larger precursor encoded by the KISS1 gene (chromosome 1q32). The full precursor — prepro-kisspeptin (145 amino acids) — undergoes proteolytic processing to yield several cleaved products: kisspeptin-54 (also called metastin), kisspeptin-14, kisspeptin-13, and kisspeptin-10. Despite being the shortest of these fragments, Kisspeptin-10 retains full bioactivity at the kisspeptin receptor and is widely used in research due to its synthetic accessibility and potency.

Molecular Identity

Sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe (YNWNSFGLRF) — 10 amino acids, amidated C-terminus. All bioactive kisspeptin fragments share this C-terminal decapeptide sequence, which is the minimal region required for receptor binding and activation.

The Receptor: GPR54 (Kiss1R)

Kisspeptin-10 exerts its biological effects through binding to GPR54 (also designated Kiss1R), a Gq/11-protein-coupled receptor expressed predominantly on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus — specifically in the arcuate nucleus (infundibular nucleus in humans) and the anteroventral periventricular nucleus (AVPV). GPR54 activation on GnRH neurons triggers intracellular calcium mobilization and phospholipase C signaling, which leads directly to GnRH secretion.

🔬

The Gatekeeper Position

Kisspeptin-10 acts upstream of every other hormone in the HPG axis. It does not act on the pituitary or gonads directly — it works exclusively at the hypothalamic level, triggering GnRH neurons to fire. This makes it the most upstream regulator in the entire reproductive hormone cascade.

The significance of this positioning cannot be overstated. GnRH neurons are the central drivers of reproductive endocrinology, but their activity is modulated by multiple inputs — kisspeptin, neurokinin B (NKB), dynorphin, estrogen feedback, leptin, and more. Among these, kisspeptin signaling through GPR54 has emerged as the primary obligate activator of GnRH release, a conclusion supported by both genetic and pharmacological evidence.

Mechanism: Triggering the GnRH → LH/FSH Cascade

The downstream signaling sequence initiated by Kisspeptin-10 follows the classical HPG axis pathway:

Kisspeptin-10 binds GPR54 on GnRH neurons in the hypothalamus
GnRH neurons fire, releasing GnRH into the hypothalamic-hypophyseal portal circulation
GnRH reaches anterior pituitary gonadotrophs, binding the GnRH receptor (GnRHR)
Gonadotrophs secrete LH and FSH into systemic circulation
LH and FSH act on gonads — stimulating steroidogenesis (testosterone, estradiol, progesterone) and gametogenesis
Gonadal steroids feed back to hypothalamic kisspeptin neurons (and others), modulating continued kisspeptin output and thus GnRH release

⚡

Cascade Amplification

A single pulse of kisspeptin-10 at the hypothalamic level propagates through three distinct amplification stages — GnRH → LH/FSH → gonadal steroids — with each stage producing 10- to 100-fold increases in downstream hormone concentrations. This makes kisspeptin the most potent upstream trigger point available for HPG axis research.

Genetic Evidence: The Discovery Story

The critical role of kisspeptin-GPR54 signaling in reproduction was revealed through human genetics. In 2003, two independent research groups reported that patients with idiopathic hypogonadotropic hypogonadism (IHH) — a condition characterized by absent or delayed puberty and low circulating gonadotropins — carried inactivating mutations in the GPR54 gene. These patients had otherwise normal hypothalamic anatomy, but their GnRH neurons could not be activated because the kisspeptin receptor was non-functional.

Seminal Research

de Roux et al. (2003) PNAS and Seminara et al. (2003) NEJM independently identified loss-of-function GPR54 mutations in patients with idiopathic hypogonadotropic hypogonadism, establishing the kisspeptin-GPR54 axis as an obligate requirement for normal human puberty and reproductive function.

This genetic evidence, combined with subsequent animal studies demonstrating that exogenous kisspeptin administration could trigger immediate LH release in multiple species, established kisspeptin as a non-negotiable gateway for reproductive hormone signaling — a finding that continues to drive research interest more than two decades later.

Kisspeptin-10 vs. Full-Length Kisspeptin (Kisspeptin-54)

Both Kisspeptin-10 and Kisspeptin-54 (metastin) activate GPR54 with comparable potency, since receptor binding depends on the shared C-terminal decapeptide region. However, they differ in practical research characteristics:

Size and synthesis: Kisspeptin-10 is smaller and more straightforward to synthesize, making it more accessible for routine research applications
Pharmacokinetics: Kisspeptin-54 has a longer circulating half-life due to its larger molecular size; Kisspeptin-10 is cleared more rapidly
Receptor binding: Both activate GPR54 through the same C-terminal motif; functional potency at the receptor is essentially equivalent
Research utility: Kisspeptin-10 is preferred for acute pulse-chase experiments and rapid-onset studies; Kisspeptin-54 is used when longer-duration receptor engagement is needed

Kisspeptin-10 as a Research Probe

Because Kisspeptin-10 acts at the very apex of the HPG axis — upstream of GnRH, LH, FSH, and all gonadal steroids — it has become a valuable research probe for assessing HPG axis responsiveness in various experimental designs. Administering Kisspeptin-10 and measuring downstream LH/FSH secretion provides a direct readout of GnRH neuron functional capacity and pituitary gonadotroph responsiveness.

This probe design is particularly useful in research investigating pubertal development, reproductive aging, hormonal feedback modulation, and the effects of metabolic status (e.g., energy deficit, obesity) on reproductive axis function. Kisspeptin neurons are uniquely sensitive to metabolic signals — particularly leptin and insulin — making them a convergence point between energy balance and reproductive endocrinology.

Beyond Reproduction: The Metastin Connection

Kisspeptin was originally discovered as a metastasis suppressor gene product in melanoma cells (hence the alternate name "metastin" for kisspeptin-54). The KISS1 gene was identified by its ability to suppress melanoma metastasis, and the peptide was subsequently found to have roles in cancer biology, placental function, and even pancreatic islet cell regulation. These non-reproductive roles remain active areas of investigation, though the overwhelming majority of kisspeptin-10 research focuses on the HPG axis.

Summary

Kisspeptin-10 is, at its core, the molecular key that unlocks the entire reproductive hormonal cascade. Its ten amino acids are sufficient to activate GPR54 on GnRH neurons, triggering the sequential release of GnRH, LH, and FSH — and thereby setting in motion the steroidogenic and gametogenic processes that define reproductive function. Its position as the most upstream, obligate activator of the HPG axis makes it one of the most important peptides in reproductive neuroendocrinology research, a distinction confirmed by the human genetic evidence that first revealed its role.

Frequently Asked Questions

Kisspeptin-10 is a decapeptide (10 amino acids) that is proteolytically cleaved from the prepro-kisspeptin precursor encoded by the KISS1 gene on chromosome 1q32. It is the minimal bioactive fragment that retains full receptor-binding activity at GPR54.

Kisspeptin-10 binds GPR54 (also known as Kiss1R), a Gq/11-protein-coupled receptor expressed primarily on GnRH neurons in the arcuate nucleus and AVPV of the hypothalamus. Receptor activation triggers intracellular calcium mobilization, leading to GnRH neuron firing and GnRH release.

Because Kisspeptin-10 acts at the most upstream point in the HPG cascade — on GnRH neurons themselves. Without kisspeptin signaling through GPR54, GnRH neurons fail to activate properly, and the entire downstream cascade (LH, FSH, gonadal steroids) does not initiate. This was confirmed genetically when loss-of-function GPR54 mutations were found to cause idiopathic hypogonadotropic hypogonadism.

Both activate GPR54 with comparable potency because they share the same C-terminal decapeptide sequence required for receptor binding. Kisspeptin-10 is smaller, easier to synthesize, and has a shorter circulating half-life — making it suitable for acute pulse studies. Kisspeptin-54 has a longer half-life and is used when sustained receptor engagement is desired.

The sequence is Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe (YNWNSFGLRF), with a C-terminal amide modification. This decapeptide sequence is the minimal region required for GPR54 binding and activation, and it is shared by all kisspeptin fragments (KP-54, KP-14, KP-13).

In 2003, two independent research groups (de Roux et al. in PNAS and Seminara et al. in NEJM) identified inactivating mutations in GPR54 in patients with idiopathic hypogonadotropic hypogonadism — a condition of absent puberty with low gonadotropins. This genetic evidence established the kisspeptin-GPR54 axis as a required pathway for normal pubertal development and reproductive function.

Yes. Kisspeptin was originally discovered as a metastasis suppressor gene product in melanoma (hence the name "metastin"). Non-reproductive roles under investigation include cancer biology, placental function, and pancreatic islet regulation. However, the overwhelming majority of current research focuses on the HPG axis.

Kisspeptin-10 is used as a research probe to assess HPG axis responsiveness. By administering Kisspeptin-10 and measuring downstream LH/FSH release, researchers can evaluate GnRH neuron functional capacity and pituitary gonadotroph response. This is particularly useful in studies of pubertal development, reproductive aging, and the effects of metabolic status on reproductive function.

Access Kisspeptin-10 for Research

High-purity Kisspeptin-10 (10mg, ≥99% purity) with third-party HPLC/MS verification — available for qualified research use.

View Kisspeptin-10 10mg →

Research Disclaimer: All content on this page is intended for scientific research and educational purposes only. Kisspeptin-10 is a research peptide and is not approved for human consumption, veterinary use, or as a dietary supplement. Choice Peptide Labs supplies peptides exclusively for in vitro research purposes. All researchers must comply with applicable local, state, and federal regulations. The information presented does not constitute medical advice.

What Is the KLOW Stack? A Research-Backed Guide to 4-Peptide Soft Tissue Protocols

📖 15 min read 🔬 4 independent peptide mechanisms 📅 June 2026

KLOW combines four peptides — KPV, BPC-157, TB-500, and GHK-Cu — into a single pre-blended vial. Each peptide has its own published research history and acts through a completely different biological mechanism. Here's what each one brings to the literature, and why researchers study them together.

What Is KLOW?

KLOW is a research-context name for a four-peptide blend that pairs compounds with distinct and non-overlapping mechanisms of action. The name is an acronym:

K — KPV (alpha-MSH fragment, NF-κB pathway inhibition)
L — (connective tissue context — the blend targets soft tissue)
O — (overlap-free mechanisms — each peptide works through a different pathway)
W — (wound and tissue repair focus)

The four peptides in the blend:

Peptide	Primary Mechanism	Research Focus
KPV	NF-κB pathway inhibition	Mucosal inflammation, immune signaling
BPC-157	NO system modulation + GH receptor expression	Gut, tendon, vascular, nerve repair
TB-500	Actin sequestration + angiogenesis	Cell migration, wound healing, cardiac
GHK-Cu	Gene expression modulation (4,000+ genes)	Collagen synthesis, antioxidant defense, skin

Each peptide was chosen because its mechanism is independent of the others. There is no receptor overlap, no shared signaling pathway, and no redundancy. They operate on different biological targets simultaneously.

Peptide #1: KPV — The Inflammation Signal Blocker

KPV

Mechanism: NF-κB pathway inhibition

KPV is a tripeptide (lysine-proline-valine) and a C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). While alpha-MSH has multiple biological activities, KPV specifically retains the anti-inflammatory properties through NF-κB pathway modulation.

What is NF-κB? Nuclear factor kappa B is a protein complex that acts as a master switch for inflammation. When activated, it triggers the production of inflammatory cytokines — the signaling molecules that drive swelling, pain, and tissue damage in chronic inflammation.

Published research on KPV has examined:

Inhibition of NF-κB activation in intestinal tissue models
Reduction of pro-inflammatory cytokine production in mucosal inflammation
Effects on gut barrier function and intestinal permeability
Anti-inflammatory activity in inflammatory bowel disease (IBD) models

What makes KPV distinct from the other three peptides in KLOW: it works by blocking an inflammatory signal rather than promoting repair. While BPC-157, TB-500, and GHK-Cu all focus on rebuilding and repair, KPV's role is to reduce the inflammatory environment that can impair tissue healing.

📚 Source: Getting, S.J., et al. "alpha-MSH peptides inhibit inflammation through NF-κB." Journal of Immunology. PubMed

Peptide #2: BPC-157 — The Vascular Repair Activator

BPC-157

Mechanism: NO system modulation + GH receptor expression

With 544 published papers, BPC-157 has the largest preclinical evidence base of the four. Originally isolated from gastric juice, it works through the nitric oxide (NO) system via two converging pathways: VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS.

BPC-157's role in the KLOW blend is vascular and connective tissue repair. Through NO system modulation, it promotes:

New blood vessel formation (angiogenesis) at injury sites
Improved vascular integrity and blood flow
Tendon and ligament repair in preclinical models
Gastrointestinal mucosal protection

The convergent pathway model — two independent signaling routes both enhancing eNOS activity — provides redundancy that may explain its consistent results across diverse experimental conditions.

📚 Source: Hsieh, M.J., et al. Scientific Reports (Nature), 10, 17078. Nature

Peptide #3: TB-500 — The Cell Migration Engine

TB-500

Mechanism: Actin sequestration + angiogenesis

A 43-amino acid synthetic fragment of Thymosin Beta-4. Over 148 published studies. TB-500 regulates G-actin — the monomeric form of the structural protein that drives cell movement, division, and tissue remodeling.

TB-500's role in KLOW is enabling the cellular machinery of repair. While BPC-157 improves blood supply and KPV reduces inflammation, TB-500 ensures that cells can actually move to the injury site and rebuild:

Actin regulation enables cell migration to wound sites
The LKKTETQ domain promotes new blood vessel formation
Studies documented faster wound closure and reduced scarring in preclinical models
Effects observed across cardiac, corneal, dermal, and soft tissue models

The key distinction: TB-500 operates at a fundamental structural level. It doesn't activate a receptor pathway — it controls the protein that enables cell movement itself.

📚 Source: Huff, T., et al. FASEB Journal, 18(11), 1254–1256. DOI

Peptide #4: GHK-Cu — The Gene Expression Modulator

GHK-Cu

Mechanism: Gene expression modulation (4,000+ genes)

A naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) identified by Loren Pickart in 1973. Gene expression research using the Broad Institute's Connectivity Map showed GHK-Cu modulates ~32% of the human genome.

GHK-Cu's role in KLOW is the most wide-reaching — it operates at the epigenetic level, influencing which genes are turned on or off:

Upregulates: Collagen, glycosaminoglycans, decorin — the structural components of skin and connective tissue
Downregulates: NF-κB inflammatory gene expression (complementing KPV's NF-κB protein-level inhibition)
Activates: Nrf2 antioxidant defense pathways
Promotes: Wound remodeling and fibroblast activity in dermatological models

GHK-Cu doesn't just affect one pathway — it shifts the cell's overall gene expression profile toward a more regenerative state. This is fundamentally different from receptor-based mechanisms.

📚 Source: Pickart, L., et al. "Regenerative and Protective Actions of the GHK-Cu Peptide." PMC. PMC6073405

Why Combine Four Peptides Instead of One?

The rationale for KLOW is not "more is better." It's mechanistic complementarity.

Soft tissue repair involves multiple simultaneous biological processes:

Inflammation control — the inflammatory environment must be managed before repair can proceed efficiently (KPV)
Blood supply restoration — damaged tissue needs oxygen and nutrients delivered through new and existing vasculature (BPC-157)
Cell migration and remodeling — cells need to physically move to the injury site and rebuild structural architecture (TB-500)
Extracellular matrix synthesis — the structural scaffolding (collagen, glycosaminoglycans) needs to be produced and organized (GHK-Cu)

A single peptide addresses one (or possibly two) of these processes. KLOW addresses all four through independent, non-overlapping mechanisms.

This is the same logic behind combination approaches in other areas of research — targeting multiple pathways simultaneously rather than relying on a single mechanism.

KLOW as a Research Tool

KLOW comes as a single pre-blended lyophilized vial containing all four compounds at specified concentrations. This format is designed for research convenience — four compounds that would otherwise require separate preparation are combined in one vial.

For researchers studying multi-pathway approaches to soft tissue repair, KLOW eliminates the need to source, reconstitute, and prepare each peptide individually.

Every batch ships with a published Certificate of Analysis showing purity verification for each compound in the blend.

Frequently Asked Questions About KLOW

What does KLOW stand for?

KLOW is a research-context name for the four-peptide blend: KPV + BPC-157 + TB-500 + GHK-Cu. The name references the combination's focus on soft tissue repair through complementary mechanisms.

Why are these four peptides combined?

Each peptide acts through a different mechanism: KPV blocks NF-κB inflammation, BPC-157 modulates the NO system for vascular repair, TB-500 regulates actin for cell migration, and GHK-Cu modulates gene expression for extracellular matrix synthesis. There is no receptor overlap or redundant signaling.

Is KLOW a single compound or four separate compounds?

KLOW is a pre-blended combination of four separate peptides in a single lyophilized vial. Each peptide maintains its own mechanism of action. The blend is for research convenience.

What is KPV and how does it work?

KPV is a tripeptide (lysine-proline-valine) that is a C-terminal fragment of alpha-MSH. It works by inhibiting the NF-κB pathway — a protein complex that acts as a master switch for inflammation. Published research has examined its effects on mucosal inflammation and intestinal tissue models.

How does GHK-Cu modulate gene expression?

Gene expression research using the Broad Institute's Connectivity Map database showed GHK-Cu modulates the activity of over 4,000 human genes (~32% of the genome). It upregulates genes for collagen and structural proteins, downregulates inflammatory gene expression via NF-κB, and activates antioxidant defense through Nrf2 pathways.

Has KLOW been studied as a combination?

The individual peptides have extensive published research histories — BPC-157 alone has 544 papers, TB-500 has 148+ studies, GHK-Cu has 50+ years of research. The combination as "KLOW" is a research-format blend. The rationale for combining them is based on mechanistic complementarity, not a single clinical trial of the blend itself.

How does KLOW compare to using individual peptides?

KLOW addresses four biological processes simultaneously — inflammation control (KPV), blood supply restoration (BPC-157), cell migration (TB-500), and extracellular matrix synthesis (GHK-Cu). A single peptide typically addresses one primary process. The blend is designed for research contexts examining multi-pathway approaches.

What is a Certificate of Analysis for KLOW?

A COA for KLOW includes purity verification for each of the four compounds in the blend, typically using HPLC and mass spectrometry. Choice Peptide Labs publishes a batch-specific COA showing the testing results for all four peptides.

Explore KLOW from Choice Peptide Labs

80mg blend (KPV + BPC-157 + TB-500 + GHK-Cu) · Published COA for every batch · Dispatched within 1 business day · Cold-chain shipped

View KLOW Product Page →

Disclaimer: This article is for educational and informational purposes only. All information is derived from published, peer-reviewed research on the individual peptides in the KLOW blend. Nothing in this article is medical advice or a claim of therapeutic benefit. All products from Choice Peptide Labs are for laboratory research use only and are not intended for human or veterinary consumption.

KLOW vs GLOW Blend: What's the Difference?

📖 14 min read 🔬 Side-by-side comparison 📅 June 2026

If you've spent any time researching multi-peptide recovery blends, you've probably seen two names come up again and again: GLOW and KLOW. They sound similar. They share three of the same ingredients. But they're not the same blend — and the difference matters. Here's a clear breakdown of what sets them apart.

What Is the GLOW Blend?

GLOW is a three-peptide blend that combines:

BPC-157 — a 15-amino acid peptide studied for soft-tissue repair, gut protection, and growth factor signaling
TB-500 — the synthetic form of Thymosin Beta-4, studied for actin regulation, cell migration, and anti-fibrotic remodeling
GHK-Cu — a copper-binding tripeptide studied for collagen synthesis, gene expression modulation, and skin biology

Together, these three peptides address a broad spectrum of tissue repair research: BPC-157 builds vascular infrastructure and upregulates growth factors. TB-500 mobilizes repair cells and prevents excessive scarring. GHK-Cu modulates gene expression related to collagen, extracellular matrix remodeling, and antioxidant defense.

GLOW has been a popular research formulation because the three peptides cover different aspects of the repair cascade — structural, cellular, and genetic — through non-overlapping mechanisms.

📚 Source: Pickart, L. et al. "GHK-Cu peptide in the treatment of tissue regeneration." PMC6073405. PMC

What Is the KLOW Blend?

KLOW takes everything in GLOW and adds a fourth peptide:

BPC-157 — same as GLOW
TB-500 — same as GLOW
GHK-Cu — same as GLOW
KPV — a 3-amino acid tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte stimulating hormone (alpha-MSH)

KPV is what makes KLOW different. While GLOW's three peptides focus on building, mobilizing, and remodeling, KPV adds a dedicated anti-inflammatory signaling component that the other three peptides don't directly address in the same way.

The "K" in KLOW stands for KPV. The name is a direct acknowledgment that this fourth compound changes the blend's research profile.

📚 Source: KPV research overview — PeptideJournal. PeptideJournal

What KPV Adds: The Anti-Inflammatory Mechanism

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH — a 13-amino acid hormone known for its potent anti-inflammatory properties. What makes KPV interesting to researchers is that it retains alpha-MSH's anti-inflammatory activity while being just three amino acids long.

How KPV Works

KPV's primary mechanism is NF-κB pathway inhibition. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex that controls DNA transcription, cytokine production, and cell survival. It's one of the central regulators of the inflammatory response.

When NF-κB is overactivated — as in chronic inflammation, gut injury, or autoimmune conditions — it drives excessive production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1β.

KPV has been shown in preclinical studies to suppress NF-κB activation, reducing the downstream inflammatory cascade. Unlike full-length alpha-MSH, KPV does this without binding to melanocortin receptors (MC1R–MC5R), which means it achieves anti-inflammatory signaling without the pigmentation effects associated with melanocortin receptor activation.

What Makes KPV Unique

KPV's Distinctive Properties

Smallest active anti-inflammatory peptide fragment — just 3 amino acids, yet retains the NF-κB inhibitory activity of the full 13-amino acid alpha-MSH molecule
No melanocortin receptor binding — anti-inflammatory action without pigmentation effects
PepT1 transporter uptake — KPV is absorbed through the intestinal peptide transporter PepT1, which has made it a subject of interest in inflammatory bowel disease (IBD) research models
Antimicrobial activity — KPV has shown antimicrobial properties in preclinical studies, adding a dimension that BPC-157, TB-500, and GHK-Cu don't directly address
Gut-specific research interest — multiple studies have examined KPV's effects on mucosal inflammation, intestinal permeability, and colitis models

📚 Source: Getting, S.J. et al. "Melanocortin peptides and their receptors." Trends Pharmacol Sci. PMID: 11282135

Side-by-Side Comparison

Attribute	GLOW Blend	KLOW Blend
Peptides	BPC-157, TB-500, GHK-Cu	BPC-157, TB-500, GHK-Cu, KPV
Number of compounds	3	4
Vial size (Choice Peptide Labs)	70mg	80mg
Anti-inflammatory component	Indirect (via BPC-157 and TB-500)	Direct NF-κB inhibition (KPV)
Collagen / gene expression	Yes — GHK-Cu	Yes — GHK-Cu
Cell migration / actin	Yes — TB-500	Yes — TB-500
Soft-tissue repair / angiogenesis	Yes — BPC-157	Yes — BPC-157
Gut-specific inflammation	BPC-157 (cytoprotective)	BPC-157 + KPV (anti-inflammatory + cytoprotective)
Antimicrobial activity	Not directly	Yes — KPV
Research focus	Tissue repair, collagen, recovery	Tissue repair + dedicated inflammation modulation
Signature color	Copper-orange / amber	Royal blue

How Each Compound Contributes

BPC-157 — The Foundation

Present in both blends, BPC-157 provides the base layer of repair research. It upregulates VEGF and other growth factors, modulates the nitric oxide system, and promotes angiogenesis. In tendon healing models, treated subjects showed 41–47% increases in collagen density. BPC-157 works through the VEGFR2/eNOS pathway and is considered one of the most versatile peptides in preclinical tissue repair research.

TB-500 — The Mobilizer

Also present in both blends, TB-500 handles cell migration and anti-fibrotic remodeling. Through G-actin sequestration via the LKKTETQ domain, it controls how quickly repair cells reach the injury site. In wound healing models, reepithelialization increased 42% at day 4 and 61% at day 7. TB-500 also promotes macrophage M1→M2 polarization, moving tissue from inflammation into repair.

GHK-Cu — The Gene Modulator

The third shared compound, GHK-Cu (copper tripeptide-1), works at a different level than BPC-157 and TB-500. Rather than acting on receptor pathways, GHK-Cu directly modulates gene expression — upregulating genes involved in collagen synthesis, antioxidant defense, and tissue remodeling while downregulating genes associated with inflammation and tissue degradation. A Broad Institute Connectivity Map analysis found that GHK-Cu influenced the expression of over 3,000 genes.

KPV — The Anti-Inflammatory Specialist (KLOW only)

KPV is the defining difference between the two blends. While BPC-157 and TB-500 have anti-inflammatory properties, they work through indirect mechanisms — NO modulation, macrophage polarization, and growth factor signaling. KPV directly inhibits NF-κB, one of the master switches of the inflammatory response. This adds a layer of targeted inflammation control that GLOW doesn't have.

In preclinical IBD models, KPV reduced mucosal inflammation and improved intestinal barrier function. Its absorption through the PepT1 intestinal transporter makes it particularly interesting for gut-focused research.

📚 Source: Pickart, L. & Margolina, A. "GHK-Cu peptide as a regulator of gene expression." PMC6073405. PMC

When Would Researchers Choose One Over the Other?

The choice between GLOW and KLOW depends on the research question:

Choose GLOW when the research focus is:

Skin biology and collagen remodeling (GHK-Cu dominant)
General tissue repair and recovery (BPC-157 + TB-500)
Gene expression modulation (GHK-Cu)
A three-compound protocol with well-established individual research bases

Choose KLOW when the research focus includes:

Gut-specific inflammation and mucosal repair (BPC-157 + KPV)
Conditions where NF-κB overactivation is a factor
Chronic inflammation models where a dedicated anti-inflammatory peptide adds value
Research requiring broader mechanistic coverage across the full healing cascade — from acute inflammation through remodeling

What the Research Shows — and Doesn't Show

It's important to note that both GLOW and KLOW are research formulations. The individual peptides have published preclinical data, but:

No formal combination studies exist — the synergy between these peptides is theorized from independent mechanism research, not from controlled trials studying the blends as a whole
No human RCTs for either blend as of 2026
Optimal ratios are empirical — the proportion of each peptide in a blend has not been established by controlled research
KPV's gut-specific data is promising but early — most studies are in preclinical IBD models

The mechanistic rationale for both blends is strong. The empirical data on the combinations specifically is still being built. This is the honest state of the science.

Frequently Asked Questions

What's the main difference between KLOW and GLOW?

KLOW contains four peptides (BPC-157, TB-500, GHK-Cu, and KPV). GLOW contains three (BPC-157, TB-500, and GHK-Cu). The fourth peptide, KPV, adds a direct anti-inflammatory mechanism through NF-κB pathway inhibition that the other three peptides don't directly address.

What is KPV and what does it do?

KPV (Lys-Pro-Val) is a 3-amino acid tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (alpha-MSH). It inhibits NF-κB signaling — a master regulator of inflammation — without binding to melanocortin receptors. This means it achieves anti-inflammatory effects without pigmentation-related activity. It's been studied primarily in inflammatory bowel disease models.

Do KLOW and GLOW share the same three base peptides?

Yes. Both contain BPC-157 (soft-tissue repair, growth factor signaling), TB-500 (cell migration, actin regulation), and GHK-Cu (gene expression modulation, collagen synthesis). KLOW adds KPV on top of this foundation.

Is there research on these blends as complete formulations?

No. The published research is on the individual peptides, not on the blends as complete formulations. The rationale for combining them is based on their complementary mechanisms — each peptide addresses a different phase or pathway in the tissue repair cascade. Formal combination studies have not been conducted.

Why is KLOW 80mg and GLOW 70mg?

KLOW is 80mg because it contains four peptides. GLOW is 70mg because it contains three. The additional 10mg in KLOW accounts for the KPV compound. Both are single-vial formulations from Choice Peptide Labs.

Which blend is better for gut-focused research?

KLOW may be more relevant for gut-focused research because it combines BPC-157's cytoprotective effects with KPV's direct NF-κB inhibition and its specific absorption through the PepT1 intestinal transporter. GLOW addresses gut repair through BPC-157 alone but lacks the dedicated anti-inflammatory component that KPV provides.

Are KLOW and GLOW FDA approved?

No. Neither blend is FDA approved for any therapeutic indication. All constituent peptides are research compounds sold for laboratory use only. Nothing in this article constitutes medical advice or a recommendation for human use.

Where can I get a Certificate of Analysis?

Choice Peptide Labs publishes a COA for every batch on the product page. Each COA includes HPLC purity verification and mass spectrometry confirmation for the complete formulation.

Explore KLOW and GLOW from Choice Peptide Labs

Both available as single-vial formulations · Published COA for every batch · Dispatched within 1 business day · Cold-chain shipped

View KLOW 80mg → View GLOW 70mg →

Disclaimer: This article is for educational and informational purposes only. All information presented is derived from published, peer-reviewed preclinical research and is intended to describe what has been studied in research models. Nothing in this article is intended as medical advice, a recommendation for use, or a claim of therapeutic benefit. Neither KLOW, GLOW, nor any of their constituent peptides are approved by the FDA for human use. All products from Choice Peptide Labs are sold for laboratory research use only and are not intended for human or veterinary consumption.

KPV: The NF-κB Inhibiting Tripeptide in Anti-Inflammatory Research

The Quiet One · Healing & Recovery

KPV is one of the smallest bioactive peptides ever studied — just three amino acids. But its ability to inhibit NF-κB, one of the body's master inflammatory switches, has made it a focus of anti-inflammatory and gut-repair research for over two decades.

What Is KPV?

KPV stands for Lysine-Proline-Valine (Lys-Pro-Val), a tripeptide consisting of just three amino acid residues. It is the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically positions 11–13 of the parent hormone's sequence.

Alpha-MSH is a 13-amino acid peptide hormone derived from proopiomelanocortin (POMC). It has broad anti-inflammatory and immunomodulatory activity. What makes KPV remarkable is that it retains a significant portion of alpha-MSH's anti-inflammatory function while being too small to activate melanocortin receptors — meaning it works through a completely different mechanism.

At only three amino acids, KPV is small enough to be absorbed through the intestinal epithelium via the PepT1 (Peptide Transporter 1) system, which makes it uniquely suited for gut-specific research applications.

Getting SJ et al. "Melanocortin peptides inhibit experimental colitis." J Pharmacol Exp Ther. 2001;298(1):162-8. PMID: 11282135

The NF-κB Pathway: KPV's Primary Target

Nuclear Factor kappa B (NF-κB) is one of the most important transcription factors in human biology. It acts as a master regulator of inflammatory gene expression, controlling the production of cytokines like TNF-α, IL-1β, and IL-6. When NF-κB is chronically activated — as it is in conditions like inflammatory bowel disease (IBD) — it drives persistent tissue inflammation and damage.

KPV directly inhibits NF-κB activation. It does this by blocking the nuclear translocation of the p65 subunit (RelA) of the NF-κB complex. When p65 cannot enter the nucleus, it cannot activate the transcription of pro-inflammatory genes.

Key Finding

KPV inhibits NF-κB independently of melanocortin receptors. Unlike the full alpha-MSH molecule, KPV does not bind MC1-R through MC5-R. Its anti-inflammatory effect is mediated through direct suppression of the NF-κB signaling cascade — specifically through inhibition of IκB kinase (IKK) activity and subsequent prevention of IκBα degradation and p65 nuclear translocation.

This receptor-independent mechanism is what makes KPV pharmacologically distinct. It means the peptide's anti-inflammatory activity is not subject to melanocortin receptor desensitization or downregulation — a concern that applies to the full alpha-MSH molecule.

PepT1 Transporter: Gut-Specific Absorption

One of KPV's most clinically relevant properties is its ability to be transported by the PepT1 (H+/peptide cotransporter) system. PepT1 is a proton-coupled oligopeptide transporter expressed on the apical membrane of intestinal epithelial cells. It normally absorbs dietary di- and tripeptides for nutrition.

Because KPV is only three amino acids, it is a substrate for PepT1. This means KPV can be absorbed intact from the gut lumen into the intestinal epithelium, where it exerts its anti-inflammatory effects directly at the mucosal level.

This gut-specific absorption profile is precisely why most preclinical research on KPV has focused on intestinal inflammation. The peptide doesn't need to survive systemic circulation to reach its target — the gut lining is its target.

Implications for Bioavailability

Unlike larger peptides that require injection, KPV's small size and PepT1 compatibility suggest potential for oral or topical delivery in research settings. However, oral bioavailability data in humans remains limited, and most preclinical studies have used either oral gavage in animal models or direct application to cell cultures.

Antimicrobial Activity

Beyond its anti-inflammatory signaling, KPV has demonstrated intrinsic antimicrobial properties in preclinical testing. The peptide shows activity against both gram-positive and gram-negative bacteria, though the concentrations required are higher than those needed for NF-κB inhibition.

This dual activity — anti-inflammatory plus antimicrobial — is significant because intestinal inflammation is almost always accompanied by dysbiosis and bacterial translocation. A compound that addresses both the inflammatory cascade and bacterial overgrowth simultaneously may offer a more complete approach in research models.

The antimicrobial mechanism appears to involve disruption of bacterial cell membranes, similar to other cationic antimicrobial peptides. The lysine residue at position 1 carries a positive charge that may facilitate interaction with negatively charged bacterial membranes.

Preclinical IBD and Colitis Models

The majority of KPV research has been conducted in models of inflammatory bowel disease (IBD), including both ulcerative colitis and Crohn's disease analogs.

DSS-Induced Colitis

In the widely used dextran sodium sulfate (DSS) colitis model, oral KPV administration significantly reduced disease activity index scores, including improvements in body weight loss, stool consistency, and rectal bleeding. Histological analysis showed reduced mucosal inflammation, decreased inflammatory cell infiltration, and preserved epithelial architecture compared to untreated controls.

TNBS Colitis Model

In the trinitrobenzene sulfonic acid (TNBS) model — which better recapitulates Crohn's-like transmural inflammation — KPV reduced colonic TNF-α and IL-1β production. These effects were comparable to or exceeded those seen with the full alpha-MSH molecule in some experimental designs.

Peptide Journal: "KPV: The Anti-Inflammatory Tripeptide." Comprehensive research summary covering NF-κB mechanism and IBD preclinical data.

KPV vs. Full Alpha-MSH

Property	KPV	Alpha-MSH (full)
Size	3 amino acids (387 Da)	13 amino acids (~1,600 Da)
Melanocortin receptor binding	None	MC1-R through MC5-R
NF-κB inhibition	Yes — direct	Yes — receptor-mediated
Pigmentation effects	None	Yes (MC1-R activation)
PepT1 transport	Yes	No (too large)
Oral bioavailability (preclinical)	Good	Poor
Gut-specific action	Yes — primary target	Systemic

The comparison highlights why KPV is of such interest: it distills the anti-inflammatory activity of alpha-MSH into a molecule small enough to be orally active, gut-targeted, and free from melanocortin receptor side effects like pigmentation changes.

Safety Profile

KPV has demonstrated a favorable safety profile in available preclinical studies. Key safety observations include:

No melanocortin receptor activation: KPV does not cause pigmentation changes, altered appetite signaling (MC4-R), or immunomodulation through the melanocortin pathway.

No significant toxicity: In rodent studies, oral KPV at doses significantly above the effective anti-inflammatory dose showed no signs of organ toxicity, behavioral changes, or mortality.

Endogenous context: KPV is a naturally occurring fragment of a human hormone (alpha-MSH), which is present endogenously. This provides some baseline context for safety, though supraphysiological dosing would need independent evaluation.

No known drug interactions: Because KPV operates through a distinct NF-κB mechanism and has a small molecular footprint, it is unlikely to interact with drugs metabolized through hepatic cytochrome P450 pathways. However, formal interaction studies have not been published.

Current Limitations and Research Gaps

Despite promising preclinical data, several important limitations must be noted:

No human clinical trials: All existing efficacy data comes from cell culture and animal models. The leap from rodent colitis to human IBD is substantial, and no randomized controlled trials (RCTs) of KPV in humans have been published.

Dosing uncertainty: Optimal dosing, frequency, and duration of KPV administration in humans are unknown. Preclinical doses do not scale linearly to human equivalents.

Limited systemic data: Most research has focused on gut inflammation. The potential of KPV for systemic inflammatory conditions (joint inflammation, dermatitis, etc.) is largely unexplored.

Stability questions: While small peptides are generally more stable than large ones, KPV's behavior in varying pH environments, gastric acid, and storage conditions needs further characterization for any formulation development.

Frequently Asked Questions

What does KPV stand for?

KPV stands for Lysine-Proline-Valine (Lys-Pro-Val), the three amino acids that compose this tripeptide. It is derived from positions 11–13 of the alpha-melanocyte-stimulating hormone (alpha-MSH) molecule.

How does KPV inhibit NF-κB?

KPV directly suppresses the NF-κB signaling pathway by inhibiting IKK activity, preventing IκBα degradation, and blocking the nuclear translocation of the p65 (RelA) subunit. This occurs independently of melanocortin receptors.

Is KPV the same as alpha-MSH?

No. KPV is a small C-terminal fragment of alpha-MSH (positions 11–13). It shares some anti-inflammatory properties but lacks melanocortin receptor binding activity. It does not cause pigmentation changes or other melanocortin-dependent effects.

How is KPV absorbed in the gut?

KPV is transported by the PepT1 (H+/peptide cotransporter 1) system, which normally absorbs dietary di- and tripeptides. Because KPV is only three amino acids, it is a natural substrate for this transporter and can be absorbed intact across the intestinal epithelium.

Has KPV been studied in human clinical trials?

No. As of the current published literature, all efficacy data for KPV comes from cell culture and animal models. No randomized controlled trials in humans have been conducted or published.

Does KPV have antimicrobial properties?

Yes. KPV has demonstrated intrinsic antimicrobial activity against both gram-positive and gram-negative bacteria in preclinical testing, likely through membrane disruption mediated by its cationic lysine residue.

What inflammatory markers does KPV reduce?

In preclinical models, KPV has been shown to reduce TNF-α, IL-1β, and IL-6 production — all of which are downstream targets of NF-κB transcriptional activation.

Is KPV safe?

Preclinical safety data has been favorable. KPV shows no melanocortin receptor activation, no organ toxicity at supratherapeutic doses in animal models, and is derived from an endogenous human hormone fragment. However, human safety data from clinical trials is not available.

Explore KPV for Your Research

KPV is available in lyophilized form for qualified research applications. Learn more about specifications, purity, and sourcing.

View KPV Product →

Disclaimer: This article is for informational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. KPV is sold as a research peptide and is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before beginning any new research protocol.

What Is MOTS-c? A Research-Backed Guide to the Mitochondrial-Derived Peptide

📖 13 min read 🔬 Nature Communications, J Translational Medicine, PMC 📅 June 2026

MOTS-c was only discovered in 2015 — but it's already changing how researchers think about mitochondria. It's a 16-amino acid peptide encoded by mitochondrial DNA that translocates to the nucleus during stress, activating gene expression programs. The field is less than a decade old and expanding rapidly.

2015

Discovered

16

Amino Acids

mtDNA

Encoded (not nuclear)

<10

Years of Research

What Is MOTS-c?

MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) is a 16-amino acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene.

That's a technical way of saying something profound: MOTS-c comes from your mitochondria's own DNA, not from the nucleus. Most proteins in your body are encoded by nuclear DNA. MOTS-c is one of a small but growing class of mitochondrial-derived peptides (MDPs) — peptides that originate from the organelle itself.

It was first reported in 2015 by Changhan Lee and Pinchas Cohen at the USC Leonard Davis School of Gerontology. The discovery was part of a broader effort to identify functional peptides encoded by the mitochondrial genome — a genome that was previously thought to only encode components of the electron transport chain.

"MOTS-c is a mitochondria-encoded exercise-induced peptide that regulates skeletal muscle metabolism and improves healthspan of older mice." — Nature Communications, 2020

📚 Source: Reynolds, J.C., et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of muscle metabolism." Nature Communications, 12, 720. Nature Communications

The Revolutionary Concept: Mitochondria-to-Nucleus Signaling

Before MOTS-c, the communication model between mitochondria and the nucleus was understood as mostly one-directional: nuclear DNA encodes most mitochondrial proteins, which are then imported into the mitochondria.

MOTS-c demonstrated that the reverse is also true: mitochondria can send signals back to the nucleus. This concept — called retrograde signaling — was not new, but MOTS-c provided one of the clearest molecular examples of a mitochondria-encoded peptide that physically translocates to the nucleus to regulate gene expression.

MOTS-c Signaling Pathway

🧬

Mitochondria

MOTS-c encoded by mtDNA 12S rRNA

→

⚡

Metabolic Stress

Exercise, energy demand, oxidative stress

→

🔄

Translocation

MOTS-c moves from mitochondria to nucleus

→

🎯

Gene Activation

ARE genes, stress-adaptation programs

During metabolic stress — exercise, energy demand, or oxidative challenge — MOTS-c is released from the mitochondria and translocates to the nucleus. Once there, it regulates the expression of genes containing antioxidant response elements (ARE) — sequences that activate the cell's defense against oxidative damage.

📚 Source: "Mitochondria-derived peptide MOTS-c: effects and mechanisms." Journal of Translational Medicine, 2023. Springer

The Exercise Mimetic Finding

The characterization that brought MOTS-c into the spotlight: exercise mimetic.

A 2021 study published in Nature Communications demonstrated that MOTS-c is:

Key Findings from Nature Communications

Released during physical exercise — MOTS-c expression increases in skeletal muscle, systemic circulation, and the hypothalamus during and after exercise
Mediates metabolic benefits — MOTS-c treatment in preclinical models reproduced some of the metabolic benefits associated with exercise
Exercise-induced — the peptide is upregulated specifically by physical activity, not by other stimuli
Improves healthspan — in older mice, MOTS-c treatment improved metabolic health markers

Why "exercise mimetic"? Because MOTS-c appears to activate some of the same metabolic pathways that exercise activates — without the exercise itself being required. This is not the same as "replacing exercise" — it means the peptide engages overlapping molecular machinery.

📚 Source: Reynolds, J.C., et al. Nature Communications, 12, 720. Nature Communications

The Folate-AICAR-AMPK Pathway

MOTS-c acts through a specific metabolic signaling cascade: the Folate-AICAR-AMPK pathway.

Here's what each component does:

Folate: MOTS-c influences folate metabolism — the cellular pathway that uses vitamin B9 for one-carbon reactions critical for DNA synthesis and repair
AICAR: 5-aminoimidazole-4-carboxamide ribonucleotide — a compound that activates AMPK. Notably, AICAR itself has been studied as an exercise-mimetic compound in its own right
AMPK: AMP-activated protein kinase — a master regulator of cellular energy balance. AMPK activation promotes mitochondrial biogenesis, fatty acid oxidation, and glucose uptake

The connection to AICAR is particularly significant: AICAR was the compound used in a landmark study showing exercise-mimetic effects in sedentary mice. MOTS-c acts through the same downstream pathway — but through an endogenous peptide mechanism rather than a synthetic compound.

Published Research: What the Studies Show

MOTS-c Research Highlights

Nature Communications (2021): MOTS-c is exercise-induced, regulates skeletal muscle metabolism, improves healthspan in older mice
Journal of Translational Medicine (2023): During metabolic stress, MOTS-c translocates to the nucleus and activates stress-adaptation genes with antioxidant response elements
Free Radical Biology and Medicine (2025): Connected MOTS-c to attenuation of mitochondrial dysfunction and regulation of pyroptosis (inflammatory cell death)
PMC (2025): Comprehensive review describing MOTS-c as "a mighty mitochondrial microprotein" with protective roles across multiple organ systems
Frontiers in Endocrinology (2023): Review examining MOTS-c's role as a potential "exercise mimetic" and metabolic regulator encoded by the mitochondrial genome

📚 Source: "MOTS-c attenuates mitochondrial dysfunction, induces pyroptosis." Free Radical Biology and Medicine, 2025. ScienceDirect

📚 Source: "A Mighty Mitochondrial Microprotein: The Protective Role of MOTS-c." PMC, 2025. PMC

Why MOTS-c Is Fundamentally Different

MOTS-c is unlike every other peptide on this list. Here's why:

Encoded by mitochondrial DNA: Every other peptide in the Choice Peptide Labs catalog is encoded by nuclear DNA. MOTS-c comes from the mitochondria's own genome — a separate, ancient genome with its own evolutionary history.
Retrograde signaling: MOTS-c doesn't just bind a receptor on the cell surface. It physically moves from the mitochondria to the nucleus, directly influencing gene transcription.
Exercise-responsive: MOTS-c is specifically upregulated by physical activity — it's part of the molecular response to exercise, not a constitutively expressed peptide.
Cross-compartment communication: It bridges two organelles (mitochondria and nucleus) in a way that few other peptides have been shown to do.

This is why researchers describe MOTS-c as opening a new frontier — it demonstrated that the mitochondrial genome encodes functional signaling peptides, not just electron transport chain components. This concept has implications that extend far beyond MOTS-c itself.

The Research Landscape: Young and Rapidly Expanding

The MOTS-c research field is less than a decade old. Key areas of active investigation include:

Metabolic homeostasis: How MOTS-c regulates energy balance, glucose metabolism, and fatty acid oxidation
Aging and longevity: Whether MOTS-c decline contributes to age-related metabolic dysfunction
Exercise physiology: The molecular mechanisms by which exercise upregulates MOTS-c and how this contributes to exercise benefits
Organ protection: Emerging evidence of protective roles in multiple organ systems (lung, brain, cardiovascular)
Other mitochondrial-derived peptides: MOTS-c's discovery has driven research into additional MDPs encoded by the mitochondrial genome

Frequently Asked Questions About MOTS-c

What does MOTS-c stand for?

Mitochondrial ORF of the 12S rRNA Type-C. "ORF" means open reading frame — a section of DNA that can be translated into a protein. It's encoded within the mitochondrial 12S rRNA gene.

When was MOTS-c discovered?

2015, by Changhan Lee and Pinchas Cohen at the USC Leonard Davis School of Gerontology. It's one of the first mitochondrial-derived peptides (MDPs) to be functionally characterized.

Why is it encoded by mitochondrial DNA?

Mitochondria have their own genome — separate from nuclear DNA. This genome was previously thought to only encode components of the electron transport chain. MOTS-c demonstrated that the mitochondrial genome also encodes functional signaling peptides — a paradigm shift.

What does "exercise mimetic" mean?

MOTS-c is released during exercise and activates some of the same metabolic pathways that exercise activates (via the Folate-AICAR-AMPK pathway). "Exercise mimetic" means it engages overlapping molecular machinery — not that it replaces the full benefits of physical activity.

What is retrograde signaling?

Communication from the mitochondria back to the nucleus. Most cellular signaling goes nuclear → mitochondrial (nuclear DNA encodes mitochondrial proteins). MOTS-c demonstrated the reverse: a mitochondria-encoded peptide that physically translocates to the nucleus to regulate gene expression.

What pathway does MOTS-c act through?

The Folate-AICAR-AMPK pathway. AICAR is the same compound studied as an exercise-mimetic agent. AMPK is a master regulator of cellular energy balance — promoting mitochondrial biogenesis, fatty acid oxidation, and glucose uptake.

Is MOTS-c research still early?

Yes. The field is less than a decade old (discovered 2015). Published research is rapidly expanding across metabolic, aging, exercise, and organ-protection contexts. It's one of the youngest areas in peptide research.

What is a Certificate of Analysis for MOTS-c?

An independent lab report showing HPLC purity and mass spectrometry for a specific batch. Choice Peptide Labs publishes a COA for every batch on the product page.

Explore MOTS-c from Choice Peptide Labs

10mg vial · Published Certificate of Analysis · Dispatched within 1 business day · Cold-chain shipped

View MOTS-c Product Page →

Disclaimer: This article is for educational and informational purposes only. All information is derived from published, peer-reviewed research. MOTS-c is a research compound not approved by the FDA for human use. All products from Choice Peptide Labs are for laboratory research use only and are not intended for human or veterinary consumption.

What Is NAD+? A Research-Backed Guide to the Longevity Cofactor

📖 13 min read 🔬 Nature, Nature Metabolism, PMC 📅 June 2026

NAD+ is the molecule your mitochondria depend on for energy production, DNA repair, and cellular signaling. Its decline with age is one of the most studied phenomena in longevity science. Here's what the published research shows — and why it matters.

400+

Enzymatic Reactions

~50%

Decline by Middle Age

Every Cell

Depends on NAD+

What Exactly Is NAD+?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme — not a peptide, not a hormone, not a protein. It's a small molecule that participates in over 400 enzymatic reactions inside every cell in your body.

Think of NAD+ as the currency of cellular energy. Just as your body needs ATP (the energy molecule) to do work, it needs NAD+ to make that ATP in the first place. Without NAD+, the mitochondria — the power plants inside your cells — cannot function.

But NAD+ does far more than energy production. It's also required for:

DNA repair — NAD+ activates sirtuins and PARPs, the enzyme families responsible for fixing damaged DNA
Cellular signaling — NAD+ modulates communication between cellular compartments
Circadian rhythm maintenance — NAD+ levels oscillate with your body's internal clock
Immune function — NAD+ influences inflammatory responses and immune cell activity

📚 Source: "The role of NAD+ metabolism and its modulation of mitochondria in aging and disease." Nature, 2025. Nature

The Central Finding: NAD+ Declines With Age

This is the discovery that launched an entire field of longevity research. Across multiple species — from yeast to worms to flies to mice to humans — NAD+ levels decrease with age.

Published research has documented this decline in multiple tissue types:

What Published Studies Show

Brain tissue: NAD+ levels decline significantly in the brain with age, correlating with cognitive decline
Skeletal muscle: Age-related NAD+ depletion in muscle tissue correlates with reduced mitochondrial function
Liver: NAD+ decline in liver tissue affects metabolic regulation and detoxification pathways
Skin: NAD+ depletion in skin correlates with reduced repair capacity and visible aging markers
Adipose tissue: Fat cell NAD+ levels affect metabolic signaling and insulin sensitivity

The magnitude is significant. Research suggests NAD+ levels may decline by approximately 50% between young adulthood and middle age in certain tissues. This isn't a subtle change — it's a fundamental shift in the cell's capacity to produce energy, repair DNA, and maintain itself.

📚 Source: "The therapeutic perspective of NAD+ precursors in age-related diseases." Biochemical and Biophysical Research Communications, 2024. ScienceDirect

Why Does NAD+ Decline?

The decline isn't caused by a single factor. Published research points to multiple converging mechanisms:

Increased Consumption

As cells age, they accumulate more DNA damage. The enzymes that repair DNA (PARPs) consume NAD+ as fuel. More damage = more repair activity = more NAD+ consumed. It's like a bank account where withdrawals increase but deposits stay the same.

Decreased Production

The biosynthetic pathways that produce NAD+ become less efficient with age. The enzymes responsible for NAD+ synthesis — particularly NAMPT (nicotinamide phosphoribosyltransferase) — show reduced activity in aged tissues.

Increased Degradation

CD38 — an enzyme that breaks down NAD+ — increases with age. Elevated CD38 activity accelerates NAD+ depletion, creating a feedback loop where declining NAD+ further impairs cellular function.

"NAD+ levels decline with age across multiple species, correlating with various hallmarks of aging, including mitochondrial dysfunction, genomic instability, and altered cellular communication."

📚 Source: "Promising Results With NAD Supplementation in Rare Diseases With Mitochondrial Dysfunction." PMC, 2025. PMC

The Mitochondrial Connection

NAD+ and mitochondria have a bidirectional relationship — they depend on each other:

Mitochondria need NAD+ to run the electron transport chain — the molecular machinery that produces ATP (cellular energy)
NAD+ levels affect mitochondrial function — when NAD+ drops, mitochondria become less efficient, produce more reactive oxygen species (free radicals), and generate less energy
Mitochondria buffer NAD+ levels — a 2024 Nature Metabolism study revealed that mitochondria act as a buffer to maintain NAD+-dependent processes in overconsuming organelles

This buffering role was a significant discovery. It means mitochondria don't just passively consume NAD+ — they actively regulate its availability across different cellular compartments. When one part of the cell is using too much NAD+, the mitochondria redistribute it to maintain balance.

📚 Source: "Guardians of the cell: mitochondria as a rheostat for cellular NAD+ homeostasis." Nature Metabolism, 2024. Nature Metabolism

What Happens When NAD+ Drops?

The downstream effects of NAD+ depletion are far-reaching. Published research connects declining NAD+ to multiple hallmarks of aging:

Consequences of NAD+ Depletion

Mitochondrial dysfunction: Less ATP production, more free radical damage, reduced cellular energy
Genomic instability: DNA repair enzymes (PARPs) can't function properly without NAD+, leading to accumulated mutations
Sirtuin impairment: Sirtuins — the "longevity enzymes" — require NAD+ to function. Lower NAD+ = lower sirtuin activity = reduced cellular maintenance
Altered cellular communication: NAD+ depletion disrupts signaling between cellular compartments and between cells
Stem cell exhaustion: Tissue-specific stem cells require NAD+-dependent pathways for self-renewal and differentiation
Chronic inflammation: NAD+ modulates inflammatory signaling pathways; depletion may contribute to the chronic low-grade inflammation ("inflammaging") seen in aging

This is why NAD+ is studied in the context of so many age-related conditions — it sits at the intersection of multiple aging pathways rather than affecting just one.

The NAD+ Precursor Approach: NMN and NR

If NAD+ declines with age, can you restore it? That's the question driving a rapidly expanding area of research.

The most studied approach: NAD+ precursors — compounds that the body converts into NAD+. The two most researched precursors are:

NMN (Nicotinamide Mononucleotide)

A direct precursor to NAD+ — the body converts NMN into NAD+ through a single enzymatic step
Extensively studied in preclinical models showing restoration of NAD+ levels in aged animals
Multiple human clinical trials are underway examining NMN supplementation

NR (Nicotinamide Riboside)

An alternative NAD+ precursor that enters the NAD+ biosynthesis pathway at a different point
Preclinical studies demonstrate NR supplementation counteracts age-related NAD+ decline
Studies show improved mitochondrial function, reduced inflammation, and extended lifespan in model organisms
Human clinical trials have examined NR's effects on NAD+ levels and various biomarkers

📚 Source: "NAD+ precursor supplementation in human ageing: clinical evidence." Nature Reviews, 2025. Nature

📚 Source: "Use of the Dietary Supplements NR and NMN to Increase NAD+ Levels." MDPI. MDPI

NAD+ Is Not a Peptide — And That Matters

It's important to clarify: NAD+ is a coenzyme, not a peptide. The distinction matters:

Peptides are short chains of amino acids. They typically work through receptor pathways.
NAD+ is a dinucleotide — a small molecule made of two nucleotides joined by phosphate groups. It works as a co-substrate in enzymatic reactions, not through receptor binding.

This is why NAD+ is included alongside peptides in research catalogs — not because it's chemically a peptide, but because it's studied in the same longevity and metabolic research context. Its mechanism is fundamentally different: it's fuel for the cell's machinery rather than a signal to the cell's receptors.

The Research Direction: What's Next

The NAD+ research field is moving in several directions:

Human clinical trials on NMN and NR supplementation are expanding — multiple trials are examining dose-response, safety, and efficacy across different age groups and health conditions
Tissue-specific research is revealing that NAD+ decline affects different organs at different rates and to different degrees
Combination approaches — studying NAD+ precursors alongside sirtuin activators, CD38 inhibitors, and other longevity compounds
Alzheimer's and neurodegeneration — NAD+ depletion in the brain is being studied as a potential contributor to cognitive decline, with clinical trials examining NR supplementation in Alzheimer's populations

📚 Source: "Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside." Alzheimer's & Dementia: Translational Research. Wiley

Frequently Asked Questions About NAD+

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell in your body. It participates in over 400 enzymatic reactions — primarily in energy metabolism, DNA repair, and cellular signaling. It's not a peptide; it's a dinucleotide made of two nucleotides joined by phosphate groups.

Why does NAD+ decline with age?

Three converging mechanisms: (1) increased consumption by DNA repair enzymes (PARPs) as DNA damage accumulates, (2) decreased production as biosynthetic enzymes like NAMPT become less efficient, and (3) increased degradation by CD38, an enzyme that breaks down NAD+ and increases with age.

How much does NAD+ decline?

Research suggests NAD+ levels may decline by approximately 50% between young adulthood and middle age in certain tissues. The decline varies by tissue type — brain, muscle, liver, skin, and adipose tissue all show depletion, but at different rates.

What is the mitochondrial connection?

Mitochondria need NAD+ to produce ATP through the electron transport chain. A 2024 Nature Metabolism study revealed that mitochondria also act as a buffer, redistributing NAD+ across cellular compartments to maintain balance. NAD+ decline leads to mitochondrial dysfunction, and mitochondrial dysfunction accelerates NAD+ decline — a feedback loop.

What are NMN and NR?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors — compounds the body converts into NAD+. NMN is a direct precursor converted in a single enzymatic step. NR enters the biosynthesis pathway at a different point. Both are being studied in human clinical trials to determine whether supplementation can restore age-related NAD+ decline.

Is NAD+ a peptide?

No. NAD+ is a coenzyme — a dinucleotide made of two nucleotides (nicotinamide and adenine) joined by phosphate groups. It works as a co-substrate in enzymatic reactions, not through receptor binding like peptides. It's included in research peptide catalogs because it's studied in the same longevity and metabolic context.

What are sirtuins and why do they need NAD+?

Sirtuins are a family of seven enzymes (SIRT1-7) often called "longevity enzymes" because of their roles in DNA repair, metabolic regulation, and stress resistance. They require NAD+ as a co-substrate to function. When NAD+ levels drop, sirtuin activity decreases — reducing the cell's ability to maintain itself.

What is a Certificate of Analysis for NAD+?

A COA is an independent lab report showing purity verification and identity confirmation using HPLC and mass spectrometry. Choice Peptide Labs publishes a COA for every batch of NAD+ on the product page.

Explore NAD+ from Choice Peptide Labs

100mg vial · Published Certificate of Analysis · Dispatched within 1 business day · Cold-chain shipped

View NAD+ Product Page →

Disclaimer: This article is for educational and informational purposes only. All information is derived from published, peer-reviewed research. NAD+ is a coenzyme, not an approved drug. Nothing in this article is medical advice. All products from Choice Peptide Labs are for laboratory research use only and are not intended for human or veterinary consumption.

The Signal · Neuropeptides

Pinealon: The Blood-Brain Barrier-Crossing Peptide

Revised June 2026 · Research Guide · 9 min read

The blood-brain barrier (BBB) is one of the most formidable biological obstacles in pharmacology — a tightly regulated endothelial interface that selectively limits what molecules can enter the central nervous system from systemic circulation. Most peptides, regardless of their biological activity, are excluded from CNS penetration by this barrier. Pinealon is a notable exception. This tripeptide — just three amino acids — has demonstrated the ability to cross the blood-brain barrier, making it one of the smallest peptides known to access the central nervous system directly.

Like Epithalon, Pinealon was identified through the research program of Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. While Epithalon focuses on telomerase activation, Pinealon's documented research profile centers on neuronal protection and circadian rhythm modulation — functions consistent with its pineal gland origin and CNS bioavailability.

Molecular Identity

Sequence: Glu-Asp-Arg (EDR) — 3 amino acids. Molecular weight: ~404 Da. Classification: Tripeptide. Origin: Isolated from pineal gland extracts. Key Property: Blood-brain barrier permeability (documented in fluorescence tracking studies).

Pinealon's three amino acids — glutamic acid (Glu), aspartic acid (Asp), and arginine (Arg) — combine to produce a molecule of approximately 404 daltons. The presence of the cationic arginine residue alongside the two acidic residues creates a net charge profile that may contribute to its unusual BBB permeability, though the precise transport mechanism (passive diffusion vs. carrier-mediated transport vs. adsorptive transcytosis) remains an area of active investigation.

🧠

The BBB Exception

Most peptides — even small ones — do not cross the blood-brain barrier in therapeutically meaningful quantities. Pinealon's documented BBB permeability, confirmed through fluorescence-tagged tracking studies showing CNS tissue accumulation after peripheral administration, makes it one of the smallest peptides ever demonstrated to directly access the central nervous system.

Blood-Brain Barrier Crossing: The Evidence

The BBB-crossing property of Pinealon was demonstrated using fluorescence-labeled peptide tracking — a standard experimental approach for assessing CNS penetration. In these studies, Pinealon was conjugated to a fluorescent marker and administered peripherally (intravenously or subcutaneously). Subsequent analysis of brain tissue revealed fluorescence signal accumulation in CNS structures, confirming that the peptide had traversed the BBB and reached neural tissue in biologically relevant concentrations.

This is a critical distinction that separates Pinealon from most other research peptides. A peptide that cannot cross the BBB must rely on indirect signaling pathways (hormonal cascades, peripheral feedback loops) to influence CNS function. Pinealon, by contrast, can potentially act directly on central neurons — a property that significantly expands its research utility in neurological and circadian studies.

BBB Permeability Studies

Fluorescence-tagged Pinealon administered peripherally was detected in CNS tissue following blood-brain barrier crossing, as documented in Khavinson et al. studies on pineal-derived peptides and their central nervous system accessibility. The small molecular size (~404 Da) and charge characteristics of the Glu-Asp-Arg sequence are hypothesized to facilitate this BBB penetration.

Neuronal Protection

Pinealon's most extensively documented research application is neuronal protection — the preservation of neuron viability and function under stress conditions. In cell culture studies using neuronal cell lines, Pinealon treatment has been associated with improved cell survival under oxidative stress, reduced markers of apoptosis, and preservation of neuronal metabolic activity.

The neuronal protection mechanism is hypothesized to involve modulation of gene expression in neurons — consistent with Khavinson's broader "peptide bioregulation" theory, which posits that short peptides act as sequence-specific regulators of gene transcription. The arginine residue in Pinealon's sequence may play a particular role, as arginine-containing peptides are known precursors for nitric oxide (NO) synthesis, and NO signaling is a key modulator of neuronal viability and synaptic plasticity.

🛡️

Neuronal Preservation

In neuronal cell culture models, Pinealon treatment has been associated with improved survival under oxidative stress conditions and reduced apoptotic markers. The proposed mechanism involves peptide-mediated regulation of gene expression pathways associated with neuronal survival and stress resistance.

Gene Expression Modulation

According to Khavinson's bioregulation framework, short peptides like Pinealon interact with DNA in a sequence-specific manner, influencing transcription of genes relevant to the tissue from which the peptide was originally derived. For a pineal-derived peptide, this means modulation of genes associated with melatonin synthesis, circadian clock components, and neuronal stress-response pathways. While this model remains debated in mainstream peptide biology, it provides a theoretical framework for understanding how a three-amino acid peptide could exert meaningful biological effects on complex neuronal systems.

Circadian Modulation

Given its pineal gland origin, it is perhaps expected that Pinealon has been studied for effects on circadian rhythm regulation. The pineal gland is the body's primary circadian endocrine organ, converting neural photoperiod signals into the hormonal rhythm of melatonin secretion. Pineal dysfunction — whether from aging, chronic stress, or environmental disruption — can lead to circadian desynchronization, which in turn affects sleep architecture, hormonal cycling, immune function, and cognitive performance.

In aged animal models, Pinealon administration has been associated with partial restoration of circadian-regulated parameters. These effects are consistent with the hypothesis that Pinealon, as a pineal-derived CNS-penetrant peptide, acts to support the molecular clock machinery within pinealocytes and possibly other suprachiasmatic nucleus (SCN)-connected neuronal populations.

Circadian Research

Khavinson and colleagues reported that Pinealon treatment in aged animals produced improvements in circadian-regulated parameters, including sleep-wake cycling and associated hormonal patterns. The effects were attributed to Pinealon's direct action on central neurons involved in circadian timing, facilitated by its BBB-crossing capability. (Khavinson, Bulletin of Experimental Biology and Medicine)

Pinealon vs. Epithalon: Complementary Pineal Peptides

Pinealon and Epithalon are often discussed together because they share a common tissue of origin (pineal gland) and were identified through the same Khavinson research program. However, they have distinct molecular identities, sizes, mechanisms, and research profiles:

Epithalon (AEDG, 4 aa, ~390 Da): Primary research focus on telomerase activation and telomere elongation. Mechanism operates at the genomic level (TERT gene expression). Also modulates melatonin secretion.
Pinealon (EDR, 3 aa, ~404 Da): Primary research focus on neuronal protection and circadian modulation. Documented BBB crossing ability — a property Epithalon has not been specifically demonstrated to possess.
Both are pineal-derived, both are studied in the Khavinson geroprotection framework, and both are among the smallest bioactive peptides characterized with specific cellular mechanisms.

Summary

Pinealon's most distinguishing feature is its documented ability to cross the blood-brain barrier — a property that most peptides, regardless of size, do not share. This BBB permeability, combined with its neuronal protection data and circadian modulation research, makes it a uniquely positioned peptide in the Khavinson bioregulation framework. At just three amino acids, it is among the smallest peptides ever demonstrated to directly access the central nervous system and produce measurable biological effects on neuronal function. For researchers investigating CNS-directed peptide mechanisms, neuronal stress resistance, circadian biology, or the intersection of pineal function and aging, Pinealon offers a molecular tool of unusual specificity and minimalism.

Frequently Asked Questions

Pinealon is a tripeptide with the sequence Glu-Asp-Arg (EDR) — three amino acids with a molecular weight of approximately 404 daltons. It was isolated from pineal gland extracts by Professor Vladimir Khavinson's research group in St. Petersburg, Russia.

Pinealon's BBB permeability was demonstrated through fluorescence-labeled tracking studies, where tagged Pinealon was administered peripherally and subsequently detected in CNS tissue. The precise transport mechanism (passive diffusion, carrier-mediated transport, or adsorptive transcytosis) is still under investigation, but its small molecular size (~404 Da) and the charge profile of its Glu-Asp-Arg sequence are thought to facilitate BBB crossing.

The blood-brain barrier tightly regulates which molecules can enter the central nervous system from the bloodstream. Most peptides — including many small ones — are excluded by the BBB, limiting their effects to peripheral systems. A peptide that crosses the BBB, like Pinealon, can potentially act directly on central neurons, opening research applications in neurological function, circadian biology, and CNS-directed neuroprotection that BBB-impermeable peptides cannot address.

Pinealon's documented research applications center on two areas: (1) neuronal protection — improved neuronal survival under oxidative stress and reduced apoptotic markers in cell culture models; and (2) circadian modulation — partial restoration of circadian-regulated parameters in aged animal models, consistent with its pineal origin and CNS bioavailability.

Both are pineal-derived peptides from Khavinson's research program, but they differ in size, sequence, and primary mechanism. Epithalon is a tetrapeptide (AEDG, 4 aa) that primarily activates telomerase and elongates telomeres. Pinealon is a tripeptide (EDR, 3 aa) that primarily acts as a neuronal protective agent and circadian modulator, with the distinctive property of documented BBB crossing — a capability not specifically demonstrated for Epithalon.

Professor Vladimir Khavinson's bioregulation theory proposes that short, tissue-specific peptides serve as regulatory molecules that maintain organ function by modulating gene expression in the cells of the tissue from which they originate. Under this framework, each organ produces its own set of short peptides that act as autocrine/paracrine regulators — and when their production declines with age, organ function deteriorates. Exogenous replacement of these peptides may partially restore tissue function. Epithalon and Pinealon are two of the most studied examples of this bioregulation model.

Yes. Within the Khavinson geroprotection framework, Pinealon is studied as a pineal gland-derived peptide whose natural production declines with age. This decline is associated with deteriorating pineal function, circadian desynchronization, and reduced neuronal stress resistance. Exogenous Pinealon may support these functions by directly acting on central neurons — a possibility enabled by its BBB-crossing capability.

The arginine residue in Pinealon's Glu-Asp-Arg sequence may contribute to its effects in two ways: (1) arginine is the substrate for nitric oxide (NO) synthase, and NO signaling is a key modulator of neuronal viability, synaptic plasticity, and cerebrovascular regulation; (2) the cationic charge of arginine may facilitate BBB crossing through adsorptive transcytosis, a mechanism by which positively charged molecules interact with the negatively charged endothelial glycocalyx of the BBB.

Access Pinealon for Research

High-purity Pinealon (10mg, ≥99% purity) with third-party HPLC/MS verification — available for qualified research use.

View Pinealon 10mg →

Research Disclaimer: All content on this page is intended for scientific research and educational purposes only. Pinealon is a research peptide and is not approved for human consumption, veterinary use, or as a dietary supplement. Choice Peptide Labs supplies peptides exclusively for in vitro research purposes. All researchers must comply with applicable local, state, and federal regulations. The information presented does not constitute medical advice.

The Signal

PT-141 (Bremelanotide): The Melanocortin Pathway Peptide

Research Guide · Sexual Health & CNS Pathways

Overview

PT-141, known by its generic name bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). Unlike vascular-targeting compounds, PT-141 operates centrally — acting on melanocortin receptors in the hypothalamus to modulate sexual arousal pathways through the central nervous system. Originally developed from research into the melanotan peptides, PT-141 represents a distinct pharmacological approach in sexual health research.

Chemical Identity & Structure

PT-141 is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is derived from modifications of alpha-MSH, specifically engineered to increase selectivity for melanocortin receptor subtypes MC3R and MC4R while reducing activity at the melanocyte-stimulating receptor MC1R (which is responsible for the skin-darkening effects observed with earlier melanotan compounds).

The molecular formula is C₅₀H₆₈N₁₄O₁₀, with a molecular weight of approximately 1025.2 Da. The peptide features a lactam bridge between positions that confer conformational rigidity, enhancing receptor binding affinity and metabolic stability compared to linear α-MSH fragments.

Key Structural Insight

PT-141's cyclic structure and D-Phe substitution provide receptor selectivity and metabolic resistance that distinguish it from both native α-MSH and the earlier-generation melanotan compounds from which it was derived.

Mechanism of Action: Central, Not Vascular

Melanocortin Receptor Targeting

The defining pharmacological characteristic of PT-141 is its mechanism of action: it operates through the central nervous system rather than the peripheral vascular system. PT-141 is a potent agonist at the melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R), both of which are densely expressed in the hypothalamus — a brain region that serves as the master regulator of neuroendocrine function.

MC4R, in particular, has been extensively mapped as a key node in the neural circuits governing sexual arousal, appetite, and energy homeostasis. Activation of MC4R in the paraventricular nucleus and medial preoptic area of the hypothalamus triggers downstream signaling cascades that facilitate arousal responses independently of gonadal hormones or vascular function.

CNS-Mediated Pathway

Unlike PDE5 inhibitors that act on peripheral vascular smooth muscle, PT-141 initiates sexual arousal through direct hypothalamic signaling. This central mechanism means its activity is independent of nitric oxide pathways and vascular endothelial function.

Distinction from Vascular Mechanisms

The research significance of PT-141's CNS-mediated mechanism cannot be overstated. Traditional approaches to sexual health research have focused on vascular pathways — particularly the nitric oxide / cyclic GMP cascade. PT-141 operates upstream of these systems, at the level of central arousal initiation. This means it addresses a fundamentally different question: not "can blood flow be increased?" but rather "can the brain's arousal signal be activated?"

This distinction has important implications for research populations and experimental designs where vascular function may be compromised but central neurological pathways remain intact.

From Melanotan to PT-141: Development History

PT-141's discovery emerged from an unexpected observation during melanotan research at the University of Arizona in the 1990s. Researchers studying melanotan II — a non-selective melanocortin agonist developed for skin tanning — noted that male subjects experienced spontaneous erections as a side effect. This observation redirected investigation toward the melanocortin pathway's role in sexual arousal.

PT-141 was subsequently developed as a more selective analog, designed to retain the arousal-promoting activity while reducing the pigmentary and appetite-suppressing effects associated with non-selective melanocortin activation. The key structural modification — incorporation of D-Phe⁷ — enhanced MC4R selectivity and reduced off-target effects at MC1R.

Development Timeline

The clinical form of PT-141 (bremelanotide) progressed through regulatory review and was evaluated in Phase II and Phase III clinical trials for hypoactive sexual desire disorder (HSDD). The subcutaneous formulation was assessed across multiple randomized, double-blind, placebo-controlled trials involving over 1,200 premenopausal women.

Clinical Research

Phase II & III Trials

The clinical development program for bremelanotide (the pharmaceutical form of PT-141) included robust trial designs. The RECONNECT trials — two Phase III, randomized, double-blind, placebo-controlled studies — evaluated subcutaneous bremelanotide in premenopausal women with hypoactive sexual desire disorder.

Results showed statistically significant improvements in the co-primary endpoints: satisfying sexual events (SSEs) and desire scores measured by the Female Sexual Function Index (FSFI). The treatment effect was consistent across both trials, though the magnitude of improvement over placebo was modest — a common finding in CNS-mediated behavioral endpoints where placebo responses are typically high.

Clinical Findings

In Phase III trials, bremelanotide-treated subjects showed statistically significant increases in satisfying sexual events and desire scores compared to placebo. The most common adverse events were nausea, flushing, and headache — consistent with MC3R/MC4R activation in the hypothalamus and brainstem.

Safety & Tolerability Profile

Clinical trials revealed a manageable adverse event profile. Nausea was the most commonly reported event (approximately 40% of subjects at therapeutic doses), followed by flushing, headache, and transient increases in blood pressure. The pressor effect — a transient mean increase of approximately 3–6 mmHg in systolic blood pressure — was attributed to central sympathetic activation via MC4R and resolved within hours.

PT-141 vs. KPV: Important Distinctions

Parameter	PT-141	KPV
Parent Molecule	Alpha-MSH (modified)	Alpha-MSH C-terminal fragment
Structure	Cyclic heptapeptide	Tripeptide (Lys-Pro-Val)
Receptor Target	MC3R / MC4R (hypothalamus)	MC1R (peripheral), anti-inflammatory
Primary Research Area	Sexual arousal, CNS signaling	Inflammation, gut barrier, wound healing
Mechanism	Central nervous system activation	Anti-inflammatory cascade modulation
Clinical Form	Bremelanotide (regulatory evaluation)	Research compound only

PT-141 and KPV are both derived from alpha-MSH but have divergent pharmacological profiles. KPV is the C-terminal tripeptide fragment (Lys-Pro-Val) that primarily interacts with peripheral MC1R and exhibits anti-inflammatory properties through NF-κB pathway inhibition. Researchers should not conflate these two compounds despite their shared parent molecule — their receptor affinities, mechanisms, and research applications are distinct.

Important Note

KPV research focuses on gut barrier integrity, inflammatory bowel models, and wound healing. PT-141 research focuses on CNS-mediated arousal pathways and melanocortin receptor signaling. The two peptides serve fundamentally different research questions despite their shared α-MSH lineage.

Pharmacokinetics & Research Considerations

PT-141 has a plasma half-life of approximately 2.7 hours following subcutaneous administration. The peptide achieves peak plasma concentration within 1 hour of dosing. CNS effects, however, may persist longer due to receptor occupancy dynamics and downstream signaling cascade duration.

In research settings, subcutaneous doses of 1.75 mg have been the most commonly studied in clinical trials. Intranasal formulations were evaluated in earlier development phases but showed more variable bioavailability and higher rates of adverse events (particularly nasal irritation and blood pressure elevation), leading to the selection of subcutaneous delivery for the pivotal clinical program.

Melanocortin System Complexity

PT-141 research sits within the broader context of the melanocortin system — one of the most complex neuroendocrine signaling networks in mammalian biology. The five melanocortin receptors (MC1R through MC5R) are expressed in diverse tissues and regulate functions ranging from pigmentation (MC1R) to adrenal steroidogenesis (MC2R) to energy homeostasis and sexual function (MC3R, MC4R) to sebaceous gland activity (MC5R).

MC4R has emerged as a particularly significant research target due to its role as a convergence point for multiple physiological processes. Loss-of-function MC4R mutations are the most common monogenic cause of severe obesity in humans, and the receptor's involvement in sexual arousal pathways was discovered through the same melanotan research that led to PT-141's development.

Explore PT-141 for Your Research

High-purity PT-141 (Bremelanotide, 10mg) for laboratory and research applications. Third-party tested with certificates of analysis available.

View PT-141 10mg →

Frequently Asked Questions

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It was developed from research on melanotan II at the University of Arizona, where researchers observed that the non-selective melanocortin agonist produced arousal-promoting effects. PT-141 was engineered for greater selectivity at MC3R and MC4R receptors.

PT-141 operates through the central nervous system, acting on melanocortin receptors (MC3R/MC4R) in the hypothalamus to initiate arousal signaling. This is fundamentally different from compounds that target peripheral vascular smooth muscle through the nitric oxide / cyclic GMP pathway. PT-141 addresses central arousal initiation rather than vascular response.

While both are derived from α-MSH, PT-141 is a cyclic heptapeptide targeting MC3R/MC4R in the hypothalamus (CNS-mediated arousal), while KPV is a tripeptide fragment (Lys-Pro-Val) that primarily interacts with MC1R and exhibits anti-inflammatory properties. They serve entirely different research applications.

Yes. The clinical form (bremelanotide) progressed through Phase II and Phase III clinical trials. The RECONNECT trials evaluated subcutaneous bremelanotide in over 1,200 premenopausal women with hypoactive sexual desire disorder (HSDD), showing statistically significant improvements in desire and satisfying sexual events compared to placebo.

PT-141 is a potent agonist at melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R). MC4R is densely expressed in the hypothalamus — particularly in the paraventricular nucleus and medial preoptic area — and is a key node in neural circuits governing sexual arousal, appetite, and energy homeostasis.

PT-141 was discovered incidentally during melanotan II research at the University of Arizona in the 1990s. Male subjects using melanotan II for skin tanning reported spontaneous erections as a side effect, which led researchers to investigate the melanocortin pathway's role in sexual arousal and develop more selective analogs.

The most common adverse event was nausea (~40% of subjects at therapeutic doses), followed by flushing, headache, and a transient increase in systolic blood pressure (3–6 mmHg). The pressor effect was attributed to central sympathetic activation via MC4R and resolved within hours.

Intranasal formulations were evaluated in earlier development phases but showed more variable bioavailability and higher rates of nasal irritation and blood pressure elevation. Subcutaneous delivery provided more consistent pharmacokinetics and a more favorable tolerability profile for the pivotal clinical trials.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. All compounds discussed are intended for research purposes only. Choice Peptide Labs sells research-grade peptides exclusively for laboratory use. Always consult a qualified healthcare professional before making any health-related decisions.

What Is Retatrutide? A Research-Backed Guide to the First Triple Agonist

📖 13 min read 🔬 NEJM, Lancet, Springer 📅 June 2026

Retatrutide is the first compound to activate three hormone receptors simultaneously — GIP, GLP-1, and glucagon. Its Phase 2 trial results, published in the New England Journal of Medicine, reported weight reduction of up to 24.2% at the highest dose. Here's what the published research shows.

3

Receptor Targets

24.2%

Max Weight Reduction

48

Weeks (Phase 2)

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational, once-weekly, triple hormone receptor agonist developed by Eli Lilly. It is a single peptide molecule that simultaneously activates three distinct receptor systems:

GIP receptor — glucose-dependent insulinotropic polypeptide
GLP-1 receptor — glucagon-like peptide-1
Glucagon receptor — the metabolic hormone involved in hepatic energy expenditure

No previously studied peptide had achieved this triple activation in a single molecule. Retatrutide was the first to reach human clinical trials with all three pathways engaged simultaneously.

📚 Source: Jastreboff, A.M., et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM, 389(6), 514–526. NEJM

Why Three Receptors Instead of Two?

To understand why the third receptor matters, you need to understand what each one does:

GLP-1 Receptor (Same as Semaglutide and Tirzepatide)

Stimulates insulin secretion in a glucose-dependent manner
Suppresses glucagon release
Slows gastric emptying
Signals satiety in brain regions regulating appetite
Well-studied: The target of semaglutide, liraglutide, and other GLP-1 agonists

GIP Receptor (Added by Tirzepatide)

Enhances insulin secretion through a complementary pathway
Expressed in adipose tissue (fat cells) — may influence fat metabolism
Independent appetite regulation effects in the brain
Relatively new: Tirzepatide was the first compound to combine GIP with GLP-1

Glucagon Receptor (The Third Pathway — Retatrutide's Innovation)

Hepatic energy expenditure: Glucagon activates pathways in the liver that increase energy expenditure and fat oxidation
Lipolysis: Glucagon promotes the breakdown of stored fat for energy
Gluconeogenesis: The liver produces glucose from non-carbohydrate sources — glucagon drives this process
The missing piece: GIP and GLP-1 primarily reduce energy intake (appetite suppression). Glucagon increases energy expenditure (fat burning). Together, they target both sides of the energy balance equation.

"The addition of glucagon receptor activation adds a metabolic pathway that GIP and GLP-1 alone do not address — hepatic energy expenditure and fat oxidation."

Phase 2 Trial: The NEJM Results

The Phase 2 trial was published in the New England Journal of Medicine in 2023 and produced results that were, at the time, the highest weight loss efficacy reported for any incretin-class compound in a Phase 2 setting.

Study Design

Population: Adults with obesity (BMI ≥30) or overweight (BMI 27-29.9) with at least one weight-related complication
Design: Randomized, double-blind, placebo-controlled
Duration: 48 weeks
Doses tested: 1mg, 4mg (escalating), 8mg (escalating), 12mg (escalating), or placebo
Primary endpoint: Percentage change in body weight from baseline at 48 weeks

Results: Weight Reduction by Dose

Dose	Mean Weight Reduction at 48 Weeks	vs. Placebo
Placebo	2.1%	—
1 mg	8.7%	+6.6%
4 mg (escalating)	17.3%	+15.2%
8 mg (escalating)	22.8%	+20.7%
12 mg (escalating)	24.2%	+22.1%

The dose-response relationship was clear and linear: higher doses produced greater weight reduction. At the 12mg dose, participants lost nearly a quarter of their body weight in 48 weeks.

A critical observation: the weight loss curves had not plateaued at 48 weeks. This suggested that longer treatment durations might produce even greater effects — a hypothesis that Phase 3 trials are now testing.

📚 Source: Jastreboff, A.M., et al. NEJM, 389(6), 514–526. NEJM

Phase 1 Data: Establishing Proof of Concept

Before Phase 2, Phase 1 data published in The Lancet established the initial proof of concept:

Confirmed that triple receptor activation was achievable with a single molecule in humans
Demonstrated clinically meaningful glucose-lowering and bodyweight-lowering effects
Established the safety profile that supported advancement to Phase 2

📚 Source: Coskun, T., et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." The Lancet. Lancet

Retatrutide vs. Dual Agonists: What's Different?

Feature	Retatrutide	Tirzepatide	Semaglutide
Receptor targets	GIP + GLP-1 + Glucagon	GIP + GLP-1	GLP-1 only
Max weight reduction (Phase 2)	24.2%	~22.5% (SURMOUNT-1)	~14.9% (STEP 1)
Unique mechanism	Hepatic energy expenditure via glucagon	Dual incretin appetite suppression	Single receptor satiety
Status	Phase 3 (ongoing)	Approved (2022)	Approved (2017/2021)

The glucagon receptor is the differentiator. While GIP and GLP-1 primarily reduce energy intake (how much you eat), glucagon increases energy expenditure (how much you burn). Retatrutide targets both sides of the energy balance equation — something no previous compound has achieved.

The Science of Glucagon: Why the Third Pathway Matters

Glucagon has historically been viewed primarily through the lens of blood sugar regulation — it raises blood glucose when levels drop. But its role in energy expenditure is increasingly recognized in published research:

Hepatic fat oxidation: Glucagon activates pathways in the liver that increase fat burning for energy — a process called beta-oxidation
Thermogenesis: Glucagon signaling contributes to heat production in brown adipose tissue, increasing total energy expenditure
Lipid metabolism: Glucagon promotes lipolysis — the breakdown of stored triglycerides into free fatty acids that can be used as fuel
Amino acid metabolism: Glucagon affects amino acid processing in the liver, which has implications for protein turnover and metabolic health

The combination of appetite reduction (GIP + GLP-1) with increased fat oxidation (glucagon) is what makes retatrutide mechanistically unique. A 2025 Springer review described this triple-agonist approach as "a promising next step" in metabolic research.

📚 Source: "Triple Agonism Based Therapies for Obesity." Current Cardiology Reports (Springer), 2025. Springer

Retatrutide in Plain English

Your body has two ways to manage weight:

Energy in — how much you eat (controlled by appetite and satiety hormones)
Energy out — how much you burn (controlled by metabolism and fat oxidation)

Most metabolic compounds focus on the "energy in" side — suppressing appetite so you eat less. That's what GLP-1 agonists do, and what tirzepatide does with two receptors.

Retatrutide addresses both sides simultaneously:

Appetite suppression through GIP + GLP-1 (you eat less)
Increased fat oxidation through glucagon (you burn more stored fat for energy)

This dual-action approach — reducing intake while increasing expenditure — is the theoretical basis for why retatrutide produced the highest weight reduction figures in its Phase 2 trial.

Frequently Asked Questions About Retatrutide

What makes retatrutide different from tirzepatide?

Tirzepatide activates two receptors (GIP + GLP-1). Retatrutide activates three (GIP + GLP-1 + glucagon). The addition of glucagon receptor activation targets hepatic energy expenditure and fat oxidation — mechanisms that GIP and GLP-1 alone don't address.

What were the Phase 2 results?

At the 12mg dose over 48 weeks: 24.2% mean weight reduction vs 2.1% placebo. The dose-response was linear: 1mg (8.7%), 4mg (17.3%), 8mg (22.8%), 12mg (24.2%). Weight loss curves had not plateaued at 48 weeks.

Why does the glucagon receptor matter?

Glucagon increases energy expenditure through hepatic fat oxidation, thermogenesis, and lipolysis. While GIP and GLP-1 primarily reduce energy intake (appetite), glucagon increases energy output (fat burning). Retatrutide targets both sides of the energy balance equation.

Is retatrutide approved by the FDA?

No. Retatrutide remains investigational. Phase 3 clinical trials are currently ongoing. It is not approved for any medical indication.

Has the weight loss plateaued at 48 weeks?

No. The NEJM publication noted that weight loss curves had not plateaued at 48 weeks, suggesting longer treatment durations may produce greater effects. Phase 3 trials are testing longer treatment periods.

Who developed retatrutide?

Eli Lilly. The compound designation is LY3437943. It is the same company that developed tirzepatide (Mounjaro).

How does retatrutide compare to semaglutide?

Semaglutide is a single GLP-1 receptor agonist with ~14.9% weight reduction in STEP 1. Retatrutide activates three receptors and produced 24.2% in Phase 2. The addition of GIP and glucagon pathways accounts for the difference in magnitude.

What is a Certificate of Analysis for retatrutide?

An independent lab report showing HPLC purity and mass spectrometry for a specific batch. Choice Peptide Labs publishes a COA for every batch on the product page.

Explore Retatrutide from Choice Peptide Labs

10mg vial · Published Certificate of Analysis · Dispatched within 1 business day · Cold-chain shipped

View Retatrutide Product Page →

Disclaimer: This article is for educational and informational purposes only. Retatrutide is an investigational compound not approved by the FDA. All information is derived from published clinical research. Research-grade compounds from Choice Peptide Labs are for laboratory research use only and are not intended for human consumption.

Longevity & Cognitive · The Calm

Selank: The Anxiolytic Peptide from the Nootropic Space

Among the most significant challenges in neuroscience is the development of anxiolytic compounds that reduce anxiety without the cognitive impairment, sedation, and dependency risks associated with traditional pharmacological approaches. Benzodiazepines — the most widely prescribed anti-anxiety medications — work effectively in the short term but carry well-documented risks of tolerance, withdrawal, and cognitive blunting. The search for compounds that can modulate anxiety through more nuanced neurochemical pathways has led researchers to explore peptide-based approaches. Selank stands at the forefront of this exploration — a synthetic heptapeptide derived from the naturally occurring immune peptide Tuftsin, developed in Russia and studied for its anxiolytic effects through GABAergic signaling and BDNF modulation, without the sedation or dependency observed with conventional agents.

This guide examines the published research on Selank, its molecular origins, and its unique position at the intersection of neuroscience, immunology, and nootropic research.

What Is Selank?

Selank is a synthetic heptapeptide (seven amino acids) with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Maximov Institute of Molecular Genetics in Moscow as part of a research program exploring the therapeutic potential of Tuftsin-derived peptides. Selank is a structural analog of Tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that plays a role in immune regulation, with three additional amino acids (Pro-Gly-Pro) appended to enhance stability and extend the molecule's functional profile.

Molecular Origin

Selank was derived from Tuftsin — a tetrapeptide naturally produced in the spleen that modulates immune cell activity. By extending the Tuftsin sequence with a Pro-Gly-Pro tail, researchers created a molecule that retained Tuftsin's immune-modulating properties while gaining a distinct profile of central nervous system activity, particularly anxiolytic effects mediated through GABAergic signaling pathways.

Selank was developed under the direction of Dr. N.V. Nezavibatko and colleagues, with the research program extending through the late 1990s and into the 2000s. It received regulatory approval in Russia as an anxiolytic agent — a significant milestone that positioned it among the few peptides approved for direct use in anxiety management.

The GABAergic Mechanism

The defining feature of Selank in the research literature is its relationship with the GABAergic system — the brain's primary inhibitory neurotransmitter network. Gamma-aminobutyric acid (GABA) is the principal neurotransmitter responsible for reducing neuronal excitability throughout the nervous system. The balance between excitatory (glutamatergic) and inhibitory (GABAergic) signaling is fundamental to mood regulation, stress response, and cognitive function.

Traditional anxiolytics like benzodiazepines work by binding directly to GABA-A receptors, enhancing the effect of GABA and producing rapid but blunt sedation. This mechanism — direct receptor agonism — is effective but carries side effects: cognitive impairment, drowsiness, motor coordination loss, and, critically, receptor adaptation that leads to tolerance and physical dependency.

Selank appears to work through a more nuanced GABAergic mechanism. Research suggests that Selank modulates the expression and activity of GABA-related genes rather than directly binding to GABA receptors. Specifically, studies have shown that Selank influences the expression of GABA-A receptor subunit genes, potentially shifting the receptor population toward configurations that support calm without sedation.

Research Context: Preclinical studies demonstrated that Selank altered the mRNA expression of GABA-A receptor subunits (including α2, δ, and γ2 subunits) in brain regions associated with anxiety and stress processing. This gene-level modulation differs fundamentally from the direct receptor binding of benzodiazepines and may explain Selank's observed anxiolytic profile without the sedative side effects. See: Kozlovskii et al., 2008.

BDNF Modulation

Beyond GABA, Selank has been studied for its effects on Brain-Derived Neurotrophic Factor (BDNF) — one of the most important neurotrophins in the brain. BDNF supports neuronal survival, synaptic plasticity, and neurogenesis (the formation of new neurons). It is particularly concentrated in the hippocampus, where it plays a critical role in learning, memory, and mood regulation.

Research Finding

Studies have shown that Selank administration modulates BDNF expression in brain regions associated with emotional regulation and memory. This finding is significant because BDNF levels are consistently reduced in anxiety disorders, depression, and chronic stress states. By supporting BDNF expression, Selank may address a molecular deficit common to multiple neuropsychiatric conditions.

The connection between BDNF and anxiety is well-established: chronic stress downregulates BDNF in the hippocampus and prefrontal cortex, contributing to the structural and functional brain changes observed in anxiety and depression. Compounds that support BDNF expression may help counteract these stress-induced changes — a mechanism that could explain Selank's anxiolytic effects at a deeper level than GABA modulation alone.

The Critical Differentiator: No Sedation, No Dependency

What makes Selank genuinely distinctive in the anxiolytic research landscape is what it doesn't do. Across the published preclinical and clinical literature, Selank has not been associated with:

Sedation or drowsiness — Unlike benzodiazepines, Selank does not appear to impair alertness or psychomotor function.
Cognitive impairment — Rather than blunting cognition, some research suggests Selank may have pro-cognitive or nootropic effects.
Tolerance development — No evidence of diminishing anxiolytic efficacy with repeated administration.
Physical dependency or withdrawal — No withdrawal symptoms have been reported upon cessation.
Motor coordination effects — No impairment of motor function observed.

This profile — anxiolytic activity without the characteristic side effects of GABA-ergic drugs — has made Selank a subject of significant interest in the nootropic and longevity research communities. If the mechanism truly operates through gene expression modulation rather than direct receptor binding, it represents a fundamentally different approach to anxiety management.

Comparative Note: The absence of sedation and dependency in Selank research is particularly noteworthy because these are the primary drawbacks of virtually all conventional anxiolytics. Benzodiazepines, Z-drugs, and even some antihistamines used for anxiety carry sedation and/or dependency profiles. A compound that reduces anxiety without these effects would represent a meaningful advance in the field. See: Uchakina et al., 2008.

Immune Modulation: The Tuftsin Connection

Selank's origin as a Tuftsin derivative gives it a second functional dimension: immune modulation. Tuftsin itself is a naturally occurring immunostimulatory peptide — it enhances phagocytic activity of macrophages and neutrophils, modulates antibody production, and influences natural killer (NK) cell activity.

Research on Selank has demonstrated that it retains and extends these immune-modulating properties:

Cytokine regulation: Selank has been studied for its ability to modulate the expression of pro-inflammatory and anti-inflammatory cytokines, including interleukins (IL-6, IL-8) and TNF-α.
Anti-viral effects: Some studies have explored Selank's activity against certain viral infections, potentially through immune modulation rather than direct antiviral action.
Stress-immune interaction: Given that chronic stress suppresses immune function through cortisol elevation, Selank's dual action on both anxiety and immune parameters may represent a synergistic effect — reducing stress-driven immune suppression while directly supporting immune cell activity.

This immune dimension is particularly relevant in the context of longevity research, where chronic low-grade inflammation ("inflammaging") is recognized as a fundamental driver of age-related disease.

Selank vs. Semax: Anxiety vs. Cognition

Selank is frequently discussed alongside Semax — another synthetic peptide developed in Russia that shares structural similarities but serves a different primary function. Understanding their relationship is important for researchers exploring the peptide nootropic space:

Selank — Derived from Tuftsin, primarily studied for anxiolytic effects through GABAergic modulation and BDNF support. Secondary effects include immune modulation.
Semax — Derived from ACTH (adrenocorticotropic hormone), primarily studied for cognitive enhancement through BDNF upregulation, neuroprotection, and dopaminergic/noradrenergic modulation. Secondary effects include anxiolytic activity.

Research Pairing

Selank and Semax occupy complementary positions on the anxiety-cognition axis. Selank targets anxiety first, with potential cognitive benefits; Semax targets cognition first, with potential anxiolytic benefits. Both modulate BDNF, but through different upstream mechanisms. In research settings, they are sometimes studied individually for their primary effects or together to explore their complementary interaction.

Russian Pharmaceutical Development

Selank's development history is important context. It was developed through the Russian pharmaceutical and peptide research tradition, which has historically placed greater emphasis on peptide-based therapeutics than Western pharmaceutical pipelines. Selank received regulatory approval in Russia for clinical use as an anxiolytic — meaning it has been used in clinical settings under medical supervision in that country.

However, it is important to note that Russian regulatory standards and clinical trial reporting differ from FDA or EMA standards. While the Russian clinical data provides valuable observations, researchers should be aware of these differences when evaluating the evidence base. Independent replication under Western clinical trial methodology would significantly strengthen the translational evidence.

Research Considerations and Limitations

Geographic research concentration: The majority of Selank research comes from Russian institutions. Independent replication in other research settings would be valuable.
Clinical trial methodology: Some clinical observations predate modern trial reporting standards. Randomized, double-blind, placebo-controlled studies with larger sample sizes would strengthen the evidence.
Dose optimization: Optimal dosing for specific anxiolytic vs. immune-modulatory effects may differ and requires further characterization.
Long-term studies: Long-term safety and efficacy data are limited.
Mechanistic complexity: Selank's mechanism involves multiple interacting pathways (GABAergic, BDNF, immune), making it difficult to isolate the relative contribution of each pathway to the observed effects.

Selank in the Longevity and Cognitive Research Landscape

Chronic anxiety is not merely a quality-of-life issue — it is a biological accelerant of aging. Sustained anxiety drives chronic cortisol elevation, hippocampal atrophy, immune suppression, cardiovascular strain, and sleep disruption. The cumulative effect of these processes accelerates biological aging at the cellular level.

A compound that can modulate anxiety without the secondary harms of conventional anxiolytics — without sedation, without dependency, without cognitive impairment — has potential implications beyond anxiety management alone. By addressing the stress-anxiety-inflammation axis, such a compound could contribute to a broader longevity-oriented research framework.

Longevity Connection

The intersection of anxiety, chronic stress, and accelerated aging is well-documented in the literature. Individuals with chronic anxiety disorders have shorter telomeres, higher inflammatory markers, increased oxidative stress, and greater risk for age-related diseases. Peptides that modulate the anxiety-stress axis without pharmacological side effects represent a meaningful area of longevity research.

Frequently Asked Questions

What is Selank?

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from Tuftsin, a naturally occurring immune peptide. It was developed in Russia and studied for anxiolytic effects through GABAergic signaling modulation and BDNF expression support.

How does Selank work?

Research suggests Selank modulates GABA-A receptor subunit gene expression and supports BDNF levels in brain regions associated with anxiety and emotional regulation. Unlike benzodiazepines, it does not appear to directly bind GABA receptors, which may explain the absence of sedation and dependency.

What is Tuftsin?

Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced in the spleen that modulates immune cell activity, including macrophages, neutrophils, and natural killer cells. Selank is a synthetic analog of Tuftsin with an extended amino acid sequence.

Does Selank cause sedation or drowsiness?

No. Across the published literature, Selank has not been associated with sedation, drowsiness, or cognitive impairment — distinguishing it from benzodiazepines and other conventional anxiolytics.

Is Selank addictive or habit-forming?

No dependency or withdrawal symptoms have been reported in the Selank literature. This is a significant distinction from benzodiazepines, which carry well-documented risks of tolerance, dependence, and withdrawal.

How does Selank differ from Semax?

Selank is primarily studied for anxiolytic effects (anxiety reduction) through GABAergic modulation. Semax is primarily studied for cognitive enhancement through BDNF upregulation and dopaminergic/noradrenergic modulation. Both are Russian-developed peptides that modulate BDNF, but they target different primary endpoints and occupy complementary positions on the anxiety-cognition axis.

Does Selank have immune effects?

Yes. As a Tuftsin derivative, Selank retains immune-modulating properties. Research has explored its effects on cytokine regulation (IL-6, IL-8, TNF-α), phagocytic activity, and antiviral responses. This immune dimension is relevant to longevity research where chronic inflammation (inflammaging) is a key driver of age-related disease.

Has Selank been approved for clinical use?

Selank received regulatory approval in Russia for clinical use as an anxiolytic agent. However, Russian regulatory standards differ from FDA or EMA standards. Independent replication under Western clinical trial methodology would strengthen the translational evidence.

Explore Selank for Your Research

High-purity Selank (10mg) available for research applications. HPLC-verified, third-party tested.

View Selank 10mg →

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. All peptides discussed are sold for research purposes only and are not approved by the FDA for human consumption. Always consult a qualified healthcare provider before making decisions about your health. Choice Peptide Labs does not claim that any product discussed can treat, cure, or prevent any disease.

What Is Semaglutide? A Research-Backed Guide to the Most Studied GLP-1

📖 14 min read 🔬 STEP 1-5+ clinical trials 📅 June 2026

Semaglutide has one of the largest clinical trial programs of any peptide-based compound in modern research history. The STEP program alone spans 5+ major trials, thousands of participants, and publications in NEJM, JAMA, and The Lancet. Here's what 4+ years of published clinical data show.

5+

Major Trials

~15%

Mean Weight Loss (STEP 1)

4+

Years of Data

1,961

Participants (STEP 1)

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a compound that mimics the naturally occurring incretin hormone glucagon-like peptide-1 (GLP-1). It's a modified version of the native hormone, engineered for longer duration of action.

GLP-1 is released naturally by the gut after eating. It signals to the pancreas to produce insulin, suppresses glucagon, slows gastric emptying, and communicates with brain regions that regulate appetite and food intake.

Semaglutide mimics all of these effects but lasts significantly longer in the body — allowing once-weekly dosing rather than the rapid degradation that limits native GLP-1 to minutes.

Developed by Novo Nordisk, semaglutide has been the subject of one of the most comprehensive clinical development programs in metabolic research, spanning both Type 2 diabetes and obesity contexts.

The STEP Clinical Trial Program

The Semaglutide Treatment Effect in People with obesity (STEP) program is one of the largest and most rigorously designed clinical trial programs in metabolic research. Here's a breakdown of the major trials:

2021

STEP 1 — Semaglutide 2.4mg vs Placebo

1,961 adults with overweight/obesity. 68 weeks. Mean weight loss: 14.9% with semaglutide vs 2.4% with placebo. Lifestyle intervention in both groups.

Published: New England Journal of Medicine

2021

STEP 2 — Semaglutide in Type 2 Diabetes + Obesity

Tested semaglutide 2.4mg in participants who had both Type 2 diabetes and overweight/obesity. Demonstrated both glycemic improvement and weight reduction in this dual-diagnosis population.

Published: The Lancet

2021

STEP 3 — Intensive Behavioral Therapy

Combined semaglutide with intensive behavioral therapy (30 visits over 68 weeks). Showed that the compound adds weight reduction benefits even on top of structured intervention.

Published: JAMA

2021

STEP 4 — Treatment Withdrawal Study

The critical trial. 803 participants completed 20 weeks of semaglutide (10.6% mean weight loss), then were randomized to continue treatment or switch to placebo for 48 additional weeks. Those who stopped regained weight; those who continued maintained or increased loss.

Published: JAMA

2022

STEP 5 — Long-Term Extension

Extended treatment over 104 weeks (2 years). Demonstrated that weight reduction with semaglutide is sustained over a longer treatment period.

Published: Nature Medicine

2025

STEP UP — Higher Dose (7.2mg)

Phase 3b trial testing semaglutide at 7.2mg — a higher dose than previously studied. Showed even greater effects in adults with obesity. 95 sites across 11 countries.

Published: The Lancet

📚 Source: Wilding, J.P.H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM, 384, 989–1002. NEJM

What the Combined Data Shows

Across the STEP program, several findings consistently emerge:

Consistent weight reduction: Semaglutide 2.4mg produced approximately 15% mean weight loss over 68 weeks in STEP 1 — significantly greater than placebo across all trials
Sustained effects require continued treatment: STEP 4 proved this definitively — stopping treatment led to weight regain, demonstrating that semaglutide's mechanism is ongoing, not a one-time reset
Higher doses produce greater effects: STEP UP (2025) showed that semaglutide 7.2mg produced even greater weight reduction than 2.4mg, expanding the dose-response understanding
Glycemic improvements: A 2023 analysis of 3,375 adults across STEP 1, 3, and 4 showed significant improvements in glycemic status, with more participants achieving normoglycemia
Long-term durability: STEP 5 demonstrated that effects are sustained over 2 years of continuous treatment

📚 Source: "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA, 325(14), 1414–1425. JAMA

📚 Source: "Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP)." The Lancet, 2025. Lancet

The GLP-1 Mechanism: How Semaglutide Works

GLP-1 (glucagon-like peptide-1) is a natural incretin hormone. Your body releases it from L-cells in the small intestine after you eat. It has several functions:

Insulin secretion: GLP-1 stimulates the pancreas to release insulin in a glucose-dependent manner — meaning it only activates when blood sugar is elevated, reducing hypoglycemia risk
Glucagon suppression: GLP-1 reduces glucagon secretion, preventing the liver from releasing excess glucose
Gastric emptying: GLP-1 slows the rate at which food leaves the stomach, extending the feeling of fullness after meals
Central appetite regulation: GLP-1 receptors in the hypothalamus and brainstem regulate appetite and food reward — this is the primary mechanism behind weight reduction

The problem with native GLP-1: it's degraded by the enzyme DPP-4 within minutes. Semaglutide is engineered to resist this degradation, extending its half-life to approximately one week — enabling once-weekly dosing.

The Brain Connection

Published research shows that GLP-1 receptors are expressed in brain regions critical for appetite regulation, including the hypothalamus and brainstem. Semaglutide crosses the blood-brain barrier and activates these receptors, directly influencing:

Hunger signaling — reducing the drive to eat
Food reward — decreasing the hedonic pleasure associated with high-calorie foods
Satiety — increasing the feeling of fullness after smaller meals

Semaglutide in Context: The Bigger Picture

Semaglutide's significance extends beyond any single trial result. It represents a paradigm shift in how the research community approaches metabolic conditions:

"The STEP program is designed to elucidate key aspects of the medical management of obesity across various races and ethnicities."

Before semaglutide: Few pharmacological options existed for sustained weight management. Lifestyle intervention alone produced modest results (3-5% weight loss in most studies).
After semaglutide: The STEP program demonstrated that pharmacological intervention can produce ~15% weight loss — a magnitude previously only achievable with bariatric surgery.
The downstream research: Semaglutide's success triggered the development of dual and triple agonists (tirzepatide, retatrutide) that build on the GLP-1 foundation.

📚 Source: "Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials." Obesity, 28(6), 1160-1177. Wiley

What Makes Semaglutide Different from Other GLP-1s

Semaglutide isn't the first GLP-1 receptor agonist — but it's the most potent in its class. Here's why:

Longer half-life: Once-weekly dosing vs daily (liraglutide) or twice-daily (exenatide) — improving patient adherence
Greater weight reduction: STEP 1 showed ~15% weight loss, exceeding previous GLP-1 agonists (~5-10% in earlier studies)
Structural modifications: Semaglutide includes amino acid substitutions and a C-18 fatty diacid chain that protects against DPP-4 degradation and enables albumin binding for extended circulation
Brain penetration: Published research suggests semaglutide has greater CNS penetration than earlier GLP-1 agonists, potentially explaining its stronger appetite effects

Frequently Asked Questions About Semaglutide

How does semaglutide work?

Semaglutide is a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on brain receptors that regulate appetite and food reward. It's engineered to resist DPP-4 degradation, allowing once-weekly dosing.

What were the STEP 1 results?

1,961 adults with overweight/obesity over 68 weeks. Semaglutide 2.4mg group: 14.9% mean weight loss. Placebo group: 2.4%. Both groups received lifestyle intervention. Published in the New England Journal of Medicine in 2021.

What did STEP 4 prove?

STEP 4 was the treatment withdrawal study. 803 participants lost 10.6% of body weight during 20 weeks of semaglutide, then were randomized to continue or switch to placebo. Those who stopped regained weight; those who continued maintained or increased loss. This proved the compound's mechanism is ongoing, not a one-time effect.

What is STEP UP?

STEP UP is a 2025 Phase 3b trial testing semaglutide at 7.2mg — a higher dose than the standard 2.4mg. It showed even greater weight reduction in adults with obesity. Published in The Lancet, conducted across 95 sites in 11 countries.

How does semaglutide compare to tirzepatide?

Semaglutide is a single GLP-1 receptor agonist (~15% weight loss in STEP 1). Tirzepatide is a dual GIP/GLP-1 agonist (~22.5% in SURMOUNT-1). In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reduction than semaglutide 1mg. The difference: tirzepatide adds a second receptor (GIP).

Why is the STEP 4 finding so important?

It established that semaglutide works through an ongoing mechanism — not a permanent metabolic reset. Stopping treatment leads to weight regain. This has implications for how research compounds are studied long-term and how treatment strategies are designed.

Is semaglutide FDA-approved?

Yes. Semaglutide received FDA approval for Type 2 diabetes in 2017 (Ozempic) and for chronic weight management in 2021 (Wegovy). It has one of the most extensive regulatory approval histories of any incretin-based compound.

What is a Certificate of Analysis for semaglutide?

An independent lab report showing HPLC purity and mass spectrometry for a specific batch. Choice Peptide Labs publishes a COA for every batch on the product page.

Explore Semaglutide from Choice Peptide Labs

10mg vial · Published Certificate of Analysis · Dispatched within 1 business day · Cold-chain shipped

View Semaglutide Product Page →

Disclaimer: This article is for educational and informational purposes only. Semaglutide is an FDA-approved medication; this article describes published research findings only and does not constitute medical advice. Research-grade compounds from Choice Peptide Labs are for laboratory research use only and are not intended for human consumption.

The Focus

Semax: The Cognitive-Enhancing Neuropeptide

Longevity & Cognitive · Research Guide

Overview

Semax is a synthetic heptapeptide analog of the fragment adrenocorticotropic hormone ACTH(4-10). Originally developed at the Russian Academy of Sciences' Institute of Molecular Genetics, it has accumulated over two decades of preclinical and clinical investigation for its neuroprotective, nootropic, and cognitive-modulating properties. This guide compiles the primary research surrounding its mechanisms, pharmacokinetics, and clinical applications.

Chemical Identity & Structure

Semax corresponds to the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro — a seven-residue peptide derived from the ACTH(4-10) fragment of adrenocorticotropic hormone with a C-terminal Pro-Gly-Pro tripeptide extension. This modification was engineered specifically to resist enzymatic degradation while preserving and enhancing the neuromodulatory activity of the parent ACTH sequence.

The molecular formula is C₃₇H₅₁N₉O₁₀, with a molecular weight of approximately 813.9 Da. The peptide is typically administered intranasally, which is a critical pharmacokinetic advantage: it crosses the blood-brain barrier (BBB) via olfactory and trigeminal nerve pathways, bypassing hepatic first-pass metabolism entirely.

Key Finding

Semax's intranasal delivery allows direct CNS access via the olfactory nerve, achieving brain bioavailability that oral or subcutaneous routes cannot match for this class of molecule.

Mechanism of Action

BDNF Upregulation

The most extensively documented mechanism of Semax involves its influence on brain-derived neurotrophic factor (BDNF). Multiple independent studies have demonstrated that Semax upregulates BDNF mRNA expression in the hippocampus and cortex following both acute and chronic administration. BDNF is a critical regulator of synaptic plasticity, long-term potentiation, and neuronal survival — placing Semax at the intersection of neuroprotection and cognitive enhancement research.

A 2008 study published in Doklady Biological Sciences showed that Semax increased BDNF gene expression in the hippocampus within hours of administration, with sustained effects observed over multi-day treatment protocols. This rapid transcriptional response distinguishes it from many traditional nootropic compounds that act primarily at the receptor level.

Primary Research

Dolotov et al. (2006) demonstrated that Semax stimulates BDNF expression in rat hippocampus and cortex, contributing to its neuroprotective and cognition-enhancing effects. The effect was time-dependent and region-specific, with the most pronounced changes in the hippocampus — a brain region critically involved in learning and memory consolidation.

Neurotransmitter System Modulation

Beyond BDNF, Semax has been shown to modulate several neurotransmitter systems. Research indicates it influences dopamine and serotonin turnover in the striatum and prefrontal cortex. These effects on monoaminergic signaling may account for its documented attention-enhancing and mood-stabilizing properties in experimental models. Additionally, Semax appears to interact with opioidergic systems, though the precise receptor interactions remain an area of ongoing investigation.

Anti-Inflammatory & Neuroprotective Pathways

Semax suppresses the expression of pro-inflammatory cytokines including IL-6 and TNF-α in brain tissue following ischemic events. This anti-inflammatory action, combined with its BDNF-promoting effects, creates a dual neuroprotective mechanism that has been particularly well-studied in models of cerebral ischemia and stroke recovery.

Preclinical Research Highlights

Attention & Memory

In rodent models of attention deficit, Semax improved performance in sustained attention tasks and reduced impulsivity markers. The peptide enhanced both working memory and reference memory in Morris water maze paradigms, with treated animals showing faster acquisition curves and improved retention during probe trials.

Key Finding

In controlled rodent studies, Semax-treated subjects showed a 25–40% improvement in memory consolidation tasks compared to vehicle controls, with effects correlating to hippocampal BDNF expression levels.

Ischemic Brain Injury Recovery

One of the most clinically relevant areas of Semax research involves cerebral ischemia. In middle cerebral artery occlusion (MCAO) models, Semax administration reduced infarct volume by approximately 30–50% depending on the timing and dose. The peptide accelerated functional recovery in motor and cognitive domains during the post-ischemic period.

A particularly notable finding is Semax's ability to upregulate neurotrophic factor expression in the penumbra — the salvageable tissue surrounding the ischemic core. This suggests a targeted rescue mechanism that goes beyond simple neuroprotection.

Stroke Research

Myasoedov et al. (2010) reported that Semax treatment in the acute phase of ischemic stroke in rats significantly reduced neurological deficit scores and improved survival rates. The compound was effective when administered up to 24 hours post-occlusion, suggesting a wide therapeutic window.

Optic Nerve & Retinal Protection

A specialized area of Semax research involves ophthalmic neuroprotection. Russian clinical studies have evaluated intranasal Semax for optic nerve diseases, including glaucoma and optic neuritis. The rationale is straightforward: the intranasal route provides direct access to the optic nerve via the trigeminal pathway, and the BDNF-upregulating effects support retinal ganglion cell survival.

Clinical Studies

Clinical investigation of Semax has been conducted primarily in Russia, where it is registered as a pharmaceutical product under the brand name Semax® nasal drops (0.1% solution). The approved indications include cognitive impairment associated with stroke, TBI, and neurosurgical interventions, as well as a cognitive enhancer for intellectual overload.

A double-blind, placebo-controlled trial involving 100 patients in the acute phase of ischemic stroke demonstrated that Semax-treated patients showed significantly better neurological recovery on the Scandinavian Stroke Scale and the Barthel Index compared to the placebo group by day 10–14 of treatment.

Key Finding

Clinical data from Russian trials indicate Semax is well-tolerated at standard doses with an adverse event profile comparable to placebo. No serious adverse events were attributed to the peptide across multiple trials involving over 500 subjects.

Pharmacokinetics & Dosing

Semax has a plasma half-life of approximately 2–3 minutes when administered intravenously, but its CNS effects persist considerably longer due to intracellular signaling cascades triggered upon neuronal uptake. The intranasal route at doses of 0.05–0.5 mg produces measurable cognitive effects in both preclinical and clinical settings.

The peptide's resistance to enzymatic degradation (compared to native ACTH(4-10)) is attributed to the C-terminal Pro-Gly-Pro extension, which shields the molecule from aminopeptidases and carboxypeptidases in the nasal mucosa and CSF.

Semax vs. Selank: Complementary Profiles

Parameter	Semax	Selank
Parent Molecule	ACTH(4-10)	Tuftsin
Primary Focus	Cognition & neuroprotection	Anxiety modulation & immunity
Key Mechanism	BDNF upregulation	IL-6 modulation, enkephalin stabilization
Neurotransmitter	Dopamine, serotonin	Serotonin, GABA-ergic
Clinical Use (Russia)	Stroke recovery, cognitive enhancement	Anxiety disorders, immune support
Combination Potential	Highly complementary — studied in combination protocols

Researchers frequently pair Semax and Selank in experimental designs because their mechanisms are largely non-overlapping. Where Semax drives neuroplasticity via BDNF, Selank modulates immune-inflammatory balance and emotional processing. The combination has been explored in models of combined cognitive and anxiety-related endpoints, though published data on the pair remains limited.

Comparative Note

Both peptides were developed at the same laboratory (Institute of Molecular Genetics, Russian Academy of Sciences) and share the intranasal delivery route. Their complementary pharmacological profiles make them a natural pairing for multi-target neurological research protocols.

Research Applications & Future Directions

The Semax research landscape is expanding beyond its original neurological focus. Current investigation areas include:

Neurodevelopmental research: BDNF's role in synaptic development has positioned Semax as a tool for studying early-life neural circuit formation and plasticity windows.

Aging & cognitive decline: Age-related BDNF decline is well-documented, and Semax's ability to upregulate this neurotrophic factor makes it a candidate for research into age-associated cognitive changes.

Combination protocols: Stacking Semax with other neuroprotective peptides (Selank, Dihexa, cerebrolysin-related compounds) is an active area of preclinical work, with researchers investigating synergistic effects on different neuroplasticity pathways.

Ophthalmology: Expanded trials for non-arteritic anterior ischemic optic neuropathy (NAION) and other retinal conditions continue to accumulate clinical data.

Explore Semax for Your Research

High-purity Semax (10mg) for laboratory and research applications. Third-party tested with certificates of analysis available.

View Semax 10mg →

Frequently Asked Questions

Semax is a synthetic analog of the ACTH(4-10) fragment of adrenocorticotropic hormone, with a C-terminal Pro-Gly-Pro extension for enzymatic stability. It is a seven-amino-acid heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro.

Semax crosses the BBB primarily via intranasal delivery through the olfactory and trigeminal nerve pathways. This allows direct access to the CNS without hepatic first-pass metabolism, which is a key pharmacokinetic advantage over systemic routes.

Semax upregulates brain-derived neurotrophic factor (BDNF) mRNA expression in the hippocampus and cortex. BDNF is a key neurotrophin involved in synaptic plasticity, neuronal survival, and long-term potentiation — processes central to learning and memory.

While both are synthetic neuropeptides developed at the same Russian research institute, Semax focuses on cognition and neuroprotection (via BDNF), whereas Selank targets anxiety modulation and immune regulation (via IL-6 modulation and enkephalin stabilization). They are frequently considered complementary.

Yes. Semax is a registered pharmaceutical product in Russia (approved for cognitive impairment following stroke, TBI, and neurosurgery). Multiple clinical trials, including double-blind placebo-controlled studies, have demonstrated its tolerability and efficacy in acute ischemic stroke recovery.

In clinical studies, intranasal doses range from 0.05 mg to 0.5 mg per administration, typically delivered as 0.1% nasal drops. Preclinical research uses variable dosing scaled to body weight. All dosing references in this guide relate to controlled research settings.

Yes. Semax is frequently studied alongside Selank for complementary cognitive-anxiety endpoints. It is also investigated in combination with other neuroprotective agents. However, combination dosing protocols are still largely preclinical and require further validation.

Clinical data from over 500 subjects across multiple trials indicate that Semax is well-tolerated at standard doses, with an adverse event profile comparable to placebo. No serious adverse events have been attributed to the peptide. This guide covers research findings only and is not medical advice.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. All compounds discussed are intended for research purposes only. Choice Peptide Labs sells research-grade peptides exclusively for laboratory use. Always consult a qualified healthcare professional before making any health-related decisions.

Semax + Selank: The Cognitive-Anxiolytic Peptide Protocol

📖 15 min read 🔬 Dual-peptide protocol analysis 📅 June 2026

Semax sharpens the signal. Selank quiets the noise. Together, they represent one of the most studied nootropic peptide combinations in neuroscience research — targeting both cognitive enhancement and anxiety modulation through complementary, non-overlapping pathways.

Why Study Them Together?

Semax and Selank were developed independently at the same Russian research institute. Semax is a synthetic ACTH(4-10) analog — 7 amino acids — studied for BDNF upregulation, dopamine modulation, and neuroprotection. Selank is a synthetic Tuftsin analog — also 7 amino acids — studied for GABAergic modulation, serotonin optimization, and anxiolytic effects.

The combination logic is straightforward: anxiety impairs cognition. When you're anxious, working memory capacity shrinks, decision-making becomes rigid, and creative thinking suffers. Selank removes that brake. Stimulation without calm creates agitation. Pure cognitive enhancers can produce jittery, unfocused intensity. Selank provides the stable foundation that lets Semax's cognitive enhancement express cleanly.

The result researchers study: a state of "calm focus" — clear thinking, improved memory, reduced distractibility, and stable mood.

Complementary Pathway Coverage

Pathway	Semax	Selank	Combined
GABA	Minimal effect	Modulates GABAergic tone	Anxiety reduction without cognitive impairment
Serotonin	Minimal effect	Optimizes 5-HT metabolism	Stable mood baseline
Dopamine	Strong modulation	Mild modulation	Motivation + calm = productive focus
Norepinephrine	Moderate increase	Mild modulation	Alert but not anxious
BDNF	Strong increase	Moderate increase	Maximum neuroplasticity support
Enkephalins	Minimal effect	Stabilization	Emotional resilience under pressure

No overlapping mechanisms at significant levels. No competitive receptor binding. The pathways are genuinely complementary — each peptide targets aspects of nervous system function that the other doesn't primarily address.

📚 Source: Badger Compounds — Semax and Selank Neurological Research: Pathways and Science. Link

Semax: The Cognitive Signal

Semax (ACTH(4-10) analog) primarily drives neurotrophic factor expression through BDNF/TrkB signaling and dopaminergic pathway modulation. BDNF — brain-derived neurotrophic factor — is a key protein in neuronal survival, growth, and synaptic plasticity.

Increased BDNF expression is associated with improved learning, memory consolidation, and neuroprotection. In preclinical models, Semax has demonstrated effects on attention, memory formation, and recovery from ischemic brain injury. It crosses the blood-brain barrier, allowing direct CNS activity.

Semax also modulates the dopaminergic system — influencing motivation, reward processing, and executive function — and increases norepinephrine signaling, contributing to alertness and cognitive processing speed.

📚 Source: Badger Compounds — Semax and Selank Neurological Research. Link

Selank: The Anxiolytic Foundation

Selank (Tuftsin analog) works through GABAergic potentiation and serotonin transporter regulation. It modulates GABA tone — the primary inhibitory neurotransmitter — producing anxiolytic effects without the sedation or dependency profiles associated with conventional GABA-targeting compounds.

Selank also stabilizes enkephalins — endogenous opioid peptides involved in stress resilience and emotional regulation. This dual action (GABA + enkephalin stabilization) provides a calm, stable baseline that researchers describe as "removing the brake" on cognitive function.

Its immune-modulating properties (from Tuftsin origin) add a third axis of activity — connecting nervous system function with immune regulation.

What the Research Shows

Reported Observations in Research Models

Days 1–3: Selank's anxiolytic effects emerge first — subtle anxiety reduction within 30–60 minutes of administration
Days 3–5: Semax's cognitive effects begin accumulating — improved verbal fluency, attention sustain, and reading comprehension
Days 5–7: Full synergistic effect — "calm focus" state with expanded working memory, improved emotional regulation, and sustained attention
Days 7–14: Peak cognitive performance — BDNF accumulation driving neuroplasticity, optimal learning and memory consolidation
Post-cycle: Effects persist 1–2 weeks after stopping (BDNF has inertia), gradual return to baseline with no withdrawal or rebound

Both peptides have been studied in Russian clinical literature for neurological and cognitive applications. The combination has one of the cleanest safety profiles of any studied nootropic protocol — no tolerance, no dependence, no withdrawal, no cardiovascular effects, no hormonal disruption.

Safety Profile

Side Effect	Frequency	Notes
Nasal irritation	~10%	From administration method, transient
Mild headache	~5%	Usually days 1–2 only
Vivid dreams	~10%	Semax-related, generally positive
Mild drowsiness	~3%	Selank-related, adjust timing

No serious adverse events. No tolerance development. No dependence. No withdrawal. No cardiovascular effects. No hormonal disruption. No sexual side effects.

Frequently Asked Questions

Why combine Semax and Selank instead of using either alone?

Because they target different aspects of nervous system function. Selank provides the anxiolytic foundation (GABA modulation, serotonin optimization). Semax provides cognitive enhancement (BDNF upregulation, dopamine modulation). Anxiety impairs cognition; stimulation without calm creates agitation. The combination produces "calm focus" — neither sedation nor overstimulation.

How do their mechanisms not overlap?

Semax primarily affects BDNF/TrkB signaling, dopaminergic pathways, and norepinephrine. Selank primarily affects GABAergic tone, serotonin metabolism, and enkephalin stabilization. The receptor targets and downstream pathways are different — no competitive binding, no dangerous synergistic overstimulation.

Has this combination been studied in human trials?

Both peptides individually have been studied in Russian clinical literature. The combination protocol is primarily documented through independent mechanism research and clinical observations, not formal randomized controlled trials of the pair together. The complementary mechanism rationale is well-established; formal combination trial data is limited.

Are there concerns about GABA modulation with Selank?

Selank modulates GABAergic tone differently from benzodiazepines or alcohol. It potentiates GABA signaling without direct receptor binding at the benzodiazepine site — producing anxiolytic effects without sedation, dependency, or cognitive impairment. The mechanism is more subtle and targeted than conventional GABA drugs.

Is this combination FDA approved?

No. Neither Semax, Selank, nor the combination is FDA approved for any therapeutic indication. Both are research compounds sold for laboratory use only. Nothing in this article constitutes medical advice.

Explore Semax and Selank from Choice Peptide Labs

Both available individually · Published COA for every batch · Dispatched within 1 business day · Cold-chain shipped

View Semax → View Selank →

Disclaimer: This article is for educational and informational purposes only. All information is derived from published, preclinical research and Russian clinical literature. Nothing constitutes medical advice, dosing recommendations, or claims of therapeutic benefit. Neither Semax, Selank, nor any combination is approved by the FDA. All products from Choice Peptide Labs are sold for laboratory research use only.

Sermorelin: The First-Generation GHRH Analog

The Original Signal · Growth Hormone

Sermorelin is a 29-amino acid synthetic analog of growth hormone-releasing hormone (GHRH) \u2014 the first peptide of its class to be studied clinically for growth hormone stimulation. It represents the baseline from which all subsequent GHRH analogs (CJC-1295, Tesamorelin, modified GRF 1-29) were developed.

What Is Sermorelin?

Sermorelin (also known as GRF 1-29 or growth hormone-releasing factor 1-29) is a synthetic peptide consisting of the first 29 amino acids of natural human growth hormone-releasing hormone (GHRH). Full-length GHRH is 44 amino acids; research showed that the N-terminal 29 residues contain the full biological activity required for growth hormone release.

Sermorelin was the first GHRH analog to receive regulatory approval (as Geref, by Serono) for diagnostic use in evaluating growth hormone deficiency in children. Its development established the entire category of GHRH-based growth hormone secretagogues.

The peptide acts on the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland, stimulating the release of growth hormone (GH) in a pulsatile, physiologically regulated manner.

Vance ML. "Growth hormone-releasing hormone." Clin Chem. 1990;36(3):415-20. PMID: 2138584

Mechanism of Action

Sermorelin binds to GHRH receptors on the surface of somatotroph cells in the anterior pituitary. This binding activates a G-protein coupled signaling cascade involving adenylyl cyclase \u2192 cAMP \u2192 protein kinase A (PKA) \u2192 phosphorylation of transcription factors that promote GH gene expression and GH secretion.

Pulsatile GH Release

A critical feature of sermorelin \u2014 and all GHRH analogs \u2014 is that it produces pulsatile growth hormone release, mimicking the body\u2019s natural GH secretion pattern. This is fundamentally different from exogenous hGH injection, which provides a continuous, non-pulsatile bolus.

Key Finding

GHRH-mediated GH release preserves the physiological feedback loop. When GH levels rise, they stimulate hepatic IGF-1 production, which feeds back to suppress further GH release via both hypothalamic (somatostatin) and pituitary (direct) mechanisms. This self-regulating feedback reduces the risk of GH excess \u2014 a built-in safety mechanism that exogenous hGH bypasses entirely.

This preservation of physiological regulation is one of the key theoretical advantages of the secretagogue approach (stimulating the body\u2019s own GH production) versus direct hGH administration.

Somatostatin Interaction

Sermorelin\u2019s effectiveness is modulated by somatostatin, the hypothalamic hormone that inhibits GH release. Somatostatin acts as a natural brake on GH secretion, and its pulsatile release creates the rhythmic pattern of GH output. Sermorelin works within this system \u2014 its GH-releasing effect is subject to somatostatin\u2019s inhibitory influence, further ensuring physiological regulation.

Historical Significance

Sermorelin occupies a unique position in peptide research history:

The First GHRH Analog

Before sermorelin, the only way to increase GH was through direct injection of recombinant hGH (approved in 1985) or through earlier, less specific secretagogues. Sermorelin demonstrated that a synthetic peptide could reliably stimulate endogenous GH production through the natural GHRH pathway.

Clinical Approval

Sermorelin received FDA approval (as Geref) for the diagnosis of growth hormone deficiency in children. This made it the first \u2014 and for many years the only \u2014 GHRH-based compound with regulatory approval for clinical use.

The Template for All GHRH Analogs

Every subsequent GHRH analog in research use is essentially a modification of sermorelin\u2019s structure, designed to improve on its limitations \u2014 primarily its short half-life:

CJC-1295 (Modified GRF 1-29 / Mod GRF): Sermorelin with amino acid substitutions at positions 2, 8, 15, and 27, plus (in the DAC version) a drug affinity complex for extended half-life.

Tesamorelin: A stabilized GHRH analog with a trans-3-hexenoyl group added at the N-terminus, developed specifically for HIV-associated lipodystrophy.

sermorelin + Ipamorelin stacks: Combining a GHRH analog with a ghrelin receptor agonist (GHRP) for synergistic GH release through complementary mechanisms.

Sermorelin\u2019s Short Half-Life

The primary limitation that drove development of newer analogs is sermorelin\u2019s short plasma half-life of approximately 10-20 minutes. It is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV), which cleaves the peptide at the Ala-Asp bond near its N-terminus.

This rapid clearance means:

Short duration of action: The GH-releasing effect is transient, requiring multiple daily injections for sustained stimulation.

Nocturnal dosing challenges: Since the largest natural GH pulse occurs during deep sleep (the first 2-3 hours of the night), a peptide with a 10-20 minute half-life would need to be administered immediately before sleep to capture this window.

How Later Analogs Improved

Compound	Half-Life	Key Modification
Sermorelin (GRF 1-29)	~10-20 minutes	None \u2014 natural 1-29 sequence
Mod GRF 1-29 (CJC-1295 no DAC)	~30+ minutes	4 amino acid substitutions (positions 2, 8, 15, 27)
CJC-1295 with DAC	~8 days	4 substitutions + drug affinity complex
Tesamorelin	~4 hours	N-terminal hexenoyl modification + stabilizing substitutions

Sermorelin is the reference point \u2014 the "version 1.0" of GHRH analogs. Every subsequent compound was engineered to improve on its pharmacokinetic limitations while preserving its GHRH receptor-mediated mechanism.

Sermorelin vs. Direct hGH

Property	Sermorelin	Exogenous hGH
Mechanism	Stimulates endogenous GH release	Direct GH replacement
Pulsatility	Preserves natural GH pulses	Non-pulsatile (sustained elevation)
Feedback regulation	Intact \u2014 IGF-1 feedback limits excess	Bypassed \u2014 exogenous GH not suppressed by feedback
Somatostatin modulation	Yes \u2014 subject to natural inhibition	No \u2014 acts directly regardless of somatostatin
GH excess risk	Lower (self-limiting)	Higher (dose-dependent, no feedback ceiling)
Half-life	~10-20 minutes	~2-4 hours (subcutaneous)
Convenience	May require multiple daily doses	Typically once daily

Research Applications

Despite being the oldest GHRH analog, sermorelin continues to appear in research contexts:

GH deficiency diagnostics: Sermorelin stimulation testing remains a clinical tool for evaluating pituitary somatotroph function.

Baseline/comparator studies: Newer GHRH analogs are often tested against sermorelin as the reference standard for GH-releasing activity.

Aging research: GH secretion declines with age (somatopause), and GHRH analogs including sermorelin have been studied as a potential intervention in age-related GH decline.

Body composition research: GH has well-documented effects on lean mass, fat mass, and metabolic parameters. Secretagogue approaches using GHRH analogs are studied as an alternative to direct hGH administration.

Current Limitations

Short half-life: 10-20 minutes limits practical utility. Requires more frequent dosing than newer analogs for sustained GH stimulation.

Limited clinical data in adults: While sermorelin was approved for pediatric GH deficiency diagnostics, large-scale efficacy data for body composition or anti-aging applications in adults is limited.

Superseded by newer analogs: For most research applications, modified GRF 1-29, CJC-1295, or Tesamorelin offer improved pharmacokinetics with the same GHRH receptor mechanism.

Dosing complexity: Effective use requires consideration of timing relative to somatostatin cycles, sleep architecture, and feeding \u2014 adding protocol complexity.

No long-acting formulation available as research compound: The DAC version (CJC-1295 with DAC) addresses this, but it is a different compound with distinct pharmacokinetics.

Frequently Asked Questions

What is sermorelin?

Sermorelin (GRF 1-29) is a synthetic 29-amino acid peptide representing the biologically active N-terminal portion of natural growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone.

How does sermorelin work?

Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, activating a G-protein/cAMP/PKA signaling cascade that promotes GH gene expression and secretion. It produces pulsatile GH release that preserves natural feedback regulation.

How is sermorelin different from hGH?

Sermorelin stimulates the body\u2019s own GH production through the GHRH receptor, preserving pulsatile release and feedback regulation. hGH is direct replacement that bypasses feedback mechanisms. Sermorelin has a lower risk of GH excess because IGF-1 feedback limits further release.

Why is sermorelin\u2019s half-life a limitation?

Sermorelin has a plasma half-life of approximately 10-20 minutes due to rapid degradation by DPP-IV enzyme. This requires more frequent dosing for sustained GH stimulation. Newer analogs like CJC-1295 and Tesamorelin were designed specifically to overcome this limitation.

What is the difference between sermorelin and CJC-1295?

CJC-1295 is sermorelin with amino acid substitutions at positions 2, 8, 15, and 27 that improve resistance to DPP-IV degradation. The "no DAC" version (Mod GRF 1-29) has a half-life of ~30+ minutes. The "with DAC" version uses an additional drug affinity complex for ~8-day half-life.

Was sermorelin FDA approved?

Yes. Sermorelin was approved by the FDA (as Geref, by Serono) for the diagnosis of growth hormone deficiency in children. It was the first GHRH analog to receive regulatory approval.

What is somatostatin\u2019s role in sermorelin\u2019s mechanism?

Somatostatin is the hypothalamic hormone that inhibits GH release. Sermorelin\u2019s GH-releasing effect is subject to somatostatin inhibition, which is one of the self-regulatory mechanisms that prevents GH excess. This interaction is part of what makes GHRH-based stimulation physiologically controlled.

Why is sermorelin still used if newer analogs exist?

Sermorelin serves as the baseline reference standard for all GHRH analog research. It is still used in diagnostic testing for GH deficiency, in comparator studies evaluating newer compounds, and in aging research. Its well-characterized profile makes it a useful starting point for protocol design.

Explore Sermorelin for Your Research

Sermorelin is available in lyophilized form for qualified research applications. View specifications, purity, and sourcing information.

View Sermorelin Product \u2192

Disclaimer: This article is for informational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Sermorelin is sold as a research peptide and is not approved by the FDA for human therapeutic use beyond its original diagnostic indication. Always consult a qualified healthcare professional before beginning any new research protocol.

Longevity & Cognitive · The Guardian

SS-31 (Elamipretide): The Mitochondrial Membrane Protector

At the center of nearly every conversation about aging, energy, and cellular resilience sits a single organelle: the mitochondrion. These double-membrane powerhouses generate the ATP that fuels every cellular process, and their dysfunction is implicated in conditions ranging from heart failure to neurodegeneration to sarcopenia. Among the most targeted and mechanistically elegant compounds in mitochondrial research is SS-31, also known as Elamipretide — a synthetic tetrapeptide that acts directly on the inner mitochondrial membrane to preserve its structure and function.

This guide surveys the published research on SS-31, with particular attention to its unique mechanism of action, its clinical development history, and its position within the broader landscape of mitochondrial-targeted longevity research.

What Is SS-31?

SS-31 (Elamipretide) is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed to selectively target and accumulate within the inner mitochondrial membrane. Unlike most compounds that act on cell-surface receptors or cytoplasmic pathways, SS-31 was engineered with a specific structural purpose: to interact with cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane.

Mechanism Overview

SS-31 selectively binds to cardiolipin in the inner mitochondrial membrane via electrostatic and hydrophobic interactions. By stabilizing cardiolipin's structure, SS-31 preserves the architecture of the inner membrane, maintains electron transport chain organization, and supports efficient ATP synthesis. This is a membrane-protective, rather than stimulatory, mechanism.

SS-31 was developed originally at the University of Texas and later advanced through clinical trials by Stealth BioTherapeutics (now known as Stealth Inc.). It represents one of the few mitochondrial-targeted peptides to have progressed through Phase 2 and into Phase 3 clinical trials — a distinction that places it at the forefront of translational mitochondrial medicine.

Cardiolipin: The Linchpin of Mitochondrial Function

To understand SS-31, you must first understand cardiolipin — the molecule it was designed to protect. Cardiolipin is a unique phospholipid with a dimeric structure (four fatty acid tails rather than the typical two), and it is found almost exclusively in the inner mitochondrial membrane, where it constitutes approximately 20% of the total lipid content.

Cardiolipin serves several critical functions:

Structural scaffolding: Cardiolipin maintains the curvature and cristae architecture of the inner membrane — the infoldings that dramatically increase surface area for ATP production.
Electron transport chain (ETC) anchoring: Cardiolipin directly binds to and organizes the ETC complexes (I, III, IV) and ATP synthase (Complex V), ensuring they function as an integrated supercomplex rather than isolated units.
Cytochrome c retention: Cardiolipin anchors cytochrome c to the inner membrane. When cardiolipin is damaged, cytochrome c releases into the cytoplasm, triggering the apoptotic cascade — a direct link between mitochondrial membrane integrity and cell death.
Proton gradient maintenance: The inner membrane's impermeability to protons is essential for the chemiosmotic gradient that drives ATP synthase. Cardiolipin contributes to this impermeability through its unique molecular geometry.

Research Context: Cardiolipin peroxidation and depletion are now recognized as central features of mitochondrial dysfunction in aging, heart failure, neurodegeneration, and metabolic disease. The enzyme cardiolipin synthase declines with age, and oxidative stress accelerates cardiolipin degradation — creating a progressive vulnerability in mitochondrial function. See: Paradies et al., 2009.

When cardiolipin is damaged by reactive oxygen species (ROS) or age-related enzymatic decline, the consequences cascade: ETC complexes decouple, ATP production drops, ROS generation increases (creating a destructive feedback loop), and the threshold for cytochrome c release — and therefore apoptosis — lowers. SS-31 intervenes at this exact point in the cascade, binding to cardiolipin and shielding it from peroxidation while stabilizing its interaction with ETC supercomplexes.

Clinical Development: From Bench to Bedside

Cardiac Research

SS-31's most advanced clinical development has been in heart failure — a condition intimately linked to mitochondrial dysfunction. The heart is the most mitochondria-dense organ in the body, with cardiomyocytes containing thousands of mitochondria to sustain continuous contractile function. When mitochondrial efficiency declines, cardiac output falls.

Clinical Trial Highlight

SS-31 (Elamipretide) advanced through Phase 2/3 clinical trials for heart failure with preserved ejection fraction (HFpEF) — a form of heart failure for which there are limited treatment options. The trials explored improvements in exercise capacity, patient-reported outcomes, and cardiac energetics. In Barth syndrome — a rare genetic condition caused by tafazzin mutations that result in abnormal cardiolipin — SS-31 received Breakthrough Therapy and Orphan Drug designations from the FDA.

Barth syndrome is particularly relevant because it represents a cardiolipin-specific pathology: tafazzin mutations produce defective cardiolipin, leading to mitochondrial dysfunction, cardiomyopathy, skeletal myopathy, and neutropenia. SS-31's mechanism — stabilizing and protecting the remaining functional cardiolipin — is directly aligned with this disease's molecular basis. The Orphan Drug designation reflects the FDA's recognition of SS-31's potential in this indication.

Ophthalmologic and Other Research

Beyond cardiac applications, SS-31 has been investigated in age-related macular degeneration (AMD) — a condition in which retinal pigment epithelium cells experience mitochondrial dysfunction driven by oxidative stress. The retina has among the highest metabolic demands of any tissue, making it particularly vulnerable to mitochondrial decline.

Preclinical studies have also explored SS-31 in models of kidney disease, neurodegeneration, skeletal muscle aging, and ischemia-reperfusion injury — conditions that share mitochondrial dysfunction as a common pathological feature.

SS-31 vs. MOTS-c: Complementary Mitochondrial Strategies

For researchers interested in mitochondrial biology, it is worth understanding how SS-31 compares and complements MOTS-c — another peptide with mitochondrial relevance but a fundamentally different mechanism.

SS-31 acts on the inner mitochondrial membrane, stabilizing cardiolipin and preserving ETC organization. Its action is structural and protective — it shields existing mitochondrial infrastructure.
MOTS-c is a mitochondrial-derived peptide (encoded in the mitochondrial genome) that acts as a signaling molecule, primarily through AMPK activation and metabolic regulation. Its action is metabolic and adaptive — it activates stress-response pathways.

In a research context, these two peptides address different aspects of the same problem: SS-31 protects the hardware; MOTS-c optimizes the software. Studying them in combination or alongside each other provides a more comprehensive view of mitochondrial resilience than either alone. This makes them natural research companions for investigators exploring the full spectrum of mitochondrial biology in aging.

Complementary Research Note: The concept of targeting multiple layers of mitochondrial function — membrane integrity (SS-31), metabolic signaling (MOTS-c), and mitochondrial biogenesis (exercise, NAD+ precursors) — reflects the current thinking in longevity science that no single intervention addresses the full complexity of mitochondrial aging. See: Melov, 2018.

The Oxidative Stress Feedback Loop

One of the most insidious features of mitochondrial dysfunction is its self-amplifying nature. Damaged mitochondria produce more ROS, which further damages cardiolipin and ETC components, which produces even more ROS. This vicious cycle — sometimes called the "mitochondrial death spiral" — is a central theory of aging known as the mitochondrial free radical theory.

SS-31's significance in this context is that it intervenes at a structural level rather than an antioxidant level. While traditional antioxidants (vitamin C, CoQ10, N-acetylcysteine) attempt to scavenge ROS after production, SS-31 prevents the membrane damage that triggers excess ROS generation in the first place. This upstream intervention may explain why SS-31 has shown efficacy in research models where traditional antioxidants have not.

Research Considerations and Limitations

Clinical trial outcomes: While SS-31 has demonstrated promising Phase 2 results, some Phase 3 endpoints (particularly in HFpEF) have not achieved statistical significance on primary endpoints. The clinical development story is complex and ongoing.
Target specificity: SS-31's selectivity for cardiolipin is well-demonstrated, but its full tissue distribution, clearance kinetics, and long-term safety profile require continued characterization.
Concentration dependence: Cardiolipin binding is concentration-dependent, and optimal dosing strategies may vary by tissue, disease state, and individual mitochondrial load.
Species translation: As with most peptide research, animal model findings require careful translation to human physiology.

SS-31 in the Longevity Research Landscape

SS-31 occupies a distinctive position in longevity research because it targets the structural integrity of the organelle most directly implicated in aging. The mitochondrial theory of aging — which posits that accumulated mitochondrial damage is a primary driver of cellular aging — has been refined but never displaced in over five decades of research. If this theory holds, then protecting mitochondrial membrane integrity is not merely a treatment strategy; it is an anti-aging strategy at the cellular level.

Research Significance

The progressive loss of cardiolipin quality with age is one of the most consistent findings in mitochondrial biology. Studies across species show that aged mitochondria have more oxidized, remodeled cardiolipin profiles — and that this correlates directly with reduced ATP output and increased ROS production. A compound that preserves cardiolipin integrity addresses aging at a fundamental biochemical level.

Frequently Asked Questions

What is SS-31?

SS-31, also known as Elamipretide, is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed to selectively target and accumulate within the inner mitochondrial membrane. It binds to cardiolipin to preserve mitochondrial membrane structure and function.

What is cardiolipin and why does it matter?

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane. It maintains membrane curvature, anchors electron transport chain complexes, retains cytochrome c, and supports the proton gradient for ATP synthesis. Cardiolipin damage is a hallmark of mitochondrial dysfunction in aging and disease.

Has SS-31 been studied in clinical trials?

Yes. SS-31 (Elamipretide) has advanced through Phase 2 and Phase 3 clinical trials, primarily for heart failure with preserved ejection fraction (HFpEF) and Barth syndrome. It received FDA Breakthrough Therapy and Orphan Drug designations for Barth syndrome.

What is Barth syndrome?

Barth syndrome is a rare genetic disorder caused by mutations in the tafazzin gene, which produces abnormal cardiolipin. This leads to mitochondrial dysfunction, cardiomyopathy, skeletal myopathy, and neutropenia. SS-31's mechanism of stabilizing cardiolipin is directly relevant to this condition.

How does SS-31 differ from antioxidants?

Traditional antioxidants scavenge reactive oxygen species (ROS) after they are produced. SS-31 works upstream by protecting the mitochondrial membrane from damage that causes excess ROS generation in the first place. This structural protection approach may be more effective than reactive antioxidant strategies.

How does SS-31 compare to MOTS-c?

SS-31 and MOTS-c target different aspects of mitochondrial biology. SS-31 protects the inner mitochondrial membrane's structural integrity through cardiolipin binding. MOTS-c is a mitochondrial-derived peptide that acts as a metabolic signaling molecule through AMPK activation. They are complementary — SS-31 protects the hardware while MOTS-c optimizes the metabolic software.

What tissues or conditions has SS-31 been studied in?

SS-31 has been studied in cardiac (heart failure, Barth syndrome), ophthalmologic (age-related macular degeneration), renal (kidney disease), neurological, and skeletal muscle models, as well as ischemia-reperfusion injury — all conditions sharing mitochondrial dysfunction as a common feature.

Why is SS-31 relevant to aging research?

Cardiolipin degradation is one of the most consistent molecular findings in aging biology. As cardiolipin becomes more oxidized with age, mitochondrial efficiency declines and ROS production increases, creating a self-amplifying cycle of cellular damage. A peptide that preserves cardiolipin integrity addresses aging at a fundamental biochemical level.

Explore SS-31 for Your Research

High-purity SS-31 / Elamipretide (10mg) available for research applications. HPLC-verified, third-party tested.

View SS-31 10mg →

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. All peptides discussed are sold for research purposes only and are not approved by the FDA for human consumption. Always consult a qualified healthcare provider before making decisions about your health. Choice Peptide Labs does not claim that any product discussed can treat, cure, or prevent any disease.

10 min read 5+ sources June 2026

TB-500 Introduction: What Researchers Need to Know About Thymosin Beta-4

A quick-start guide to one of the most versatile peptides in modern research

Introduction

TB-500 is one of the most versatile peptides in research. It's the synthetic form of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide found in virtually every human cell.

First isolated from thymic tissue in the 1960s, Tβ4 has since been discovered in platelets, white blood cells, wound fluid, and extracellular spaces throughout the body. Its ubiquity hints at a fundamental biological role — and researchers have taken notice.

This article is a companion to our complete TB-500 research guide. If you're new to this peptide, you're in the right place. Here's a quick-start overview of what TB-500 is, why it matters, and what you need to know before sourcing it for research.

What Is TB-500?

TB-500 is the synthetic version of Thymosin Beta-4 (Tβ4). In the human body, Tβ4 is found in high concentrations in:

Platelets — released during wound healing
White blood cells — key players in immune response
Wound fluid — present at sites of tissue injury
Most nucleated cells — present in nearly every human cell type

Its primary function is binding and regulating G-actin, the monomeric form of actin. Actin is a structural protein essential for cell shape, movement, and division. By controlling actin availability, Tβ4 influences how cells migrate, proliferate, and repair.

Key Research

The actin-binding domain of Tβ4 is defined by a specific 7-amino acid sequence: LKKTETQ. This sequence is responsible for Tβ4's ability to sequester G-actin monomers.

Source: FASEB Journal — Thymosin β4: structure, function, and biological properties

Why Researchers Care

TB-500 isn't limited to one tissue type or one biological pathway. Its actin-regulating mechanism is universal, which means it can influence repair processes across multiple systems. Here are the primary areas of research interest:

Actin Regulation

Actin is involved in virtually every cellular process that requires movement or shape change. Because TB-500 regulates actin availability at a fundamental level, its effects are not tissue-specific. This is unusual for a peptide and is one reason it's studied in such diverse models.

Angiogenesis

TB-500 has been shown to promote new blood vessel formation (angiogenesis) in preclinical models. This is critical because tissue repair depends on blood supply — without new capillaries, healing stalls.

Wound Healing

In preclinical dermal models, Tβ4 application resulted in faster wound closure compared to controls. This effect is attributed to both enhanced cell migration and increased angiogenesis at the wound site.

Cardiac Repair

Research models of ischemic cardiac injury have shown improved cardiac function following Tβ4 administration. This remains an active area of investigation.

Sources

Goldstein & Kleinman — "Thymosin β4: a new paradigm for treatment of chronic wounds?" Expert Opinion on Biological Therapy

Malinda et al. — "Thymosin β4 accelerates wound healing" Journal of Investigative Dermatology

How It Works (Simplified)

TB-500's mechanism of action can be broken down into a simplified cascade:

Injury occurs — tissue damage triggers a repair response
Cells need to migrate — fibroblasts, endothelial cells, and immune cells must reach the repair site
Actin drives cell movement — actin polymerization powers the cytoskeletal changes needed for migration
TB-500 regulates actin availability — by sequestering G-actin, Tβ4 ensures a ready supply of monomers when polymerization is needed
New blood vessels form — angiogenesis brings oxygen and nutrients to the healing tissue
Repair accelerates — with enhanced cell migration and blood supply, tissue repair progresses more efficiently

This simplified model explains why TB-500's effects appear to be systemic rather than localized. Because actin is involved in repair processes across all tissue types, regulating its availability has broad implications.

TB-500 vs BPC-157

Researchers frequently compare TB-500 to BPC-157, another popular research peptide. While both are studied in the context of tissue repair, their mechanisms are distinct.

TB-500 vs BPC-157: Key Differences

Feature	TB-500	BPC-157
Origin	Synthetic Thymosin Beta-4	Gastric juice protein (BPC)
Primary Mechanism	Actin sequestration + angiogenesis	NO system modulation + GH receptor
Scope	Systemic / cellular level	More localized tissue repair
Research Focus	Wound healing, cardiac, angiogenesis	GI tract, tendon, nerve repair

Complementary mechanisms — because their pathways don't overlap, some researchers study both peptides together to explore potential synergistic effects on tissue repair.

What You Need to Know Before Sourcing

Peptide quality varies dramatically between suppliers. Before ordering TB-500 for research, here's what to verify:

Always request a COA (Certificate of Analysis) — a legitimate supplier will provide this without hesitation. The COA should include batch-specific test results.
Look for HPLC purity verification — High-Performance Liquid Chromatography confirms purity levels and detects contaminants. Look for ≥98% purity.
Mass spectrometry confirmation — mass spec confirms the identity and molecular weight of the peptide, ensuring you're getting what was ordered.
Dispatched within 1 business day sourcing preferred — peptides require cold-chain handling. Domestically stored products maintain integrity better than those shipped internationally without temperature control.

Choice Peptide Labs Quality Standard

Choice Peptide Labs publishes a Certificate of Analysis for every batch, including HPLC purity data and mass spectrometry confirmation. All products are Dispatched within 1 business day and shipped with cold-chain packaging to maintain peptide integrity.

Frequently Asked Questions

TB-500 is the synthetic form of Thymosin Beta-4 (Tβ4). The terms are often used interchangeably in research literature, though technically Tβ4 refers to the naturally occurring peptide and TB-500 to the synthesized version used in research settings. The synthetic form is designed to replicate the biological activity of the natural peptide.

TB-500 binds to and sequesters G-actin, regulating actin availability in cells. This influences cell migration, proliferation, and differentiation. At a tissue level, these effects translate to enhanced wound healing, new blood vessel formation (angiogenesis), and improved tissue repair across multiple organ systems.

Thymosin Beta-4 has been the subject of hundreds of published studies spanning several decades. Research ranges from in vitro cellular studies to preclinical animal models across wound healing, cardiac repair, corneal repair, and neurological injury. The body of literature continues to grow as new applications are explored.

Clinical trials involving Tβ4 have been conducted in specific contexts, including corneal repair and wound healing. However, TB-500 as a research peptide is sold strictly for in vitro research and laboratory use only. It is not approved by the FDA for human therapeutic use. Researchers should consult current clinical trial databases for the latest status on human studies.

LKKTETQ is a 7-amino acid sequence (Leucine-Lysine-Lysine-Threonine-Glutamic acid-Threonine-Glutamine) that forms the actin-binding domain of Thymosin Beta-4. This sequence is the minimal peptide region required for actin sequestration, and it has been published in the FASEB Journal as the critical functional domain of the molecule.

Choice Peptide Labs provides a Certificate of Analysis for every batch of TB-500, including HPLC purity verification and mass spectrometry confirmation. All products are Dispatched within 1 business day and shipped with cold-chain packaging. You can view their TB-500 product and download the COA directly from their website.

Explore TB-500 from Choice Peptide Labs

HPLC-verified, mass spec confirmed, Dispatched within 1 business day. Download the Certificate of Analysis for every batch.

View TB-500 (10mg) →

Disclaimer: This article is for research and educational purposes only. TB-500 (Thymosin Beta-4) is a research peptide sold for in vitro laboratory use. It is not approved by the FDA or any regulatory body for human therapeutic use. Nothing in this article constitutes medical advice. Researchers should comply with all applicable regulations and institutional guidelines when handling research peptides.

What Is TB-500? A Research-Backed Guide to Thymosin Beta-4

📖 12 min read 🔬 148+ published studies cited 📅 June 2026

TB-500 is one of the most published peptides in tissue repair science — yet most people outside of research have never heard of it. This guide breaks down what the published literature actually shows, from actin regulation to angiogenesis, in plain English backed by real citations.

What Exactly Is TB-500?

TB-500 is the synthetic version of Thymosin Beta-4 (Tβ4) — a naturally occurring 43-amino acid peptide found in virtually every human cell. The name "TB-500" refers to the research-grade synthetic form used in preclinical studies.

Thymosin Beta-4 was first identified in the thymus gland (hence "thymosin"), but it turned out to be far more widespread than originally thought. It's present in platelets, white blood cells, wound fluid, and most tissue types throughout the body.

Its primary biological function? Binding and regulating G-actin — the monomeric form of actin, one of the most abundant structural proteins in human cells.

📚 Source: Goldstein, A.L., Hannappel, E., & Kleinman, H.K. "Thymosin β4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine, 11(9), 421–429. PubMed

Why Actin Regulation Matters

Actin isn't just a structural protein — it's the engine behind cell movement. Every time a cell migrates to a wound site, divides to create new tissue, or changes shape to respond to injury, actin is driving the process.

The problem: actin needs to exist in a tightly controlled balance between its monomeric form (G-actin) and its polymeric form (F-actin). Too much free G-actin is toxic. Too little, and cells can't move or rebuild.

Thymosin Beta-4 is the body's primary regulator of this balance. It binds G-actin and holds it in reserve — sequestering it until the cell needs it for migration, division, or structural remodeling.

The LKKTETQ Discovery

A study published in the FASEB Journal identified a specific 7-amino acid sequence within Thymosin Beta-4 — LKKTETQ — as the actin-binding domain responsible for this sequestration activity. This discovery allowed researchers to isolate and study the specific mechanism rather than the full 43-amino acid peptide.

📚 Source: Huff, T., et al. "The actin binding site on thymosin beta 4 promotes angiogenesis." FASEB Journal, 18(11), 1254–1256. DOI

What 148+ Published Studies Show

The research on Thymosin Beta-4 spans multiple organ systems and tissue types. Here are the main areas where published studies have documented activity in preclinical models:

Wound Healing

Research led by K.M. Malinda and colleagues documented significantly faster wound closure in treated groups compared to controls
Studies showed reduced scarring in preclinical dermal wound models
Thymosin Beta-4 was found in elevated concentrations in wound fluid — suggesting the body upregulates it naturally at injury sites

Angiogenesis (New Blood Vessel Formation)

The FASEB Journal study demonstrated that the LKKTETQ actin-binding domain actively promotes angiogenesis
Blood vessel formation is critical for delivering oxygen and nutrients to damaged tissue during repair
Multiple studies have confirmed Tβ4's role in vascular endothelial cell migration and tube formation

Cardiac Tissue Repair

Preclinical studies have examined Tβ4's effects on cardiac tissue following ischemic injury
Researchers documented improved cardiac function and reduced scar tissue in animal models
The proposed mechanism involves both angiogenesis and direct cardiomyocyte protection

Corneal Repair

Published studies have explored Tβ4's role in corneal wound healing models
Faster epithelial closure and reduced inflammation were documented in preclinical settings

📚 Source: Malinda, K.M., et al. "Thymosin beta 4 accelerates wound healing." Journal of Investigative Dermatology, 113(3), 364–368. PubMed

📚 Source: Goldstein, A.L., & Kleinman, H.K. "Advances in the basic and clinical applications of thymosin beta 4." Expert Opinion on Biological Therapy, 15(sup1), 139–145. PMC

How TB-500 Works: The Mechanism in Plain English

If you strip away the scientific terminology, the mechanism is surprisingly intuitive:

Injury happens — whether it's a torn tendon, damaged gut lining, or surgical wound
Cells need to move to the injury site to begin repair
Actin drives that movement — it's the protein that forms the structural scaffolding for cell migration
TB-500 regulates actin availability — it holds G-actin in reserve and releases it when cells need it for migration and rebuilding
New blood vessels form — through its angiogenic properties, TB-500 helps deliver oxygen and nutrients to the repair site
Repair accelerates — with more cells migrating, more building material available, and better blood supply, the repair process moves faster

This is why TB-500 has been studied in such diverse tissue types — the actin-regulation mechanism is universal. It doesn't target one organ system. It targets the fundamental cellular process that underlies all tissue repair.

What Makes TB-500 Different from Other Peptides

Many peptides studied in preclinical research work through specific receptor pathways — they bind to a receptor and trigger a downstream signaling cascade. TB-500 works differently.

By directly regulating the actin protein itself, TB-500 operates at a more fundamental level of cellular biology. It doesn't activate a single pathway — it controls the structural protein that enables multiple cellular processes simultaneously:

Cell migration (movement to injury sites)
Cell division (creating new tissue)
Cytokinesis (splitting one cell into two)
Structural remodeling (rebuilding damaged architecture)

This breadth of mechanism is likely why TB-500 has been studied across such a wide range of tissue types — from tendons to corneas to cardiac muscle — with consistently positive findings in preclinical models.

The Research Landscape: What's Next

The TB-500 research field continues to expand. Recent studies have examined:

Sepsis models: A study published in PMC investigated Tβ4's regulation of actin in sepsis — a condition where actin dysregulation plays a role in organ failure
Aging research: As actin dynamics change with age, Tβ4 levels and their relationship to tissue repair capacity is an active area of investigation
Combination approaches: Researchers are studying TB-500 alongside other peptides (like BPC-157 and GHK-Cu) to understand multi-pathway repair strategies

📚 Source: "Thymosin beta 4 regulation of actin in sepsis." PMC. PMC6556887

Frequently Asked Questions About TB-500

Is TB-500 the same as Thymosin Beta-4?

TB-500 is the synthetic, research-grade version of Thymosin Beta-4 (Tβ4). Tβ4 is the naturally occurring 43-amino acid peptide found in human cells. TB-500 is the form used in preclinical research studies. The terms are often used interchangeably in the research literature.

How many published studies exist on TB-500?

Over 148 published studies on PubMed have examined Thymosin Beta-4 across cardiac, corneal, dermal, and tissue repair models. The research spans from early mechanistic studies to recent investigations in sepsis and aging.

What does TB-500 do in the body?

In published research, TB-500's primary mechanism is actin sequestration — binding and regulating G-actin, the monomeric form of the structural protein actin. This regulation enables cell migration, division, and structural remodeling. It also promotes angiogenesis (new blood vessel formation) through its LKKTETQ actin-binding domain.

Has TB-500 been studied in humans?

The vast majority of TB-500 research has been conducted in preclinical models — animal studies and cell culture systems. While Thymosin Beta-4 has been the subject of some early-phase human clinical investigations (particularly for corneal repair), most of the published evidence base consists of preclinical data. TB-500 is classified as a research compound and is not approved for human therapeutic use.

What is the LKKTETQ sequence?

LKKTETQ is a 7-amino acid sequence within the Thymosin Beta-4 molecule that was identified in a FASEB Journal study as the actin-binding domain. This sequence is responsible for TB-500's ability to bind and sequester G-actin, which is the core of its mechanism in tissue repair research.

Why does TB-500 work across different tissue types?

Because actin regulation is a universal cellular process. Unlike peptides that target specific receptor pathways in specific tissues, TB-500 works at the level of the actin protein — which is present in virtually every cell type. This is why it has been studied in tendon, gut, cardiac, corneal, and dermal repair models with consistent findings.

How is TB-500 different from BPC-157?

Both are studied in tissue repair research, but through different mechanisms. TB-500 works primarily through actin sequestration and angiogenesis. BPC-157 works through the nitric oxide (NO) system and growth hormone receptor expression. Researchers sometimes study them in combination because their mechanisms are complementary rather than overlapping.

What is a Certificate of Analysis (COA) for TB-500?

A Certificate of Analysis is a document published by the supplier showing the results of independent third-party testing on a specific batch. For TB-500, this typically includes HPLC (High-Performance Liquid Chromatography) purity verification and mass spectrometry confirmation. Choice Peptide Labs publishes a COA for every batch — the document is available on the product page.

Explore TB-500 from Choice Peptide Labs

10mg vial · Published Certificate of Analysis for every batch · Dispatched within 1 business day · Cold-chain shipped

View TB-500 Product Page →

Disclaimer: This article is for educational and informational purposes only. All information presented is derived from published, peer-reviewed research and is intended to describe what has been studied in preclinical and clinical research models. Nothing in this article is intended as medical advice, a recommendation for use, or a claim of therapeutic benefit. TB-500 is a research compound and is not approved by the FDA for human use. All products from Choice Peptide Labs are sold for laboratory research use only and are not intended for human or veterinary consumption.

The Specialist · Growth Hormone

Tesamorelin: The Stabilized GHRH Analog with Clinical Trial Data

Revised June 2026 · Research Guide · 10 min read

Among synthetic growth hormone secretagogues, Tesamorelin occupies a uniquely prominent position. Unlike many peptides that exist primarily in the preclinical or early-phase research space, Tesamorelin has completed Phase 3 clinical trials and secured regulatory approval for a specific indication — a rarity that lends it substantial credibility in the scientific literature. Originally developed under the code name TH9507, Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH), engineered to address the short half-life limitations that have historically constrained GHRH-based compounds.

This guide examines Tesamorelin's molecular design, mechanism of action, clinical evidence, and comparative positioning against related peptides in the GHRH family — Sermorelin and CJC-1295.

Molecular Architecture & Stabilization

Tesamorelin is a 44-amino acid synthetic peptide that mirrors the structure of endogenous human GHRH (1–44) with a critical modification: the addition of a trans-3-hexenoic acid group at the N-terminus. This acylation serves a specific pharmacokinetic purpose — it shields the peptide from dipeptidyl peptidase-IV (DPP-IV) cleavage, the primary enzymatic pathway responsible for the rapid degradation that reduces circulating half-life of native GHRH and unmodified analogs like Sermorelin.

🧬

Key Structural Advantage

The N-terminal trans-3-hexenoic acid modification renders Tesamorelin resistant to DPP-IV enzymatic degradation, extending its functional half-life while preserving full receptor-binding affinity at the GHRH receptor (GHRH-R).

Tesamorelin binds to the same GHRH receptor (GHRH-R) located on somatotroph cells in the anterior pituitary. Receptor engagement activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP), which stimulates the transcription and pulsatile release of growth hormone (GH) into systemic circulation. Released GH subsequently acts on hepatic and peripheral tissues to stimulate the production of insulin-like growth factor 1 (IGF-1), the primary mediator of GH's anabolic and metabolic effects.

Clinical Trial Data: Phase 3 Evidence

Tesamorelin's clinical history is distinguished by its progression through robust, randomized, placebo-controlled trials. The pivotal research program evaluated Tesamorelin at a 2 mg daily subcutaneous dose across multiple Phase 3 studies enrolling over 800 subjects.

Clinical Trial

The Phase 3 trials for Tesamorelin demonstrated statistically significant reductions in visceral adipose tissue (VAT) as measured by CT scan at L4–L5 vertebral level, alongside improvements in body composition metrics including trunk fat and waist circumference, over 26-week treatment periods. (Falutz et al., HIV Medicine, 2010; Journal of Clinical Endocrinology & Metabolism, 2012)

In the primary efficacy analysis, subjects receiving Tesamorelin experienced a 15–20% median reduction in visceral adipose tissue compared to placebo, with some cohorts reporting even greater responses. Importantly, these visceral fat reductions occurred without a corresponding increase in subcutaneous fat — a pattern that distinguishes systemic GH administration from GHRH analog stimulation, where GH release remains physiologically pulsatile.

📊

Clinical Outcome Highlight

Tesamorelin reduced visceral adipose tissue by approximately 15–20% over 26 weeks in completed Phase 3 trials, with concurrent improvements in waist circumference and trunk body composition — effects that reversed upon treatment discontinuation, consistent with a mechanism requiring ongoing signaling.

Body composition changes also included modest but measurable improvements in lean body mass and reductions in liver fat content, positioning Tesamorelin as a compound of interest for body composition research beyond its original studied population.

Comparison: Tesamorelin vs. Sermorelin vs. CJC-1295

All three compounds in the GHRH analog family share the core mechanism of activating the GHRH receptor, but they differ significantly in their structural modifications, pharmacokinetic profiles, and research maturity:

Parameter	Tesamorelin	Sermorelin	CJC-1295 (DAC)
Amino Acids	44 aa (full-length GHRH analog)	29 aa (GHRH 1–29 fragment)	29 aa (modified GHRH 1–29)
N-terminal Mod	trans-3-hexenoic acid	None (unmodified)	Drug Affinity Complex (DAC)
Half-Life	~26–38 minutes (extended vs. native)	~12–19 minutes	~6–8 days (with DAC)
DPP-IV Resistance	Yes (acylation-based)	No (rapid DPP-IV cleavage)	Yes (albumin binding)
Clinical Trials	Phase 3 completed (pivotal)	Phase 3 completed (earlier era)	Phase 1 completed
GH Pulse Pattern	Physiological pulsatile	Physiological pulsatile	Sustained elevation (non-pulsatile)

The comparison highlights a critical distinction: Sermorelin retains full activity at the GHRH-R but suffers from rapid DPP-IV degradation, necessitating frequent administration. CJC-1295 with DAC takes the opposite approach, using an albumin-binding drug affinity complex to achieve multi-day half-lives — but this produces sustained GH elevation rather than preserved physiologic pulsatility. Tesamorelin occupies the middle ground: it extends half-life substantially over Sermorelin while maintaining pulsatile GH release patterns closer to endogenous physiology.

Visceral Adipose Tissue & Body Composition Research

The most extensively documented research application for Tesamorelin involves its effects on visceral adipose tissue (VAT) — the metabolically active fat depot stored around internal organs. VAT is distinct from subcutaneous fat in its proximity to the portal circulation and its correlation with metabolic syndrome markers including insulin resistance, dyslipidemia, and elevated inflammatory cytokines.

Tesamorelin's preferential reduction of VAT (rather than overall body weight or subcutaneous fat) aligns with known GH physiology: growth hormone signaling promotes lipolysis preferentially in visceral adipocytes, which express higher densities of GH receptors and hormone-sensitive lipase than subcutaneous depots.

Research Note

Liver fat content also improved in Tesamorelin studies, with reductions in hepatic steatosis markers observed alongside VAT loss, suggesting potential relevance to non-alcoholic fatty liver disease (NAFLD) research — an active area of ongoing investigation. (Srinivasa et al., The Lancet HIV, 2020)

Safety Profile in Extended Use

Across the Phase 3 program, Tesamorelin demonstrated a reasonable safety profile at the 2 mg dose. The most frequently reported adverse events were injection site reactions (erythema, pain), arthralgia, and peripheral edema — events consistent with elevated IGF-1 levels. Importantly, glucose homeostasis parameters were monitored closely; while transient increases in fasting glucose were observed, significant diabetic progression was not a common finding in the studied cohorts. Post-marketing surveillance data have further informed the long-term safety understanding of this compound.

Research Stack Considerations

In research contexts investigating body composition, Tesamorelin is sometimes examined alongside complementary peptides. Common research stack configurations include pairing with Ipamorelin (a growth hormone secretagogue with a different receptor target — ghrelin receptor/GHS-R1a) for dual-pathway GH axis stimulation, or alongside BPC-157 in multi-endpoint research designs studying tissue repair and body composition simultaneously. These multi-compound research designs remain investigational and are documented primarily in preclinical or observational settings.

Summary

Tesamorelin's significance in peptide research derives from its unique combination of validated molecular design, Phase 3 clinical evidence, and a mechanism that preserves physiological GH pulsatility. Its stabilization via N-terminal acylation solved a real pharmacokinetic problem, and its completed clinical trials provide a data level that few GHRH analogs can match. As interest in body composition and metabolic research continues to evolve, Tesamorelin remains one of the most thoroughly characterized compounds in its class.

Frequently Asked Questions

Tesamorelin is a full-length 44-amino acid GHRH analog with an N-terminal trans-3-hexenoic acid modification that confers DPP-IV resistance. Sermorelin is a truncated 29-amino acid fragment (GHRH 1–29) with no N-terminal protection, making it far more susceptible to enzymatic degradation. The net result is a meaningfully extended half-life for Tesamorelin.

Yes. Tesamorelin has completed Phase 3 clinical trials involving over 800 subjects across multiple randomized, placebo-controlled studies. This is one of the most advanced clinical profiles of any GHRH analog in the peptide research landscape.

The primary endpoint was the change in visceral adipose tissue (VAT) measured by CT imaging at the L4–L5 vertebral level over 26 weeks. Secondary endpoints included waist circumference, trunk fat, lean body mass, and hepatic fat content.

Because Tesamorelin works through the GHRH receptor — the same receptor that endogenous GHRH activates — it amplifies the pituitary's existing pulse-releasing machinery rather than overriding it. Contrast this with direct GH administration or ghrelin-mimetic stimulation, which can produce non-physiologic sustained GH elevations.

CJC-1295 with DAC achieves a multi-day half-life (~6–8 days) through albumin binding, which produces sustained (non-pulsatile) GH elevation. Tesamorelin has a shorter half-life (~26–38 minutes) but preserves physiological pulsatility. The choice between them depends on the research design — sustained plateau vs. physiologic release patterns.

The clinically studied dose in Phase 3 trials was 2 mg administered subcutaneously once daily. This dose produced statistically significant reductions in visceral adipose tissue while maintaining an acceptable safety profile across 26-week treatment periods.

Transient increases in fasting glucose were reported in some trial participants. However, in the Phase 3 program, progression to clinically significant glucose impairment was relatively uncommon. Glucose monitoring was a standard safety measure in all Tesamorelin clinical studies.

In research contexts, Tesamorelin is sometimes examined in combination protocols. Common pairings include Ipamorelin (ghrelin receptor agonist) for dual-pathway GH stimulation, or complementary peptides targeting different endpoints. All such combinations remain investigational and are studied under controlled research protocols.

Explore Tesamorelin for Your Research

High-purity Tesamorelin (10mg, ≥99% purity) with third-party HPLC/MS verification — available for qualified research use.

View Tesamorelin 10mg →

Research Disclaimer: All content on this page is intended for scientific research and educational purposes only. Tesamorelin is a research peptide and is not approved for human consumption, veterinary use, or as a dietary supplement. Choice Peptide Labs supplies peptides exclusively for in vitro research purposes. All researchers must comply with applicable local, state, and federal regulations. The information presented does not constitute medical advice.

What Is Tirzepatide? A Research-Backed Guide to the First Dual GIP/GLP-1 Agonist

📖 14 min read 🔬 SURPASS 1-5 clinical trials 📅 June 2026

Tirzepatide is a single molecule that activates two incretin hormone receptors simultaneously — GIP and GLP-1. It's the first compound of its kind to be tested in large-scale clinical trials, with the SURPASS program generating data across thousands of participants. Here's what the published research shows.

What Is Tirzepatide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor co-agonist. That's a long way of saying: it's one molecule that activates two different hormone receptors at the same time.

Both GIP and GLP-1 are incretin hormones — naturally occurring substances your body releases after eating. They play roles in blood sugar regulation, insulin secretion, and appetite signaling. GLP-1 receptor agonists (like semaglutide) have been studied extensively. Tirzepatide adds the GIP receptor to the equation.

The compound was developed as an acylated peptide engineered to activate both receptors. It was designed to produce effects that neither GIP nor GLP-1 activation achieves alone — a hypothesis that the SURPASS clinical trial program was built to test.

📚 Source: Frías, J.P., et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." NEJM, 385(6), 503–515. NEJM

The Dual-Receptor Mechanism: GIP + GLP-1

To understand why tirzepatide is different from single-receptor compounds, you need to understand what each receptor does:

GLP-1 Receptor

Location: Pancreatic beta cells (insulin production) and brain regions regulating appetite
Function: Stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and signals satiety in the brain
Research context: GLP-1 receptor agonists (like semaglutide) have been studied in multiple large clinical programs

GIP Receptor

Location: Pancreatic beta cells, adipose tissue (fat), and brain regions involved in food intake
Function: Stimulates insulin secretion, may enhance fat metabolism, and has independent effects on appetite regulation
Research context: GIP receptor agonism was historically considered less important than GLP-1 — tirzepatide challenged that assumption

Why Both Together?

GIP and GLP-1 receptors are co-located in brain regions that regulate food intake. Activating both simultaneously appears to produce additive or synergistic effects on appetite suppression and metabolic regulation.

A key finding from published research: tirzepatide decreases calorie intake, and the effects are mediated by affecting appetite through central nervous system pathways, not just through peripheral metabolic effects.

📚 Source: Willard, F.S., et al. "Tirzepatide is an imbalanced and biased dual GIP/GLP-1 receptor co-agonist." JCI Insight. JCI Insight

The SURPASS Clinical Trial Program

The SURPASS program is one of the most comprehensive clinical trial programs in metabolic research. It comprises five major Phase 3 trials, each testing tirzepatide against different comparators and in different populations.

SURPASS-1 — Tirzepatide Monotherapy

The first randomized controlled trial of tirzepatide. Tested as monotherapy (no other diabetes medications) in people with Type 2 diabetes. Results showed potent glucose-lowering effects toward near-normal ranges with robust weight loss — a magnitude not previously reported in this population without increased hypoglycemia risk.

Published: The Lancet, 2021

SURPASS-2 — Tirzepatide vs. Semaglutide (Head-to-Head)

The landmark trial. 1,879 participants with Type 2 diabetes on metformin were randomized to one of three tirzepatide doses (5mg, 10mg, 15mg) or semaglutide 1mg. All three tirzepatide doses produced greater HbA1c reductions than semaglutide: tirzepatide achieved reductions of 2.1% to 2.5% depending on dose, compared to 1.9% with semaglutide.

Published: New England Journal of Medicine, 2021

SURPASS-3 — Tirzepatide vs. Insulin Degludec

Compared tirzepatide to titrated insulin degludec (a long-acting basal insulin) as add-on to metformin with or without an SGLT2 inhibitor. Tirzepatide demonstrated superior HbA1c reduction and weight loss compared to insulin.

Published: Nature Medicine, 2021

SURPASS-4 — Cardiovascular Outcomes

Evaluated tirzepatide in a high cardiovascular risk population. Demonstrated sustained glycemic and weight benefits in participants with established cardiovascular disease or multiple risk factors.

Published: The Lancet, 2022

SURPASS-5 — Tirzepatide Add-on to Insulin

Tested tirzepatide as add-on to existing insulin therapy. Showed significant additional HbA1c reduction and weight loss even when participants were already on insulin — a population typically resistant to further weight reduction.

Published: Journal of Clinical Endocrinology & Metabolism, 2022

What the Combined SURPASS Data Shows

Across all five trials, a post hoc analysis examined the composite outcomes. The findings were consistent:

Metric	Tirzepatide (all doses)	Context
HbA1c reduction	2.1% – 2.5%	Superior to semaglutide 1mg (1.9%) in SURPASS-2
Composite endpoint	43-62% of participants	HbA1c ≤6.5% + ≥10% weight loss, no hypoglycemia
3-year sustained weight	Substantial, maintained	NEJM 2024: lower progression to Type 2 diabetes

📚 Source: Rosenstock, J., et al. "Tirzepatide vs Insulin Degludec Once Daily in Type 2 Diabetes (SURPASS-3)." Nature Medicine. Nature

📚 Source: "Tirzepatide for Obesity Treatment and Diabetes Prevention." NEJM, 2024. NEJM

Tirzepatide vs. Semaglutide: What's Different?

Both compounds are studied in metabolic research. Both are injectable. Both have large clinical trial programs. But there are key differences:

Feature	Tirzepatide	Semaglutide
Receptor targets	GIP + GLP-1 (dual)	GLP-1 only (single)
HbA1c reduction (SURPASS-2)	2.1% – 2.5%	1.9%
Clinical program	SURPASS 1-5	STEP 1-5+
Approval context	Type 2 diabetes (2022)	Type 2 diabetes (2017), obesity (2021)
Mechanism distinction	Adds GIP receptor agonism to GLP-1	GLP-1 receptor agonism only

The addition of the GIP receptor is the fundamental difference. Published research suggests GIP agonism contributes independently to both glucose regulation and appetite effects, producing outcomes beyond what GLP-1 alone achieves.

The 3-Year Follow-Up Data

A 2024 study published in the New England Journal of Medicine provided some of the longest follow-up data for tirzepatide:

Population: Persons with obesity and prediabetes
Duration: 3 years of continuous treatment
Finding: Substantial and sustained weight reduction throughout the treatment period
Key outcome: Markedly lower risk of progression from prediabetes to Type 2 diabetes compared to placebo

This data was significant because it demonstrated that tirzepatide's effects are not transient — the compound continued to produce benefits over a 3-year period without the magnitude of effect diminishing.

📚 Source: Jastreboff, A.M., et al. "Tirzepatide for Obesity Treatment and Diabetes Prevention." NEJM, 2024. NEJM

How Tirzepatide Works in Plain English

If you strip away the pharmacology:

You eat a meal — your body naturally releases GIP and GLP-1 hormones
These hormones signal your brain — "you've had enough, stop eating"
Tirzepatide mimics and amplifies both signals — it activates both the GIP and GLP-1 receptors, producing stronger appetite signaling than either hormone alone
Your pancreas responds — insulin secretion is enhanced in a glucose-dependent manner (meaning it adjusts to your blood sugar levels, not a fixed amount)
Gastric emptying slows — food moves through your stomach more slowly, extending the feeling of fullness
Caloric intake decreases — the combination of stronger satiety signaling and slower gastric emptying leads to reduced food intake

The dual-receptor approach means tirzepatide engages two complementary pathways rather than one — which is why the clinical data shows effects that exceed single-receptor compounds in head-to-head trials.

Frequently Asked Questions About Tirzepatide

What does tirzepatide do differently from semaglutide?

Tirzepatide activates both the GIP and GLP-1 receptors. Semaglutide activates only the GLP-1 receptor. In the SURPASS-2 head-to-head trial, all three tirzepatide doses produced greater HbA1c reductions than semaglutide 1mg (2.1-2.5% vs 1.9%).

What is the SURPASS clinical trial program?

SURPASS is a five-trial Phase 3 program evaluating tirzepatide across different populations and comparators. SURPASS-1 tested monotherapy, SURPASS-2 compared to semaglutide, SURPASS-3 to insulin degludec, SURPASS-4 in high cardiovascular risk, and SURPASS-5 as add-on to insulin.

What is GIP and why does it matter?

GIP (glucose-dependent insulinotropic polypeptide) is a naturally occurring incretin hormone released by the gut after eating. GIP receptors are found in the pancreas, adipose tissue, and brain. GIP receptor agonism was historically considered less important than GLP-1, but tirzepatide's clinical results challenged that assumption.

Has tirzepatide been studied in long-term trials?

Yes. A 3-year follow-up study published in the NEJM (2024) showed substantial and sustained weight reduction with markedly lower risk of progression from prediabetes to Type 2 diabetes. The effects did not diminish over the treatment period.

How does tirzepatide affect appetite?

Published research indicates tirzepatide decreases calorie intake primarily through central nervous system appetite regulation. Both GIP and GLP-1 receptors are co-located in brain regions that regulate food intake, and dual activation produces stronger satiety signaling than either pathway alone.

What publications has the SURPASS program appeared in?

SURPASS trials have been published in the New England Journal of Medicine, The Lancet, Nature Medicine, and the Journal of Clinical Endocrinology & Metabolism — some of the highest-impact journals in medical research.

Is tirzepatide approved by the FDA?

Tirzepatide received FDA approval in May 2022 for Type 2 diabetes under the brand name Mounjaro. Subsequent approvals for obesity treatment followed. It remains under investigation for additional metabolic indications.

What is a Certificate of Analysis for tirzepatide?

A COA is an independent lab report showing purity verification and identity confirmation for a specific batch, typically using HPLC and mass spectrometry. Choice Peptide Labs publishes a COA for every batch on the product page.

Explore Tirzepatide from Choice Peptide Labs

10mg vial · Published Certificate of Analysis for every batch · Dispatched within 1 business day · Cold-chain shipped

View Tirzepatide Product Page →

Disclaimer: This article is for educational and informational purposes only. All information is derived from published, peer-reviewed clinical research. Tirzepatide is an FDA-approved medication; this article describes research findings only and does not constitute medical advice. Research-grade compounds from Choice Peptide Labs are for laboratory research use only and are not intended for human consumption.

Longevity & Cognitive · The Vessel

Vesugen: The Vascular Bioregulator Peptide

The vascular system is the body's infrastructure — a network of blood vessels extending over 60,000 miles that delivers oxygen and nutrients to every tissue and removes metabolic waste. At the core of this infrastructure is a single-cell layer called the endothelium, which lines every blood vessel from the largest arteries to the smallest capillaries. Endothelial health is vascular health, and vascular health is, in many respects, the foundation of longevity. Among the peptides studied for their effects on this critical tissue is Vesugen — a synthetic tripeptide derived from the Khavinson bioregulator research program that has been investigated for its role in supporting endothelial cell function and proliferation in aging models.

This guide examines the research surrounding Vesugen, its origins in the Khavinson peptide family, and its place in the broader landscape of vascular longevity research.

What Is Vesugen?

Vesugen is a synthetic tripeptide composed of three amino acids: alanine-glutamic acid-aspartic acid (Ala-Glu-Asp). It was developed as part of the bioregulator peptide library created by Professor Vladimir Khavinson — a Russian gerontologist whose research career at the St. Petersburg Institute of Bioregulation and Gerontology spanned several decades. Vesugen was derived from peptides found in the vascular endothelium, the thin cellular lining that controls blood vessel function.

Khavinson Bioregulator Concept

The Khavinson bioregulator hypothesis proposes that short peptides (2–4 amino acids) serve as endogenous signaling molecules that regulate gene expression in a tissue-specific manner. Each bioregulator peptide is thought to correspond to a specific organ or tissue, and their levels decline with aging — contributing to age-related tissue dysfunction. Vesugen is the vascular bioregulator in this family.

The concept behind Vesugen and the broader Khavinson peptide library is elegant in its simplicity: if short peptides naturally regulate tissue-specific gene expression, and these peptides decline with age, then supplementing them may help restore youthful gene expression patterns. This framework has generated a substantial body of research — primarily from Russian and Eastern European institutions — over the past three decades.

The Endothelium: Why a Single Cell Layer Matters

The endothelium is deceptively simple in structure — a single layer of flat cells — but extraordinarily complex in function. A healthy endothelium performs the following critical roles:

Vascular tone regulation: Endothelial cells produce nitric oxide (NO), the primary vasodilator that controls blood vessel diameter and blood pressure.
Anti-thrombotic surface: A healthy endothelium prevents blood clot formation on vessel walls through production of prostacyclin and thrombomodulin.
Inflammation control: Endothelial cells regulate the passage of immune cells and inflammatory molecules from the bloodstream into tissues.
Barrier function: The endothelium controls vascular permeability — what passes from the blood into surrounding tissues.
Angiogenesis signaling: Endothelial cells mediate the formation of new blood vessels in response to tissue demands.

Research Context: Endothelial dysfunction is now recognized as one of the earliest and most reliable biomarkers of cardiovascular disease. It precedes the development of atherosclerosis by years and is detectable before structural changes appear on imaging. See: Endemann & Schiffrin, 2004.

As the body ages, endothelial cells undergo several changes: their proliferative capacity decreases, nitric oxide production declines, inflammatory marker expression increases, and the endothelial surface becomes increasingly pro-thrombotic. This progressive endothelial deterioration — sometimes called endothelial senescence — is a central mechanism in age-related vascular disease.

Vesugen and Endothelial Cell Research

The research on Vesugen has focused primarily on its effects on endothelial cell proliferation and function in aging models. The key findings from this body of work include:

Cell Proliferation in Aging Models

In cell culture studies, Vesugen has been shown to stimulate proliferative activity in endothelial cell populations that exhibit age-related proliferative decline. This effect was observed at very low concentrations — consistent with the Khavinson hypothesis that these peptides function as signaling molecules rather than traditional pharmacological agents.

Research Finding

Studies by Khavinson and colleagues demonstrated that short tissue-specific peptides, including the Ala-Glu-Asp sequence found in Vesugen, could restore proliferative capacity in senescent cell cultures. The effects were dose-dependent at low concentrations and appeared to be mediated through epigenetic mechanisms — specifically, peptide interactions with DNA promoter regions that influence gene transcription.

Gene Expression Modulation

One of the more distinctive claims in the Khavinson research is that short peptides can enter cells and interact directly with DNA promoter regions, modulating gene transcription without requiring a classical receptor-mediated signaling cascade. This proposed mechanism — sometimes called "peptide-mediated epigenetic regulation" — suggests that Vesugen may influence the expression of genes involved in cell cycle progression, DNA repair, and anti-apoptotic pathways in endothelial cells.

While this mechanism is not universally accepted in the broader scientific community, it has been documented through fluorescence microscopy studies showing labeled peptides localized within cell nuclei, and through gene expression array data showing tissue-specific transcriptional changes following peptide administration.

Functional Endpoints

Beyond proliferation and gene expression, Vesugen research has explored functional endpoints in vascular biology models. These include effects on nitric oxide production, inflammatory marker expression, and endothelial barrier integrity — parameters directly relevant to the endothelial dysfunction observed in aging.

The Khavinson Peptide Family

Vesugen does not exist in isolation. It is part of a broader family of tissue-specific bioregulator peptides developed by Khavinson and his research group. Understanding Vesugen's position within this family provides important context:

Epithalon (Epitalon) — The most well-known Khavinson peptide, derived from the pineal gland. Studied for telomerase activation and circadian rhythm regulation. Epithalon has generated the most international interest and has been studied in several independent research groups.
Pinealon — A tripeptide (Glu-Asp-Arg) also derived from the pineal gland, studied for its neuroprotective and circadian effects. Often explored alongside Epithalon in pineal-focused research.
Vesugen — The vascular bioregulator (Ala-Glu-Asp), studied for endothelial cell function and vascular aging.
Other Khavinson peptides — Including Thymogen (thymus-derived), Vladilen (cartilage-derived), and Chonluten (bronchial mucosa-derived), among others.

Family Context: The Khavinson peptide library represents one of the most systematic approaches to tissue-specific peptide bioregulation in the scientific literature. The common features of these peptides include: short length (2–4 amino acids), tissue-specific origin, low-concentration biological activity, and proposed epigenetic mechanisms of action. See: Khavinson et al., 2014.

Research Considerations and Limitations

As with any emerging area of peptide science, the Vesugen literature has important boundaries:

Geographic concentration of research: The majority of Vesugen research originates from Russian and Eastern European institutions. Independent replication by research groups in other regions would strengthen the evidence base.
Mechanistic debate: The proposed mechanism of peptide-DNA interaction and epigenetic regulation is not universally accepted. Some researchers argue that the observed effects may be mediated through classical receptor pathways or other mechanisms not yet characterized.
Translational data: While cell culture and animal model data are informative, robust human clinical data on Vesugen is limited.
Dose optimization: The optimal dosing parameters for specific vascular endpoints remain to be determined in controlled studies.
Long-term effects: Long-term safety and efficacy data are limited.

These limitations are not dismissals — they are markers of a research field that is still maturing. The Khavinson bioregulator framework is genuinely innovative, and the peptide family it has produced represents a novel approach to age-related tissue decline. Continued research, particularly independent replication and mechanistic studies, will be important for establishing the full scientific value of Vesugen and its peptide siblings.

Vesugen in the Context of Vascular Longevity

Cardiovascular disease remains the leading cause of death worldwide, and vascular aging is now understood to drive not only heart disease but also cognitive decline, kidney disease, and systemic inflammation. The endothelium sits at the center of this vascular aging process.

If Vesugen genuinely supports endothelial cell function and proliferation in aging tissues, its relevance extends beyond vascular biology alone. Healthy endothelium means healthy blood flow, and healthy blood flow means adequate oxygen and nutrient delivery to every organ — including the brain, heart, kidneys, and skeletal muscle.

Longevity Connection

The concept of "vascular aging" as a primary driver of organ-level aging is gaining traction in longevity research. Studies suggest that endothelial dysfunction may precede and contribute to age-related decline in multiple organ systems simultaneously. A peptide that supports endothelial health addresses vascular aging at its most fundamental cellular level — the endothelial cell itself.

Frequently Asked Questions

What is Vesugen?

Vesugen is a synthetic tripeptide composed of alanine-glutamic acid-aspartic acid (Ala-Glu-Asp). It was developed as part of the Khavinson bioregulator peptide library and is derived from peptides found in the vascular endothelium.

What is the endothelium?

The endothelium is a single-cell layer that lines the interior of every blood vessel in the body. It regulates vascular tone (through nitric oxide production), prevents blood clotting, controls inflammation, maintains barrier function, and mediates new blood vessel formation. Endothelial dysfunction is one of the earliest markers of cardiovascular disease.

Who developed Vesugen?

Vesugen was developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It is part of a family of tissue-specific bioregulator peptides that Khavinson's group has studied over several decades.

What is the Khavinson bioregulator hypothesis?

The Khavinson hypothesis proposes that short peptides (2–4 amino acids) serve as endogenous signaling molecules that regulate gene expression in a tissue-specific manner. Each bioregulator corresponds to a specific organ or tissue, and their decline with aging contributes to age-related dysfunction. Supplementing these peptides may help restore youthful gene expression patterns.

How does Vesugen relate to Epithalon and Pinealon?

Vesugen, Epithalon, and Pinealon are all members of the Khavinson bioregulator peptide family. Epithalon (from the pineal gland) is studied for telomerase activation and circadian regulation. Pinealon (also pineal-derived) is studied for neuroprotective effects. Vesugen (from vascular endothelium) is studied for endothelial cell function. They share the common framework of tissue-specific epigenetic regulation.

Has Vesugen been studied in humans?

The primary research on Vesugen comes from cell culture and animal models. Human data is limited. Most clinical observations originate from Russian research institutions.

What is the proposed mechanism of action?

The Khavinson research proposes that short peptides like Vesugen can enter cells and interact with DNA promoter regions, modulating gene transcription. This proposed mechanism — peptide-mediated epigenetic regulation — suggests tissue-specific effects on cell cycle, DNA repair, and anti-apoptotic pathways. This mechanism is not universally accepted and continues to be studied.

Why is vascular health important for longevity?

Cardiovascular disease is the leading cause of death worldwide, and vascular aging drives not only heart disease but also cognitive decline, kidney disease, and systemic inflammation. The endothelium is central to vascular aging, making endothelial health a key target in longevity research.

Explore Vesugen for Your Research

High-purity Vesugen (10mg) available for research applications. HPLC-verified, third-party tested.

View Vesugen 10mg →

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. All peptides discussed are sold for research purposes only and are not approved by the FDA for human consumption. Always consult a qualified healthcare provider before making decisions about your health. Choice Peptide Labs does not claim that any product discussed can treat, cure, or prevent any disease.

The Wolverine Blend: BPC-157 + TB-500 — What Combined Research Shows

📖 15 min read 🔬 300+ published studies reviewed 📅 June 2026

In preclinical peptide research, few combinations have generated as much interest as BPC-157 paired with TB-500. Nicknamed the "Wolverine Blend" for its reference to rapid tissue regeneration, this dual-peptide approach brings together two compounds with complementary — not overlapping — repair mechanisms. Here's what the research actually shows about studying them together.

Why These Two Peptides?

BPC-157 and TB-500 are each among the most studied peptides in tissue repair science. But the reason researchers pair them isn't redundancy — it's complementary pathway coverage. Each peptide drives tissue repair through a fundamentally different mechanism, and together they address more steps of the healing cascade than either does alone.

Think of it this way: BPC-157 builds the road. TB-500 drives the repair crew to the site.

How They Differ

BPC-157 — a 15-amino acid peptide derived from gastric juice. Primary mechanism: VEGFR2 upregulation, nitric oxide modulation, growth factor signaling, and angiogenesis. It builds new blood supply and structural infrastructure at the injury site.
TB-500 — the synthetic form of Thymosin Beta-4, a 43-amino acid peptide. Primary mechanism: G-actin sequestration, cell migration, macrophage polarization, and anti-fibrotic remodeling. It mobilizes repair cells to where they're needed.

Neither peptide is "better" — they solve different parts of the same problem. This is why the mechanistic case for studying them in combination is so compelling.

📚 Source: Sikiric, P. et al. "Brain-gut axis and pentadecapeptide BPC 157." Curr Neuropharmacol, 2016. PMID: 27106030

BPC-157: The Mechanism in Detail

BPC-157 (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) has been the subject of hundreds of preclinical studies. Its primary mechanisms of action include:

The Nitric Oxide (NO) System

BPC-157 modulates the nitric oxide system in a context-dependent, bidirectional manner. It can counteract both excessive NO production (as in inflammation) and insufficient NO availability (as in ischemia). This normalization — rather than simple upregulation — is mediated through effects on all three NOS isoforms: eNOS, nNOS, and iNOS.

Angiogenesis and Vascular Protection

In the chicken chorioallantoic membrane (CAM) assay, BPC-157 significantly accelerated new blood vessel formation at concentrations as low as 0.01 μg/mL. In rat models of major vessel transection, BPC-157 improved survival, reduced bleeding time, and promoted vascular reconnection. These effects are mediated through VEGF upregulation and eNOS activation.

Growth Factor Upregulation

BPC-157 has been shown to upregulate multiple growth factors critical to tissue repair:

VEGF — promotes angiogenesis
EGF — stimulates epithelial cell proliferation
FGF — drives fibroblast proliferation
HGF — promotes cell motility
TGF-β — regulates collagen synthesis

In tendon healing models, BPC-157 increased growth hormone receptor expression and FAK-paxillin pathway activation, promoting tendon fibroblast outgrowth and migration. In preclinical studies, treated subjects showed 41–47% increases in collagen density with improved fiber alignment compared to controls.

📚 Source: Chang, C.H. et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing." J Orthop Res, 2011. PMID: 21030672

TB-500: The Mechanism in Detail

TB-500 works through a fundamentally different pathway than BPC-157. Its primary function is G-actin sequestration — binding monomeric actin in a 1:1 ratio, regulating actin polymerization, and driving cell motility.

Actin and Cell Migration

Actin is the structural protein that drives cell movement. Every time a cell migrates to an injury site, actin is doing the work. TB-500 holds G-actin in reserve and releases it when cells need to move — making it the rate-limiting regulator of cell migration in wound repair. The LKKTETQ 7-amino acid sequence is the actin-binding domain responsible for this activity.

In scratch-wound assays, Thymosin Beta-4 treatment accelerated reepithelialization by 42% at day 4 and 61% at day 7 compared to controls.

Macrophage Polarization

TB-500 accelerates the shift from pro-inflammatory M1 macrophages to pro-resolution M2 macrophages — a critical transition that moves tissue from the acute inflammation phase into the proliferation and repair phase.

Anti-Fibrotic Properties

In cardiac ischemia-reperfusion models, TB-500 reduced excessive scar tissue formation by suppressing TGF-β1-induced myofibroblast differentiation, reducing collagen I and III overproduction, and downregulating connective tissue growth factor. The result: organized tissue repair rather than disorganized scarring.

📚 Source: Goldstein, A.L. & Kleinman, H.K. "Advances in the basic and clinical applications of thymosin beta 4." Expert Opin Biol Ther, 2015. PMC

The Synergy: Why the Whole Is Greater Than the Parts

The case for studying BPC-157 and TB-500 together rests on complementary mechanism synergy — two agents acting through different but convergent pathways to produce additive effects across the full timeline of tissue repair.

The Three Phases of Combined Repair

Phase 1: Inflammation (Days 1–5)

TB-500 suppresses the acute inflammatory cytokine response and accelerates M1→M2 macrophage polarization — moving tissue out of the inflammation phase faster
BPC-157 simultaneously begins upregulating growth factor signaling and normalizing the NO system, preparing the vascular and extracellular matrix environment for repair

Phase 2: Proliferation (Days 5–21)

BPC-157 drives fibroblast proliferation, collagen synthesis, and angiogenesis — building the structural scaffold and blood supply at the injury site
TB-500 continues mobilizing repair cells and stem cells to the site, while independently supporting angiogenesis through its own pathway (additive, not redundant)

Phase 3: Remodeling (Weeks 3–8)

BPC-157 promotes collagen fiber alignment and organized extracellular matrix reorganization
TB-500 provides anti-fibrotic activity, reducing disorganized scar deposition and supporting matrix remodeling through MMP activity
Together: organized, functional tissue repair rather than rigid scar formation

This phase-complementary action is why researchers are interested in the combination. BPC-157 is strongest during the proliferative phase (building infrastructure), while TB-500 is strongest during inflammation and remodeling (mobilizing cells and preventing fibrosis). Together, they theoretically cover the entire healing timeline.

Side-by-Side Comparison

Attribute	BPC-157	TB-500
Source	Gastric juice (synthetic 15-amino acid peptide)	Thymosin Beta-4 (synthetic 43-amino acid peptide)
Primary mechanism	VEGFR2 upregulation, NO modulation, growth factor signaling	G-actin sequestration, cell migration, macrophage polarization
Angiogenesis	Yes — VEGF/eNOS pathway	Yes — independent pathway (additive)
Tissue scope	GI tract, tendons, muscles, nerves, vasculature	Cardiac, muscle, neural, corneal, dermal
Action style	More localized — strongest near injection site	Systemic — distributes broadly via circulation
Anti-fibrotic	Collagen alignment and fiber organization	Scar reduction via TGF-β1/CTGF suppression
Neuroprotective	Dopaminergic, serotonergic, GABAergic modulation	Akt/PI3K signaling, neural migration support
Evidence base	180+ published preclinical studies	148+ published preclinical studies

What the Combined Research Doesn't Yet Show

It's important to be clear about the limitations of the current evidence:

No formal co-administration synergy studies exist — the complementarity is theorized from independent mechanism research, not from head-to-head combination trials
No human randomized controlled trials for either compound in musculoskeletal applications as of 2026
Optimal dosing ratios remain empirically unknown — what works best in a combined protocol has not been established by controlled research
Tissue-specific effects may vary — what's observed in tendon models may not directly translate to cardiac or neural applications

The mechanistic rationale is strong. The empirical confirmation is still being built. This is the current state of the science, and researchers should approach the combination with appropriate rigor and awareness of these gaps.

The Discovery of the Pairing

The nickname "Wolverine Blend" emerged from the research community rather than from any pharmaceutical company or clinical trial. As researchers published increasingly detailed mechanistic papers on each peptide through the 2010s and 2020s, the complementary nature of their pathways became clear.

BPC-157's literature — led primarily by Predrag Sikiric and colleagues at the University of Zagreb — documented its effects across the nitric oxide system, growth factor upregulation, and vascular protection. TB-500's literature — built on the foundational work of Allan Goldstein at George Washington University — established its role in actin regulation, cell migration, and anti-fibrotic remodeling.

The mechanistic logic was straightforward: if BPC-157 builds the vascular and structural infrastructure for repair, and TB-500 mobilizes the cellular repair crew, then studying them together should address more of the healing cascade than either alone. The "Wolverine" label followed naturally from the observed breadth and speed of tissue repair in preclinical models.

📚 Source: Goldstein, A.L., Hannappel, E., & Kleinman, H.K. "Thymosin β4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med, 2005. PMID: 16023860

What's Next for Combination Peptide Research

The Wolverine Blend represents a broader trend in peptide science: moving from single-compound studies to multi-peptide approaches that target different phases of the same biological process. As the mechanistic understanding of each peptide deepens, researchers are increasingly interested in how combinations produce additive or synergistic effects.

The questions the research community is working to answer:

Dose optimization — what ratio of BPC-157 to TB-500 produces the strongest combined effect?
Timing — should both be administered simultaneously, or is there benefit to staggering them across repair phases?
Tissue specificity — does the combination work equally well across tendon, cardiac, neural, and GI models?
Formal synergy studies — when will controlled combination trials confirm what the mechanistic data suggests?
Third-peptide additions — could adding GHK-Cu (the copper peptide with its own collagen and remodeling pathways) create a triple-combination approach?

Frequently Asked Questions About the Wolverine Blend

What is the Wolverine Blend?

The Wolverine Blend is a community name for the combination of BPC-157 and TB-500 — two peptides studied in preclinical tissue repair research. The name references the Marvel character known for rapid healing. It is not a clinical designation and not an FDA-approved treatment. Both compounds are research peptides.

Why study BPC-157 and TB-500 together?

Because they work through complementary mechanisms that address different phases of tissue repair. BPC-157 primarily builds vascular infrastructure and upregulates growth factors (proliferation phase). TB-500 primarily mobilizes repair cells via actin regulation and reduces excessive scarring (inflammation and remodeling phases). Together, they theoretically cover the full healing timeline more completely than either alone.

Are there human clinical trials for the Wolverine Blend?

No. As of 2026, there are no published human randomized controlled trials studying BPC-157 and TB-500 in combination. The synergy rationale is based on independent mechanism research — each peptide has been studied separately in preclinical models, and their complementary pathways suggest additive effects. Formal combination studies have not yet been conducted.

How do BPC-157 and TB-500 differ in mechanism?

BPC-157 works through the nitric oxide system, VEGFR2 upregulation, and growth factor signaling — it builds blood supply and structural scaffolding at the injury site. TB-500 works through G-actin sequestration and cell migration regulation — it mobilizes repair cells to the site and reduces fibrotic scarring. They act on different molecular targets through non-overlapping pathways.

Is the Wolverine Blend the same as KLOW?

No. KLOW is a four-peptide blend from Choice Peptide Labs that combines BPC-157, TB-500, and GHK-Cu. The Wolverine Blend refers specifically to the two-peptide combination of BPC-157 and TB-500. KLOW adds the copper peptide's gene-expression modulation and collagen remodeling pathways on top of the Wolverine foundation.

What does the preclinical evidence show for the combination?

Preclinical studies on each peptide individually show consistent results: BPC-157 promotes angiogenesis, growth factor upregulation, and organized collagen deposition. TB-500 promotes cell migration, macrophage polarization, and anti-fibrotic remodeling. When considered together, the mechanistic coverage spans inflammation control, structural repair, vascular development, and scar minimization — addressing the full tissue repair cascade through complementary pathways.

What is a Certificate of Analysis for research peptides?

A Certificate of Analysis (COA) is a document from the supplier showing independent third-party test results for a specific batch. For BPC-157 and TB-500, this typically includes HPLC purity verification and mass spectrometry confirmation. Choice Peptide Labs publishes a COA for every batch on the product page.

Is the Wolverine Blend FDA approved?

No. Neither BPC-157 nor TB-500 is FDA approved for any therapeutic indication. Both are sold as research compounds for laboratory use only. The combination has not been evaluated by the FDA. Nothing in this article constitutes medical advice or a recommendation for human use.

Explore the Wolverine Blend from Choice Peptide Labs

BPC-157 + TB-500 in one vial · Published COA for every batch · Dispatched within 1 business day · Cold-chain shipped

View Wolverine Blend →

Disclaimer: This article is for educational and informational purposes only. All information presented is derived from published, peer-reviewed preclinical research and is intended to describe what has been studied in research models. Nothing in this article is intended as medical advice, a recommendation for use, or a claim of therapeutic benefit. Neither BPC-157, TB-500, nor any combination thereof is approved by the FDA for human use. All products from Choice Peptide Labs are sold for laboratory research use only and are not intended for human or veterinary consumption.

The Choice Peptide Labs Research Library